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Resumen
Los linfocitos B ejercen una función fundamental en la inmunidad humoral mediante la
secreción de anticuerpos. El evento más característico de la biología de los linfocitos B
maduros es la diversificación secundaria de sus genes de inmunoglobulinas durante la
reacción de centro germinal (CG) para generar un repertorio prácticamente ilimitado de
anticuerpos con distintas especificidades. La desaminasa inducida por activación (AID,
de sus siglas en inglés) inicia la diversificación secundaria de anticuerpos en linfocitos B
de  CG  mediante  la  desaminación  de  citosinas  en  los  genes  de  inmunoglobulinas.
Sorprendentemente,  AID  también  puede  ejercer  su  actividad  en  otras  regiones  del
genoma,  dando  lugar  a  mutaciones  o  translocaciones  cromosómicas  con  potencial
oncogénico. Por tanto, es fundamental comprender los mecanismos responsables de la
especificidad de diana de esta enzima. Sin embargo, su estudio se ha visto limitado por la
extrema dificultad para detectar mutaciones inducidas por AID, ya que ocurren en muy
baja frecuencia.
En este trabajo hemos desarrollado una novedosa aproximación basada en captura y
enriquecimiento para la identificación de dianas mutacionales de AID en linfocitos B de
centro germinal. Secuenciamos 1588 regiones genómicas con una elevada profundidad
de lectura e identificamos 275 genes mutados por AID, incluyendo 30 de las 35 dianas de
AID  previamente  descritas.  Además,  hemos  identificado  un  nuevo  “punto  caliente”
(hotspot)  para  la  actividad  de  AID.  Basándonos  en  las  características  moleculares
observadas  en  los  genes  mutados  por  AID  hemos  desarrollamos  un  modelo  de
aprendizaje  automático  (machine  learning)  que  permite  predecir  nuevas  dianas
mutacionales de AID y lo hemos validado experimentalmente. También encontramos
que  las  vías  de  reparación  por  excisión  de  bases  y  de  desapareamiento  de  bases  se
respaldan  mutuamente  para  reparar  de  forma  fiel  la  mayor  parte  de  las  lesiones
inducidas por AID. Por último, nuestros datos establecen un nuevo vínculo entre las
mutaciones inducidas por AID y el desarrollo de linfomas.
Abstract
B lymphocytes are key effectors of the humoral immune response through the secretion
of  antibodies.  The  most  distinctive  event  in  mature  B  lymphocytes  biology  is  the
secondary  diversification  of  their  immunoglobulin  genes  during  the  germinal  center
(GC) reaction, which is fundamental to generate a repertoire of antibodies with virtually
unlimited  specificities.  Activation  Induced  Deaminase  (AID)  initiates  secondary
antibody  diversification  in  GC  B  cells  through  the  deamination  of  cytosines  on
immunoglobulin genes. Remarkably, AID can also target other regions in the genome,
triggering  mutations  or  chromosome  translocations,  with  major  implications  for
oncogenic transformation.  However, understanding the specificity of AID has proved
extremely challenging, mostly because of the difficulty to detect AID-induced mutations,
which occur at very low frequencies. 
In  this  work  we  have  developed  a  novel  capture-based  approach  to  explore  AID
mutagenesis in a representation of the B cell genome. We have sequenced at very high
depth 1588 genomic regions from GC B cells and identified 275 genes targeted by AID,
including 30 of the previously known 35 AID targets. We have also identified the most
highly mutated hotspot for AID activity described to date. Further, integrative analysis of
the molecular features of mutated genes coupled to machine learning has produced a
powerful predictive tool for AID targets, which has been experimentally validated. We
have also found that Ease Excision Repair and Mismatch Repair pathways back-up each
other to faithfully repair most of AID-induced lesions.  Finally, our data establishes a
novel link between AID mutagenic activity and lymphomagenesis.
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I. introduction
Introduction
1. The immune system: innate and adaptive immunity
Immunity emerged during evolution to protect organisms against deleterious agents. From the simplest
bacterial immune systems, such as CRISPR-Cas or restriction modification systems, to the complex
immune system of vertebrates, all immune responses are triggered by the recognition of an exogenous
factor as foreign. This recognition activates effector functions in the cell that culminate in the removal
of the factor that prompted the response.
Higher vertebrates present two types of defense mechanisms:  innate and adaptive immunity. Innate
immunity  is  rapid,  non-specific and acts as a first barrier  against  infection.  The innate response is
elicited by the recognition of molecular patterns that are commonly present in pathogens and allows
their efficient elimination. In addition, innate immunity is fundamental to activate adaptive immunity .
The adaptive response is  defined by two features, specificity and memory: specificity to distinguish
between different, even closely related, pathogens and molecules and respond to them; and  immune
memory, which results in a faster and more efficient removal of the pathogen upon reinfection. The
main players of the adaptive immune response are T and B lymphocytes. T lymphocytes participate in
the removal of intra-cellular pathogens and contribute to the activation of other immune cell subsets,
while B lymphocytes are specialized to develop humoral responses against extra-cellular pathogens.
The activity of both B and T lymphocytes relies on the expression of the antigen receptors, TCR (T Cell
Receptor)  and  BCR  (B  Cell  Receptor),  which  specifically  recognize  antigens  (proteins  or
polysaccharides, generally) present in pathogens. Each T or B lymphocyte expresses a unique receptor
which is specific to a single antigen, such that the collection of T or B cells in an organism provide an
inmensely diverse TCR and BCR repertoire that to proficiently combat virtually any infection.
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2. B cell differentiation and antibody diversification
The BCR is a multiprotein complex composed of two modules: a membrane bound immunoglobulin
(Ig) molecule, which is responsible for antigen binding, and an Igα/β heterodimer (CD79a/CD79b),
endowed with signalling function. Igs, also called antibodies in their secreted form, are composed of
four polypeptides: two identical heavy chains (IgH) and two identical kappa (κ) or lambda (λ) light
chains (IgL) (Figure 1 A,B). Both heavy and light chains are formed by an N-terminal variable region
and a C-terminal constant region. The variable region is responsible for antigen recognition, and can be
further subdivided into hypervariable regions (or complementarity determining regions, CDRs) and
framework  regions  (FWRs).  There  are  3  CDRs  in  the  light  and  heavy  chains  that  determine  the
specificity  of  the  antibody,  and 4  interspersed  FWRs that  serve  as  a  scaffold  to  favor  the  contact
between the CDRs and the antigen. On the other hand, the constant region defines the isotype of the
antibody and its effector funcion, i.e. the mechanism by which the antigen will be removed.
The BCR drives the differentiation, maintenance and activation of B lymphocytes and is therefore a key
molecule for humoral immunity. During early development in the bone marrow, the assembly of a pre-
BCR is an absolute requirement for B cells to survive (Kitamura et al., 1991); mature B cell persistence
in the periphery is dependent on BCR signalling (Lam et al., 1997); and upon antigen encounter in the
secondary lymphoid organs, the BCR is central for B cell activation, clonal selection of B cells and their
terminal differentiation to plasmatic and memory cells (reviewed in Victora and Nussenzweig, 2012).
Thus,  B  cells  are  driven by  BCR signals  to  make vital  cell-fate  decisions  at  several  stages  of  their
development. 
Antibodies can specifically bind and eliminate a practically unlimited number of foreign antigens. It is
estimated that  mammals  can generate in the order of  1011 different  antibodies (Chapter 1,  Tasuku
Honjo, Michael Reth, Andreas Radbruch, Frederick Alt, 2015). This hugely diverse repertoire originates
from active somatic gene editing taking place at the Ig loci. Three different genes encode, respectively,
the  IgH  chains  and  the  Igκ and  Igλ  light  chains.  Ig  genes  have  an  analogous  organization  in  all
mammals, although there are differences in their chromosomal locations and the number and sequence
of  different  gene  segments  in  each  locus  may  vary.  The  IgH  locus  is  composed  of  multiple  gene
segments termed VH (variable), JH (joint), DH (diversity) and CH (constant). In mice, there are around
100 functional VH, 10-15 DH and 4 JH segments encoding the IgH variable region; and 8 CH segments
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encoding the constant region of the different IgH isotypes (Cμ, Cδ, Cγ1, Cγ2a, Cγ2b, Cγ3, Cε and Cα)
(Retter, J Imm, 2007) (Figure 1C). On the other hand, the human IgH locus contains 123 Vh, 26 Dh
and 6 Jh segments; and there are 11 Ch segments: 9 coding (Cμ, Cδ, Cγ3, Cγ1, Cα1, Cγ2, Cγ4, Cε1 and
Cα2) and 2 pseudogenes (Matsuda et al., 1998). The IgL κ and IgL λ loci are composed by VL, JL and CL
segments and also exhibit some differences in number beween human and mice.  As we will explain
below, diversification of antibody genes generally occurs in two different stages: primary diversification
in the bone marrow and secondary diversification in germinal centers. 
Figure  1  |  Immunoglobulin  structure.  (A)  Schematic  and  3D  (B) representation  of  the  immunoglobulin
molecule.  The antibody molecule  is  a  dimer of  heterodimers  (one  heavy and one  light  chain)  connected by
disulfide bonds. The antigen binding site is formed by the heavy and light chain variable regions (VH, VL); the
constant regions form the effector arm.  (C)  Schematic representation of the germline murine immunoglobulin
heavy  chain  (IgH)  locus  (not  to  scale).  Variable  (V),  Diversity  (D)  and  Joint  (J)  segments  undergo  V(D)J
recombination to produce a unique rearrangement per cell. The rearranged VDJ region will be subject to somatic
hypermutation  (SHM)  during  the  germinal  center  reaction.  There  are  eight  constant  (C)  genes  specifying
different antibody isotypes. Except for IgD -which can be expressed by alternative splicing-, each constant region
is preceded by a switch (S) and intronic (I) region. Upon activation, B cells can switch from IgM/D to any of the
other six isotypes. 
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2.1. Early B cell differentiation and primary antibody diversification
B cells generate in the bone marrow from hematopoietic stem cells (HSCs) through a tightly regulated
process (Figure 2) that concludes with the expression of a functional BCR. The driving force of B cell
development is the rearrangement of IgH and IgL loci, which constitutes the primary diversification of
antibodies (see below). The rearrangement of the IgH locus by V(D)J recombination is initiated at the
proB stage of  B cell  differentiation in the bone marrow.  Successful  IgH rearrangement  enables  the
expression of the IgH chain, which pairs with the invariant Surrogate Light Chains VpreB and λ5 and
the signal-transducing subunits Igα/β to form the pre-BCR in preB cells  (Karasuyama et al.,  1990;
Tsubata and Reth, 1990). Signals from the pre-BCR trigger an intense proliferative stage of preB cells
which gives raise to the largest expansion of differentiating cells. This is followed by the rearrangement
of the IgL locus by V(D)J recombination. B cells that have successfully rearranged both the IgH and IgL
loci  express  a  functional  BCR and are  called  immature  B cells.  At  this  stage,  there  is  a  tolerance
checkpoint  by  which  immature  B  cells  expressing  an  autoreactive  BCR  are  subject  to  deletion
(apoptosis),  anergy (unresponsiveness to antigen), or  receptor editing (further recombination of the
IgL locus to replace the BCR by a non self-reacting version) (reviewed in Pelanda and Torres, 2012).
Primary antibody diversification by V(D)J recombination is a site-specific reaction that takes place in
an  antigen-independent  fashion  in  the  bone  marrow.  During  V(D)J  recombination,  a  random
combination of VH, DH and JH segments is assembled in each individual differentiating B cell, followed
by  an  analogous  reaction  at  the  Igκ or  Igλ  locus.  V(D)J  recombination  is  initiated  by  the
Recombination Activating Gene enzymes (RAG1/2), which form a tetrameric complex recognizing the
recombination signal sequences (RSS) flanking each V, D and J segment. RAG1 and RAG2 create a loop
between two RSS, bring them together and generate a DNA double strand break (DSB) at each RSS.
These DSBs are resolved by Non-Homologolous End-Joining (NHEJ) resulting in the assembly of V, D
and J segments into the variable domain of IgH (reviewed in  Arya and Bassing, 2017; Bassing et al.,
2002). The random choice of a single V, D and J segment to be recombined is responsible for the large
array of different receptors produced by V(D)J recombination. In addition, the imprecise joining of V,
D and J segments implies the excision, duplication and insertion of nucleotides and further increases
the variability of the rearranged segments (Max et al., 1979; Sakano et al., 1979; Seidman et al., 1979).
Light chains also undergo an analogous process of recombination of their V and J gene segments once
the IgH locus has been successfully rearranged. Due to the random nature of V(D)J recombination,
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only a fraction of the rearrangements is functional, i.e. contain a productive VDJ (IgH locus) or VJ (IgL
loci) exon that can be assembled into a surface-expressed BCR. In the case of the IgH locus, if one allele
is  productively  rearranged,  the  recombination of  the  other  allele  is  prevented.  In the  IgL loci,  the
productive rearrangement of Igκ precludes Igλ rearrangement. Thus, Igλ exclusively undergoes V(D)J
recombination if Igκ is non-productively rearranged or if a self-reactive Igκ light chain is subject to
receptor  editing. This  process  is  called  allelic  exclusion and  ensures  that  B  lymphocytes  are
monospecific and express only one functional Ig per cell (reviewed in Vettermann and Schlissel, 2010). 
V(D)J recombination, together with the imprecise joining by NHEJ, generates a primary repertoire of
about 105-106 different antibody specifities (Bassing et al., 2002; Di Noia and Neuberger, 2007). 
2.2. The Germinal Center Reaction and secondary antibody diversification
Immature B cells that express a functional IgM/D BCR on their membrane exit the bone marrow and
migrate to the periphery, where they can recirculate and populate secondary lymphoid organs. There,
they can encounter and respond to foreign antigens. Upon antigen binding by the BCR, a mature B
lymphocyte can engage in the Germinal Center (GC) Reaction, an essential event for the generation of
high affinity antibodies with diverse effector functions. This secondary antibody diversification takes
place through Somatic Hypermutation (SHM) and Class Switch Recombination (CSR) (Figure 2). SHM
introduces point mutations in the V(D)J rearranged variable region of the Ig loci (reviewed in (Di Noia
and Neuberger, 2007; Methot and Di Noia, 2017), while CSR is a region specific recombination reaction
that  replaces  the  primary IgM isotype with  IgG,  IgA or  IgE isotypes.  GCs originate  in  secondary
lymphoid  organs  which are  structured  in  follicles.  Follicles  are  mostly  composed  by  naïve  B cells
surrounded by T cells. The GC reaction begins with the acquisition of the antigen by naïve B cells,
which migrate to the T cell rich zone of the follicle and are fully activated by co-stimulatory signals
from specificity-matching  CD4+ helper  T cells  (TH).  This interaction is  mainly mediated by CD40
ligand, expressed by the TH cell, which engages its receptor CD40 in the antigen-stimulated B cell, and
triggers an intense proliferation and clonal expansion of the B lymphocyte that initially recognized the
antigen. The mature GC can be divided into two compartments: the dark zone (DZ) and the light zone
(LZ). The DZ consists of a cluster of highly proliferative B cells called centroblasts that are actively
introducing mutations at their Ig variable regions by SHM. These mutations can modify the affinity of
the antibody. In the LZ, centrocytes are selected by the affinity of their BCRs for the cognate antigen in
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the context of T follicular helper and follicular dendritic cell help. As a result, B cells whose BCRs have
gained affinity for the antigen receive anti-apoptotic signals, while B cells bearing a BCR with decreased
affinity undergo apopotosis (Figure 2). These proliferation/SHM/selection events can be repeated in
iterative cycles and thus result in the increase of the antibody affinity for the antigen that initiated the
response, a process called affinity maturation. In addition, a subset of centrocytes can undergo CSR in
the LZ.  In CSR a recombination occurs between the highly repetitive switch regions of  the IgM/D
constant  chain  (Cμ/Cδ)  and  a  downstream  switch  region  (Cα,  Cε  or  Cγ)  culminating  with  the
replacement of an IgM/D isotype by either an IgA, IgE or IgG isotype. Thus, CSR modulates the effector
function of  the  antibody allowing a  single  variable region (i.e.  a  single  specificity)  to  have  several
effector capabilites (reviewed in Stavnezer and Schrader, 2014; Stavnezer et al., 2008; Xu et al., 2012). As
a result of the GC reaction, B cell clones with high affinity BCRs terminally differentiate into plasmatic
or memory B cells (reviewed in Mesin et al., 2016) (Figure 2).
Besides SHM and CSR, birds and some mammals (rabits,  cows, sheep and pigs) can diversify their
immunoglobulin  loci  by  immunoglobulin  gene  conversion  (IGC),  a  process  of  homologous
recombination  that  replaces  pieces  of  the  VDJ  region  with  portions  of  5’-encoded  pseudo-genes
(reviewed in  Tang and Martin,  2007).  Although mechanistically different,  SHM, CSR and IGC are
triggered by a single enzyme, the activation induced deaminase (AID). 
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Figure 2 |  B cell development, activation and terminal differentiation.  B cells originate from bone marrow
Hematopoietic Stem Cells (HSC). The most distinctive event of B cell differentiation in the bone marrow is V(D)J
recombination. This process takes place during the proB and preB stages through recombination of the variable
regions of the immunoglobulin (Ig) genes. As a result, a primary repertoire of highly diverse BCRs is generated,
with single B cell clones carrying specific rearrangements. Immature B cells expressing a functional rearranged
BCR  migrate  to  the  secondary  lymph  organs  (periphery)  where  they  can  enter  the  Germinal  Center  (GC)
reaction upon antigen encounter.  Interaction with T helper cells (TH) further stimulates the B cell, leading to
clonal expansion and initiating the GC reaction. B cell activation increases AID expression which triggers the
remodeling of Ig genes by Somatic Hypermutation (SHM) and Class Switch Recombination (CSR). B cell clones
that increase the affinity of their BCRs for the cognate antigen will receive stimulatory signals from T follicular
helper  (TFH) and dendritic  cells  (DC).  Depending on the  strength of  BCR signalling these clones will  either
undergo a new round of SHM (low strength; dashed grey line) or differentiate into memory (moderate strength)
or plasma (high strength) cells. On the other hand, B cell clones that decrease the affinity of the BCR for the
antigen will enter apoptosis (red line).
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3. Activation induced deaminase
AID was first identified in a substractive library screening as an upregulated mRNA in CH12F3 cells
stimulated to switch in vitro (Muramatsu et al., 1999). Later on, genetic experiments showed that AID
is absolutely required for SHM and CSR in mice and humans (Muramatsu et al., 2000; Revy et al., 2000)
and for gene conversion in chicken (Arakawa et al., 2002; Harris et al., 2002). Indeed, AID deficiency in
humans leads to an immunodeficiency called Hyper IgM type II (HIGM2) syndrome  (Revy et al.,
2000).  The genetic analysis of these patients, together with new cases later identified  (Caratão et al.,
2013; Durandy, 2009; Imai et al., 2005; Meyers et al., 2011; Quartier et al., 2004) has allowed a better
understanding of the structure-function organization of AID protein. AID is a small, 198aa protein
with  a  molecular  mass  of  24KDa.  It  is  very  well  conserved  between  mice  and  humans,  with  an
aminoacid sequence homology of ~92%. AID comprises a nuclear localization signal (NLS) in the N-
terminal region (residues 1-30) and a nuclear export signal (NES) in the C-terminal region (residues
183-198) that control AID shuttling to and from the nucleus (Ito et al., 2004; explained in more detail
in chapter 3.4);  a catalytic  CMP/dCMP-type deaminase domain placed in the central region of the
protein (residues 23-129); and an APOBEC-like domain (residues 108-181). Up to date, 40 different
AID mutations have been identified in HIGM2 patients (Caratão et al., 2013). AID mutants in the N-
terminus have been shown capable of CSR but not SHM (Shinkura et al., 2004), whereas AID mutants
in the C-terminus can initiate SHM but not CSR (Barreto et al., 2003; Ta et al., 2003). Pure AID protein
has not  been crystalized to date,  but  two different  labs have resolved the crystal  structure of  AID
soluble variants, which provided some hints to AID biology: Goodman’s lab identified a “specificity
loop” accounting for AID preference to deaminate WRC (W = A/T; R = A/G) motifs  (Pham et al.,
2016, 2017); Wu’s lab reported a “bifurcated substrate-binding surface” which explains the preference of
AID to act on G4 structures by simultaneous capture of two adjacent single-stranded DNA strands
(Qiao et al., 2017).
Due to its homology to APOBEC1, an RNA editing enzyme, AID was first proposed to act on RNA.
However, this hypothesis has been abandoned in light of genetic and biochemical evidence proving that
AID deaminates cytidine residues on DNA (Chaudhuri et al., 2003; Maul et al., 2011; Petersen-Mahrt et
al., 2002; Pham et al., 2003; Ramiro et al., 2003); and targets ssDNA but not dsDNA, RNA or DNA-
RNA hybrids (Bransteitter et al., 2003; Chaudhuri et al., 2003; Dickerson et al., 2003; Pham et al., 2003) .
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In this chapter we will introduce the molecular mechanisms underlying these two key reactions for
secondary antibody diversification.
3.1. The Neuberger model for AID deamination
In 2002, Neuberger’s lab proposed a unifying model to explain how DNA deamination by AID could
initiate both SHM and CSR (Petersen-Mahrt et al., 2002) building on a previous speculative model for
SHM  by  Scharff  and  colleagues  (Poltoratsky  et  al.,  2000) and  on  the  idea  that  all  diversification
programs might  be  triggered by a  common type of  DNA lesion  (Ehrenstein and Neuberger,  1999;
Maizels, 1995; Sale et al., 2001; Weill and Reynaud, 1996). Cytosine (C) deamination by AID would
turn it into a uracil (U) and generate a U:G mismatch in the DNA. The U:G mismatch could be directly
replicated so that an adenine residue (A) would be introduced opposed to the uracil, leading to a C→T
transition mutation in one of the daughter cells (or a G→A transition if the deamination ocurred in the
non-transcribed  DNA  strand)  (Phase  Ia  of  SHM;  (Petersen-Mahrt  et  al.,  2002;  Rada  et  al.,  1998;
Wiesendanger et al., 2000; Figure 3). Alternatively, the U:G mismatch could be recognized by the DNA
repair  machinery,  namely  the  Base  Excision  Repair  (BER)  or  Mismatch  Repair  (MMR) pathways.
Uracil-N-glycosylase (UNG) could detect the U:G mismatch and remove the uracil, leaving an abasic
site  that  would  be  replicated  through  by  translesion  synthesis  (TLS)  polymerases  enabling  the
generation of both C→T transitions and C→G or C→A transversions (Phase Ib of  SHM; (Petersen-
Mahrt et al., 2002; Rada et al., 1998; Wiesendanger et al., 2000; Figure 3). Alternatively, the recognition
of the U:G mismatch by the MMR pathway via MutS Protein Homolog 2/6 (MSH2/6) dimer would
account for mutations at A/T nucleotides (Phase II of SHM; Rada et al., 1998; Wiesendanger et al.,
2000;  Figure 3). These molecular pathways could explain SHM triggered by a C→U deamination. In
addition, abasic sites could be substrates for endonucleases and generate single strand breaks close to
the mismatch. Two proximal abasic sites in opposite  strands could generate a double strand break
(DSB) and thus initiate CSR (Figure 3; further explained in chapter 3.2).
This  deamination  model  has  been  extensively  validated  through  genetic  evidence,  which  will  be
explained below.
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Figure 3 | Neuberger’s deamination model. Schematic representation of the DNA deamination model. Cytosine
deamination by AID generates a U:G mismatch that can be either directly replicated over or further processed by
the Base Excision Repair (BER) and/or Mismatch Repair (MMR) pathways to give rise to point mutations (SHM)
or double strand breaks -DSB- (CSR). Direct replication of the unrepaired uracil will lead to a C→T transition
mutation  in  one  of  the  daughter  cells.  Furthermore,  the  U:G  mismatch  can  be  recognized  by  the  MSH2/6
heterodimer which recruits exonuclease I (EXO I) and excises the mismatch and a stretch of the surrounding
DNA. The gap will be filled by Pol η, giving rise to mutations at A/T pairs adjacent to the deaminated cytosine.
The U:G mismatch can also be recognized by UNG, which generates an abasic site by uracil excision. On one
hand, this abasic site can be processed by APE1/2 and lead to DNA double strand breaks that can be sensed by the
Non-Homologous End Joining pathway (NHEJ) and trigger CSR. On the other hand, translesion polymerases
(TLS), such as  Rev1, can replicate the abasic site producing transition and transversion mutations at C/G pairs.
See text for further details.
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3.1.1. Uracil-N-Glycosylase in Somatic Hypermutation
Evidence for the role of UNG in antibody diversification came from three genetic studies from the
Neuberger  lab  performed in bacteria  (Petersen-Mahrt  et  al.,  2002),  chicken DT40 cells  (Noia  and
Neuberger, 2002) and mice (Rada et al., 2002). First, processing of AID-induced uracils by UNG was
shown in AID-expressing  E. coli (Petersen-Mahrt et al., 2002). Later, chemical inhibition of UNG in
DT40 B cells revealed a shift in the mutational pattern of the Ig variable region to a severe increase in
transitions and an equivalent  reduction in transversions at  C:G pairs  (Noia and Neuberger,  2002).
Furthermore,  a  mouse  model  deficient  for  UNG showed a similar  mutation pattern at  C:G, while
mutations at  A:T pairs  remained practically  unaltered in the absence of  UNG (Rada et  al.,  2002).
Remarkably, this phenotype has been also observed in humans bearing inactivating mutations in UNG
(Imai  et  al.,  2003).  These  studies  showed  that:  1)  UNG  is  critical  for  the  generation  of  C/G
transversions; 2) in its absence the U:G mismatches can be directly replicated to give raise to C/G
transitions or processed by the MMR, main responsible for the introduction of A/T mutations (see
below).  Multiple evidence has further reinforced the role of UNG in antibody diversification (Krijger
et al., 2009; Maul et al., 2011; Ranjit et al., 2011; Saribasak et al., 2006; Sharbeen et al., 2012; Zahn et al.,
2013; reviewed in Methot and Di Noia, 2017).
In general, misincorporated nucleotides are recognized by the BER pathway and polymerase β mediates
high-fidelity canonical repair of the abasic sites generated by UNG. However, in the context of AID-
induced deaminations at Ig loci, these mismatches can be either faithfully repaired by Pol β (Wu and
Stavnezer, 2007) or replicated in an error-prone fashion, leading to the mutation pattern explained
above. It has been proposed that this mutagenic resolution could be carried out by TLS polymerases.
TLS polymerases are specialized in the insertion of bases opposite DNA lesions that stall the replication
fork. Due to their large, relaxed catalytic site they are more prone to error than conventional replicative
polymerases. There is solid evidence of a role for REV1 in the generation of transversion mutations
dowstream  UNG  (Jansen  et  al.,  2006):  REV1  is  very  efficient  introducing  deoxycytidine  residues
opposed to an abasic site  (Nelson et al., 1996) and its deficiency in mice leads to a complete loss of
C→G transversions in the coding (non-transcribed) strand and a reduction in the non-coding strand
(Jansen et al., 2006). This suggests that other TLS polymerases could be involved in the generation of
C→G transversions (Reviewed in  Weill  and Reynaud,  2008).  Additionally,  the  implication  of  other
bypass polymerases, such as polymerase ζ (Reviewed in  Seki et al., 2005; Weill and Reynaud, 2008),
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polymerase θ  (Di Noia and Neuberger, 2007), polymerase ι  (Faili et al., 2002; Maul et al., 2016) or
polymerase  μ  (Domínguez  et  al.,  2000;  Ruiz  et  al.,  2001,  2004), cannot  be  ruled  out.  While  the
mechanism responsible for the switch from high-fidelty to error-prone polymerases remains unkown,
recent studies point to monoubiquitination of PCNA as a mediator (Arakawa, PloS Biol, 2006).
Besides UNG, there are three more DNA glycosylases able to escind uracils in vertebrates: SMUG1, 
TDG and MBD4. However, these seem to play little if any natural role in antibody diversification (Di 
Noia et al., 2006; Rada et al., 2004; Visnes et al., 2009).
3.1.2. Mismatch Repair in Somatic Hypermutation
In addition to mutations at  C:G pairs,  which are explained by either direct  replication of the U:G
mismatch or error-prone BER, SHM also generates mutations at A/T nucleotides. This outcome mostly
originates  from the action of  the MMR pathway,  as  demonstrated by the severe reduction in A/T
mutations  found  in  mice  deficient  for  Msh2 or  Msh6 (Phung  et  al.,  1998;  Rada  et  al.,  1998;
Wiesendanger et al., 2000). The residual A/T mutations in this models suggest that UNG could be also
contributing to this kind of mutations (Delbos et al., 2007; Rada et al., 2004). Indeed, mice deficient for
UNG and MSH2 present  an Ig mutation pattern completely devoid of C/G transversions and A/T
mutations and exclusively composed of C/G transitions (Rada et al., 2004). This indicates, first, that in
the  absence  of  UNG  and  MSH2  U:G  mismatches  are  directly  replicated;  and  second,  that  uracil
excision by UNG provides a backup for the second phase of SHM (Rada et al., 2004).
The MSH2/6 complex can recognize  and excise  the  U:G mismatch,  together  with  a stretch of  the
surrounding DNA, by  exonuclease I  (Bardwell et al., 2004). Monoubiquitinated PCNA then recruits
TLS polymerases  to  fill  the  gap,  which  leads  to  transitions  and  transversions  at  A/T  nucleotides.
Evidence points to polymerase η (pol η) as the main contributor to this error-prone synthesis (Delbos
et al.,  2005, 2007; Wilson et al.,  2005): pol η functionally interacts with the MSH2/MSH6 complex
(Wilson et  al.,  2005);  its  deficiency  produces  a  C/G biased mutation  pattern  (85% C/G,  15% A/T
mutations) (Delbos et al., 2005); and the combined absence of MSH2 and pol η in mice completely
abrogates  mutations  in  A/T  pairs  (Delbos  et  al.,  2007).  Only  in  the complete  absence  of  pol  η,
polymerase κ can exert a backup function and contribute to A/T mutations (Faili et al., 2009).
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A long standing question in the field is understanding why BER and MMR, which are usually involved
in the faithful repair of DNA lesions, contribute to introduce mutations in the context of AID-induced
U:G mismatches  (Krokan et al., 2014). In this regard, previous work from our lab showed that the
choice between an error-free or error-prone outcome by UNG is influenced by the local  sequence
context in the IgH locus (Pérez-Durán et al., 2012). In addition, Liu and colleagues proposed that the
choice between error-prone and error-free repair by BER and MMR is locus specific (Liu et al., 2008).
In this work, we will explore the biology of BER and MMR pathways to try to add to the understanding
of these relevant questions. 
3.2. AID and class switch recombination (CSR)
CSR is a recombination reaction that takes place between switch regions, highly repetitive sequences
located upstream of all the IgH constant genes, with the exception of Cδ. B cells emerging from the
bone marrow express IgM or IgD by alternative splicing. CSR replaces the Cμ/Cδ IgH constant region
by a downstream (Cα, Cε or Cγ) constant region and involves the generation of DNA double strand
breaks (DSBs), which act as a substrate for recombination. CSR is  triggered by the deamination of
cytosine residues in the IgH switch regions by AID, which generates a U:G mismatch. Uracil removal
by UNG is a crucial event for CSR, since mice deficient for UNG  (Rada et al.,  2002) and humans
bearing inactivating mutations in UNG  (Imai et al.,  2003) have drastically impaired CSR. A single
strand DNA break in the abasic  site is  then introduced by APE1/2 endonucleases  (Guikema et al.,
2007). If two ssDNA breaks occur close enough on opposite strands of the DNA, they can give raise to
a DSB. The formation of DSBs in Sμ (donor) and a downstream switch region -Sα, Sε or Sγ- (acceptor)
enables recombination by Non-Homologous End Joining (NHEJ) and results in the replacement of IgH
Cμ by a different IgH C segment, thus completing CSR. This process requires the coordinated action of
a number of  different proteins:  MRE11-RAD50-NBS1 (MRN complex) senses the DSB; ATM then
binds MRN via NBS1 and phosphorylates NBS1, TP53BP1, P53, CHK2, and H2AX, which causes the
accumulation of other repair proteins and results in repair by NHEJ. In addition, Ku70-Ku80 can also
bind to DNA and recruit enzymes that effect the recombination, such as XRCC4-ligase IV complex,
which  can  fuse  two  DSBs  to  complete  the  reaction  (reviewed  in  Stavnezer  and  Schrader,  2014;
Stavnezer et al., 2008; Xu et al., 2012).
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3.3. AID and gene conversion
In contrast to mice and humans, chickens have a single copy of the V and J segments at IgH and IgL
loci,  and nearly identical D segments in IgH, and they diversify their antibodies primarily by gene
conversion. Gene conversion is a diversification mechanism that generates templated changes in the
sequence of the IgV region making use of the 25 pseudo variable gene segments (ΨV) upstream the VL
or VH regions as templates to replace homologous sequences of functionally rearranged VJ and VDJ
segments. Gene conversion is initiated by deamination of cytosines into uracils by AID (Arakawa et al.,
2002; Harris et al., 2002). Uracils are then excised by UNG (Di Noia JM and Neuberger MS, 2004; Noia
and Neuberger, 2002) and the resulting abasic site can give rise to SSBs or DSBs that are resolved by the
Homologous Recombination machinery. Thus, either abasic sites or SSB/DSBs can trigger IGC as long
as there are 3’ free ends to initiate homology search and prime DNA synthesis. In the presence of donor
ΨV sequences, the 3’ free end is used for homology search and invasion of the ΨV region by the V
region forming a loop. Extension through the loop copies the template ΨV sequence into the V region
and the structure is  then resolved by the HR machinery,  generating diversity in the IgV segments
(reviewed in  Tang and Martin, 2007). Therefore, the upstream pseudogene only serves as a template
and remains unaltered, allowing further rounds of gene conversion. Chickens use gene conversion at
different stages of B-cell development. After V(D)J recombination in the yolk sac, B cell precursors
colonize  the  Bursa  of  Fabricius,  and  diversify  their  V  regions  through  several  rounds  of  gene
conversion to generate a pool  of  naïve B cells  with a diverse range of receptor specificities.  In the
secondary  lymphoid  organs,  chicken  GC  B  cells  diversify  their  antibody  repertoire  both  by  gene
conversion and SHM (Arakawa et al., 1998; reviewed in Tang and Martin, 2007). 
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3.4. Target specificity of AID
3.4.1. AID targeting to immunoglobulin genes
One of the most relevant, yet unresolved, questions about AID biology is to understand what are the
molecular players that drive it to the Ig genes and what defines the boundaries of mutagenesis within
the Ig loci to the variable and switch regions.
Long  before  the  discovery  of  AID,  mutation  analysis  of  collections  of  human  V(D)J  rearranged
sequences revealed that SHM preferentially focuses in small, degenerate motifs called hotspots (Dörner
et  al.,  1998;  Rogozin and Diaz,  2004;  Rogozin and Kolchanov,  1992).  These  hotspots  were initially
defined as WRCY and their reverse complement RGYW (Dörner et al., 1998; Rogozin and Kolchanov,
1992) and further refined to WRCH/DGYW (Rogozin and Diaz, 2004), where W = A/T; R = A/G; Y =
C/T, H = A/C/T; D = A/G/T. Biochemical evidence proved that AID preferentially mutates cytosines
lying within WRC motifs (Bransteitter et al., 2003; Pham et al., 2003); and in vivo analysis of SHM has
also demonstrated a preference for AID to mutate WRCY motifs  (Pérez-Durán et al., 2012; Yeap et al.,
2015; Zarrin et al., 2004). However, it seems obvious that the low complexity of these sequence motifs
makes them highly unlikely to be the sole contributors to AID target specificity.
Transcription is  an absolute requirement for AID activity on Ig genes.  The first hint  suggesting an
important role for transcription in SHM came from the observation that SHM of an Igκ transgene was
dependent on the presence of the 3’ kappa transcriptional enhancer (Betz et al., 1994).  Later on, the
Storb lab showed in a transgenic mouse model that a kappa promoter placed upstream of an Ig Cκ
region was enough to trigger SHM in this normally unmutated sequence  (Peters and Storb, 1996).
Further work revealed a direct correlation between transcription levels and hypermutation (Fukita et
al., 1998). Later on, biochemical studies in synthetic DNA substrates and E. coli systems proved that
AID targets ssDNA that is exposed during transcription  (Chaudhuri et al., 2003; Pham et al., 2003;
Ramiro  et  al.,  2003).  The link  between expression  and  AID activity  has  since  been  reinforced  by
multiple evidences (reviewed in  Storb, 2014). However, transcription alone is not enough to explain
AID targeting, since genes known to be highly transcribed in B cells do not accumulate mutations
(reviewed in Kenter et al., 2016).
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A role for secondary structures in AID targeting has also been proposed. Transcription through the low
complexity,  GC  rich  IgH  switch  regions  can  generate  R-loops  and  G-quadruplexes.  R-loops  are
structures that form during transcription when the nascent RNA hybridizes to the template DNA, thus
producing an RNA-DNA hybrid that displaces the non-template ssDNA. R-loops can also arise during
replication, where RNA-DNA hybrids prime DNA synthesis (reviewed in (Santos-Pereira and Aguilera,
2015)). G-quadruplexes (G4) are four-stranded structures formed by the stacking of G-quartets, which
arise from intra-strand base pairing of guanines by hydrogen bonding into planar structures. Structural
analysis of a soluble form of AID showed that it preferentially binds “structured substrates” such as G-
quadruplex and branched DNA (Qiao et al., 2017), and a recent work reported that spliced intronic IgH
transcripts that form G4 RNA structures can bind AID and contribute to its targeting to switch regions
for mutation  (Zheng et al., 2015). Regarding R-loops, the classic view posits that they favor SHM by
generating  abundant  ssDNA  substrates  for  AID  activity.  However,  this  hypothesis  has  not  been
supported by in vivo evidence and the contribution of R-loops to SHM remains speculative (Parsa et al.,
2012; Romanello et al., 2016; Ronai et al., 2007; reviewed in Pavri et al., 2017). Conversely, there is solid
evidence that  R-loops occur  in switch regions  (Yu et  al.,  2003) and are  required for  efficient  CSR
(Shinkura, Nat Imm, 2003), with R-loop frequency directly correlating with CSR efficiency (Zhang et
al., 2014).
Regulatory  sequences  at  the  Ig  locus  also  play  a  role  in  AID  targeting  beyond  their  effect  on
transcription. A first example was provided by the finding that an intronic 3’ enhancer was required for
SHM  of  an  Igκ  transgene  (Betz  et  al.,  1994).  More  recently,  an  enhancer  called  DIVAC  (from
Diversification Activator) (Blagodatski et al., 2009) has been identified as crucial for SHM in chicken
DT40 cells (Blagodatski et al., 2009) and found conserved in mammalian Ig loci  (Buerstedde et al.,
2014). In addition, the IgH 3’ regulatory region (3’RR), long known to be required for CSR (reviewed
in Pinaud et al., 2011), has also been shown necessary for SHM (Rouaud et al., 2013). The mechanisms
involved  in  AID targeting  by  these  regulatory  elements  remain  unknown.  Given the  fact  that  the
DIVAC contains many transcription factor binding sites and the 3’RR spans ~30Kb, it seems very likely
that they act as a docking platform to recruit other cofactors that in turn contribute to the recruitment
of AID, such that AID would target the Ig loci as part of a multiprotein complex. Back in 1996, a SHM
model was proposed by the Storb lab in which a “mutator factor” (AID) travelled together with the
transcription machinery  (Peters and Storb, 1996; Storb et al.,  1998). On those lines, several studies
indicate that AID specifically interacts with components of the transcription machinery, such as RNA
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polymerase II (RNAP II), SPT5 or the RNA exosome, among others (Basu et al., 2011; Nambu et al.,
2003; Nowak et al., 2011; Pavri et al., 2010; Xu et al., 2010). Genome-wide profiling of RNAP II and
SPT5 in B cells led to the hypothesis that AID targets DNA at places where RNA PolII is stalled, with
SPT5 as the main responsible for recruiting AID to halted RNA PolII (Pavri et al., 2010). This idea was
reinforced  by  the  finding  that  topoisomerase  I  inhibition  increases  SHM  by  preventing  DNA
unwinding ahead of the transcription fork and contributing to RNA PolII pausing (Maul et al., 2015).
Furthermore, the RNA exosome also interacts with RNAP II via SPT5/6 and has been implicated in the
targeting of AID to both strands of transcribed dsDNA (Basu et al., 2011). Finally, AID activity at the
three Ig loci has been reported to occur within superenhancer (SE) domains interconnected by long-
range interactions (Qian et al., 2014). Together, these findings suggest that the transcription machinery,
RNA PolII stalling, the recruitment of the RNA exosome and transcription regulatory elements favor
AID targeting to the Ig loci.
A recent work approached the notion that the Ig genes provide a privileged context for SHM. Yeap and
colleagues  used  a  mouse  model  in  which  a  “passenger”  sequence  was  introduced  in  place  of  the
endogenous IgV exon on one IgH allele, while the other allele was normal to ensure B cell maturation
and GC formation  (Yeap et  al.,  2015).  They found that  both alleles were  equally mutated by AID,
indicating that gene location rather than Ig primary sequences have a major role for SHM.
3.4.2. AID targeting to non-immunoglobulin loci
Despite primarily targeting Ig loci, AID also targets other regions in the genome, although at much
lower frequencies. The first evidence for AID off-targeting was provided by the finding that  Bcl6 was
mutated in human memory, but not naive, B cells (Shen et al., 1998) and in human lymphoma samples
(Pasqualucci  et  al.,  1998),  with  Bcl6 consistently  displaying  the  mutation  hallmarks  of  Ig  SHM.
Following this discovery, additional genes such as Fas (Müschen et al., 2000), Cd79a/b (Gordon et al.,
2003),  Myc,  Pim1,  Pax5, RhoH (Pasqualucci  et  al.,  2001) and many others  (Liu  et  al.,  2008) were
identified to be mutated by AID. In vitro transgene mutation assays further support these observations:
AID has been shown to mutate transcriptionally active transgenes in lymphoma cell lines (Bachl et al.,
2001) and in AID-overexpressing non-B cell lines (Yoshikawa et al., 2002). In addition, AID was proved
essential for the generation of c-myc/IgH translocations (Ramiro et al., 2004) by inducing DNA DSBs
both at IgH and c-myc loci  (Robbiani et al., 2008). These and other studies  (Kovalchuk et al., 2007;
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Pasqualucci  et  al.,  2008) provided  the  first  link  between  AID off-target  activity  and  chromosome
translocations (TCs). Further work reported that AID can generate DNA lesions (DSBs) in other non-
Ig  genes,  which  can  lead  to  their  translocation  (Robbiani  et  al.,  2009).  Finally,  high-throughput
profiling of AID binding showed widespread interaction of AID with many genes across the genome
(Yamane et al., 2011) and genome-wide maps of AID-induced TCs and DSBs suggested that AID can
be mistargeted to hundreds of off-targets (Chiarle et al., 2011; Klein et al., 2011; Staszewski et al., 2011).
The mechanisms driving AID off-targeting remain object of intense study. Recent publications indicate
that many TCs triggered by AID occur at regions where sense and antisense transcription converge
(Meng et al., 2014; Qian et al., 2014). This convergent transcription (ConvT) arises at superenhancers,
where antisense transcription originates within sense transcribed genes (Meng et al., 2014; Qian et al.,
2014). In the same line, the RNA exosome has also been implicated in targeting AID to divergently
transcribed loci  (Pefanis et  al.,  2014). A hypothetical model based on these findings posits that:  1)
ConvT induces RNAP II stalling, which helps recruit  AID via SPT5; 2) RNA exosome detects and
degrades antisense transcripts while contributing to AID recruitment; 3) Both RNAP II stalling and
RNA exosome action facilitate AID access to ssDNA. Furthermore, ChIP-Seq studies suggest that AID
off-targeting may also have an epigenetic component, with marks of active enhancers and transcription
elongation providing nucleosome accessibility to AID  (Wang et  al.,  2014).  Together,  these  findings
begin to define a set of transcription-related features relevant for AID off-targeting, but further work
will be necessary to unveil the molecular mechanisms responsible for AID aberrant activity (Figure 4).
3.5. Regulation of AID activity
3.5.1. Transcriptional regulation of AID
Aicda expression is mostly restricted to activated B cells and it is triggered by cytokines and cell to cell
interactions in the context of an antigen induced activation. Aicda is highly expressed in GC B cells, but
strongly repressed in memory and plasmatic B cells (Crouch et al., 2007; Shaffer et al., 2002). Aicda can
be regulated by both activating and repressing transcription factors, such as c-MYB, E2F, ID2 -negative
regulators- or PAX5 -a positive regulator- (Gonda et al., 2003; Tran et al., 2010). Indeed, there are 4 well
conserved regulatory regions in Aicda gene containing binding sites for up to 19 transcription factors
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(Stavnezer, 2011). Thus, AID expression is tightly linked to the transcriptional program of the activated
B cell and the balance between repressing and activating signals limits AID expression to this specific
stage. AID haploinsufficiency (Sernández et al., 2008; Takizawa et al., 2008) further supports that AID
levels are physiologically limited, maybe to minimize its deleterious function.
3.5.2. Post-transcriptional regulation of AID
Aicda expression levels can also be regulated by microRNAs, non-coding RNA molecules of small size
(20-23nt)  that  bind  complementary  mRNAs  and  either  promote  their  degradation  or  block  their
translation. There is strong evidence for AID regulation by two microRNAs, miR-155 and miR-181b,
which bind conserved sites in the 3’-UTR of Aicda and repress AID expression. miR-155 parallels AID
expression in splenic B cells activated in vitro (Teng et al., 2008). Mutation of miR-155 binding site at
the 3’-UTR of Aicda leads to a 2-3x increase of AID mRNA and protein and increases CSR (Dorsett et
al., 2008; Teng et al., 2008) and IgH/c-myc translocations (Dorsett et al., 2008). On the other hand,
miR-181b  is  expressed  in  resting  B  cells  and  progressively  downregulated  upon  B  cell  activation
(Yébenes et al., 2008). miR-181b overexpression downregulates  Aicda mRNA levels and impairs CSR
(Yébenes et al., 2008). Together, miR-155 and miR-181b fine-tune AID expression, with experimental
evidence suggesting a non-overlapping function by which miR-181b would prevent premature AID
expression in resting B cells and miR-155 would act as safety control to limit AID levels in activated B
cells.
3.5.3. Post-translational regulation of AID
A further layer of regulation occurs at the post-translational level, where subcelullar localization and
stability  of  AID protein,  together with  phosphorylation,  balance AID quantity  and activity.  AID is
predominantly cytoplasmic in resting B lymphocytes. This is mostly due to the cooperative action of
active  cytoplasmic  retention  (Methot  et  al.,  2015;  Patenaude  et  al.,  2009) and  nuclear  export
mechanisms (Brar et al., 2004; Ito et al., 2004; McBride et al., 2004). In the cytoplasm, AID interacts
with HSP90, which prevents its proteasomal degradation  (Orthwein et al., 2010); and EEF1A, which
indepently  contributes  to  sequestering  AID  in  the  cytoplasm  (Methot  et  al.,  2015).  Upon  B  cell
activation, AID shuttles to the nucleus by an active transport mechanism (Ito et al., 2004; Patenaude et
47
Introduction
al., 2009) where it exerts its deaminating function. Of note, AID is quickly degraded in the nucleus by
both ubiquitin dependent and independent pathways (Aoufouchi et al., 2008; Uchimura et al., 2011).
Thus,  AID is  much more stable in the cytoplasm than in the nucleus,  which safeguards the B cell
genome  from  its  deletereous  activity.  In  addition,  AID  activity  can  also  be  regulated  by
phosphorylation. There is experimental evidence for phosphorylation of AID in up to five conserved
residues (Ser3, Thr27, Ser38, Thr140 and Tyr184), although only three have been proven to affect AID
activity  when phosphorylated: Ser38 and Thr140,  which increase  AID activity  in  vivo;  and  Thr27,
which inhibits  SHM and CSR  in  vitro (Basu  et  al.,  2005;  McBride  et  al.,  2006,  2008;  reviewed in
Orthwein and Di Noia, 2012).
3.5.4. Cell-cycle linked regulation 
Recent  evidence  points  to  a  cell-cycle  linked  regulation  of  AID  activity  that  coordinates  protein
shuttling to the nucleus with a stage of DNA damage tolerance that favours AID mutagenesis. In that
sense,  it  has  been  shown  that  nuclear  localization  of  AID in  G1  phase  is  well  tolerated,  while  it
compromises  cell  viability  during S-G2M  (Le and Maizels,  2015).  In addition,  AID degradation is
slower in G1 than in S or G2-M phase in this system (Le and Maizels, 2015). Further work in primary B
cells has demonstrated that IgH loci deamination is restricted to early G1 phase and suggested that
nuclear  disassembly/reassembly  together  with  post-mitotic  transcription  resumption  renders  DNA
vulnerable to damage (Wang et al., 2017).
Together, the mechanisms presented above define a tight spatiotemporal regulation of AID activity that
balances the introduction of mutations in Ig loci with the maintenance of genome integrity.
48
Introduction
3.6. AID biology beyond B lymphocytes: expression and activity in non-lymphoid tissues
Although initially believed to be exclusively expressed in germinal center B cells,  numerous studies
have reported AID expression outside the B cell compartment. AID expression has been detected in a
variety of pluripotent tissues, such as oocytes, spermatocytes, primordial germ cells or embryonic stem
cells (Bhutani et al., 2010; Morgan et al., 2004; Popp et al., 2010; Schreck S et al., 2006); and has been
proposed to play a role in epigenetic programming during early development through the deamination
of 5-methylcytidine into thymine (Bhutani et al., 2010; Morgan et al., 2004; Popp et al., 2010). However,
the  involvement  of  AID  in  active  demethylation  remains  controversial  (reviewed  in  Ramiro  and
Barreto, 2015). In addition, AID is expressed in these tissues at levels orders of magnitude lower than
those  found  in  GC  B  cells,  which  poses  some  concern  on  the  physiological  relevance  of  these
observations. Other studies have linked inflammation to AID expression through the NF-κB pathway,
which normally contributes to the induction of AID in B lymphocytes (Dedeoglu et al., 2004; Tran et
al., 2010). For instance, in vitro activation of this pathway by TNFα triggers AID expression in different
non-B cell types (Endo et al., 2007, 2008; Matsumoto et al., 2007). In addition, infection by H. pylori
produces aberrant  AID expression in human gastric  epithelial  cells  (Matsumoto et al.,  2007);  liver
tissue  from  hepatitis  patients  expresses  AID  (Kou  Tadayuki  et  al.,  2006);  and  mouse  models  of
inflammatory  bowel  disease  present  AID expression  in  colon epithelium  (Takai  et  al.,  2012).  This
ectopic  AID  expression  has  been  related  to  gastric  carcinogenesis  (Matsumoto  et  al.,  2007),
hepatocarcinoma (Endo et al., 2007; Kou Tadayuki et al., 2006) and colitis-associated colorectal cancer
(Takai et al., 2012) where somatic mutations (presumably introduced by AID) have been identified in
Tp53,  c-myc  and Pim1.  Additionally,  several  epithelial  breast  cancer cell  lines  have  been shown to
express AID (Babbage et al., 2006). These findings suggest that AID deregulation could contribute to
the  development  of  a  wide  variety  of  non  B-cell  neoplasias,  particularly  in  the  epithelial  context.
Previous work from our lab tested this hypothesis by generating conditional mouse models of AID
overexpression in pancreas and colon epithelium and showed that AID expression alone, even at levels
similar to those found in GC B cells, is not sufficient to promote carcinogenesis in these tissues (Pérez‐
García et al., 2015).
49
Introduction
4. AID off-targeting and lymphomagenesis
As we have introduced before, AID targeting is not restricted to the Ig loci. SHM has been found in a
number of non-Ig genes both in humans and mice (Liu et al., 2008; Müschen et al., 2000; Pasqualucci et
al.,  2001; Shen et al.,  1998), and AID can generate mutations and DSBs that  lead to chromosomal
tranlocations between the IgH locus and a proto-oncogen, a hallmark of many mature human B cell
lymphomas (Kovalchuk et al., 2007; Pasqualucci et al., 2008; Ramiro et al., 2004, 2006, Robbiani et al.,
2008, 2009). AID depletion delays the onset of lymphomagenesis in different  in vivo models, such as
IL6  (Ramiro  et  al.,  2004)  and  pristane  (Kovalchuk  et  al.,  2007)  induced  plasmacytomas  or  Bcl6
overexpression driven lymphomas (Pasqualucci et al., 2008). This establishes a direct link between AID
off-targeting and B cell malignant transformation. Moreover, it has been described that the generation
of translocations also depends on UNG (Ramiro et al., 2006), which suggests a common mechanism
for  SHM,  CSR and  translocations.  Finally,  a  mouse  model  overexpressing  AID in  B cells  showed
extensive genomic damage and widespread DSBs, indicating that AID may be sufficient to produce the
DNA lesions underlying lymphomagenesis (Robbiani et al., 2009).
Therefore,  there  is  strong  evidence  for  AID off-target  activity  and the  development  of  lymphoma
through  the  generation  of  chromosome  translocations.  In  this  work,  we  aim  at  improving  the
understanding  of  the  molecular  mechanisms  that  define  AID  specificity.  This  will  likely  provide
insights on how genomic integrity is maintained in hypermutating B lymphocytes and why SHM is
mistargeted to genes relevant for carcinogenesis.
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Figure  4  |  AID activity  during  the  Germinal  Center  Reaction.   Schematic  representation  of  AID  activity
outcomes in the Germinal Center. Upon activation, B cells express high levels of AID, which is translocated to the
nucleus. Once there, AID deaminates cytosine residues in the variable or switch regions of the Ig loci to trigger
SHM and CSR, respectively (left panel). However, AID activity is not restricted to Ig genes and can also act on
other genes (off-targets),  leading to point mutations or translocations with oncogenic potential  (right  panel).
Adapted from Methot&Di Noia, 2017.
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II.  objectives
Objectives
Activation  Induced  Deaminase  (AID)  plays  a  critical  role  in  the  immune  response  by
diversifying  the  antibody  repertoire  through  the  deamination  of  cytosines  in  the
immunoglobulin  loci.   However,  it  can  also  introduce  DNA lesions  in  other  regions  of  the
genome, leading to mutagenic events and translocations with oncogenic potential. However, the
mechanisms driving AID target specificity remain poorly understood. In this thesis work, we
approached the following objectives:
1.  To  develop  a  high  throughput  strategy,  based  on  target  enrichment  and  next  generation
sequencing, for the identification of AID targets.
2. To identify and characterize AID targets in Germinal Center B lymphocytes.
3. To analyze the contribution of the Base Excision Repair and Mismatch Repair pathways to the
resolution of AID-induced deaminations.
4.  To  analyze  the  contribution  of  AID  mutational  activity  to  Germinal  Center  derived
malignancies.
III. methods
Materials and methods
Mice 
Ung and  Msh2 mutant mice used in this study were generated by crossing  Ung-/- mice  (Nilsen et al.,
2000) and  Msh2-/- mice  (Reitmair  et  al.,  1995).  Aicda-/- mice  have  been  previously  described
(Muramatsu et al., 2000). Mice were housed in specific pathogen-free conditions. Male and female mice
between  20-28  weeks  were  used  for  the  experiments,  unless  specified  otherwise  (gene  expression
profiling by RNA-Seq). Number of animals per group to detect biologically significant effect sizes was
calculated using appropriate statistical sample size formula. All experiments were done in concordance
to EU Directive 2010/63EU and Recommendation 2007/526/EC regarding the protection of animals
used for experimental and other scientific purposes, enforced in Spanish law under RD 53/2013.
Isolation of mouse B cells from secondary lymphoid organs
Mice were euthanized by CO2 exposure. Peyer’s patches were isolated from the ileum of necropsied
mice and stored in ice in “complete” RPMI medium (RPMI-1640 -Sigma Aldrich- supplemented with
10% (v/v) Fetal Bovine Serum (FBS), HEPES (20mM), penicilin (50 U/ml) and streptomicin (50μg/ml)
until processed. Organ disgregation was performed in 70μm pore nylon cell strainers (BD Falcon) in
complete RPMI medium and cell suspensions were centrifugued 10’ at 400 x G and 4ºC. Cell pellets
thereof obtained were resususpended in PBS 1X 1% (v/v) FBS.
DNA capture library
A set of 1588 genomic regions was selected as a representation of the genome. Details on gene selection
can be found in “Results” section. Briefly, RNA probes were designed in SureDesign/eArray platform
(Agilent) to capture the first 500bp from the TSS of a collection of 1375 different genes.  To optimize
capture yield, probes covered 50 extra nucleotides at the 5’ and 3’ boundaries of our regions of interest.
Furthermore, they were designed to yield a 5x tiling frequency. This means that each nucleotide to be
captured is covered by at least 5 different probes and implies a high density coverage by 20 tightly tiled
120nt-long baits for each of the 1588 regions to be captured. Finally, a  custom SureSelectXT capture
library was synthesized by the manufacturer. 
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DNA capture and sequencing
Germinal center (Cd19+Fas+GL7+) B cells were isolated from Peyer's patches of  Ung+/-Msh2+/-,  Ung-/-
Msh2+/-, Ung+/-Msh2-/-, Ung-/-Msh2-/- mouse littermates and  Aicda-/- mice (Table 1) by sorting in a BD
Biosciences FACSAria cell sorter after staining with anti-mouse antibodies to Cd19, Fas and GL7 (BD
Biosciences). Staining was perfomed in PBS 1X 1% (v/v) FCS; cells were washed in PBS 1X 1% (v/v)
FCS (10’ centrifugation at 400 x G and 4ºC),  resuspended in “sorting buffer” (PBS 1X 2% (v/v) FCS
15mM HEPES) and filtered through a pre-separation 70μm pore filter (BD Biosciences). FACS sorted
cells were lysed in lysis buffer (50mM Tris pH=8, 200mM NaCl, 10mM EDTA pH=8, 1% SDS) and
proteinase  K  (1/50  from  a  20mg/ml  stock).  Genomic  DNA  (gDNA)  was  purified  by  a  two-step
extraction by phenol:chloroform:isoamyl alcohol (25:24:1) and chloroform followed by precipitation in
absolute  ethanol  plus  Pellet  Paint  coprecipitant  (Merck Millipore)  and washing  with  75% ethanol.
Quantification was done in an Invitrogen Qubit Fluorometer. DNA capture, library preparation and
DNA sequencing was performed by the Genomics Unit at CNIC following manufacturer's instructions.
Briefly, gDNA (1,1μg per sample) was fragmented in a Covaris sonicator to ~150-200 nucleotide long
(average size) fragments and purified using Agencourt AMPure XP beads. Quality was assessed with
the 2100 Bioanalyzer (Agilent).  Then, fragment ends were repaired,  adapters were ligated,  and the
resulting library was amplified and hybridized with our custom SureSelectXT (Agilent) library of RNA
probes. DNA-RNA hybrids were then captured by magnetic bead selection. After indexing, libraries
were single-end sequenced in an Illumina HiSeq 2500 platform following manufacturer's instructions.
Genotype # mice exp1 # mice exp2
Ung-/-Msh2-/- 37 8
Ung-/-Msh2+/- 46 8
Ung+/-Msh2-/- 46 2
Ung+/-Msh2+/- 10 11
Aicda-/- 31 -
Table 1 | Summary of mice used in this study.
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Target enrichment assessment by qRT-PCR
Noxa1,  Ostn and Pcna amplifications were quantified with SYBR green assay (Applied Biosystems) in
an  AbiPrism  AB7900  Standard  real-time  PCR  system.  Gapdh amplifications  were  used  as
normalization controls.  Primers  used for  the  amplifications are indicated in  Table  2. SDS software
(Applied Biosystems) was used for the analysis of the data.
Oligonucleotide Sequence (5'-3')
Gapdh 
Forward TGA AGC AGG CAT CTG AGG G
Reverse CGA AGG TGG AAA GTG GGA G
Ostn 
Forward CAT AGT GTT GCT GTG GTT
Reverse CAT TAT ATT GGT CTG CTG TT
Noxa1 
Forward CGC GGG ACA GCA ATG AGA AG
Reverse CCA TCT ACT CAG TTT CAA GGA
Pcna 
Forward CTC CAG CAC CTT CTT CAG
Reverse TCT CAT CTA GTC GCC ACA
Table 2 | Primers used for qRT-PCR.
Sanger sequencing
Regions to be sequenced were amplified from 160-200ng genomic DNA in 4 independent reactions
(40-50ng  DNA  each)  to  minimize  possible  PCR  biases.  Primers  used  are  indicated  in  Table  3.
Amplification  reactions  were  carried  in  a  final  volume of  25μl  using  2.5U of  Pfu  Ultra  HF DNA
polymerase  (Agilent)  and the  following PCR setup:  95º  for  2  min;  25  (Cd19,  Cdk4)  or  26  cycles
(miR142, Hist1h1b) of denaturation at 94º for 30 s, annealing at 57º (miR142, Hist1h1b) or 58º (Cd19,
Cdk4) for 30 s, extension at 72º for 1 min; final stage of 72º for 10 min. 
3’  A-tailing  was  performed  to  make  PCR  products  suitable  for  TA  cloning  by  adding  0,5μl  Taq
polymerase (New England Biolabs) to each reaction (10’  extension at  72ºC) inmediately after PCR
amplification. PCR products were purified from a 1% agarose gel (Illustra Gel Band Purification Kit,
GE Healthcare) and cloned into pGEM-T Easy vector (Promega) following manufacturer instructions.
Competent  DH5α  E.  Coli  bacteria  were  heat-shock  transformed  with  the  constructs  and  grown
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overnight in LB-Amp IPTG/X-Gal (40μL X-gal; 20μl IPTG per plate) plates. Individual, white (X-Gal
negative) colonies (192-288 per gene) were picked into 96 well plates. Plasmidic DNA was then isolated
(Plasmid MiniPrep Kit, Millipore) and sequenced by Sanger sequencing using SP6 universal primer.
Sequence analysis was performed using SeqMan software (Lasergene).
Oligonucleotide Sequence (5'-3')
Hist1h1b 
Forward ATG CCT TAG ACT TCA CCG CC
Reverse TTG TAA CCT TGA GTC GCC GC
miR142 
Forward CGG TCC CTG GGA AGT TAC AC
Reverse AAC GAG AGG CAA ACA GTC TTC A
Cd19 
Forward GCC CCT CTT CCC TCC TCA TA
Reverse CCT GCA CCC ACT CAT CTG AA
Cdk4
Forward TCT GGC AGC TGG TCA CAT GG
Reverse GAT CAC CAG CTA GTC GTC CC
Table 3 | Primers used for Sanger sequencing.
PCR-Seq to validate machine learning approach
40-50ng  of  genomic  DNA  were  amplified  using  the  primers  included  in  Table  4.  Amplification
reactions were carried in a final volume of 25μl using 2.5U of Pfu Ultra HF DNA polymerase (Agilent)
(95º for 2 min; 26 cycles of 94º for 30 s, 55º for 30 s and 72º for 1 min; final stage of 72º for 10 min).
PCR  products  were  purified  (Illustra  Gel  Band  Purification  Kit,  GE  Healthcare)  following
manufacturer’s  protocol,  fragmented  using  a  Covaris  sonicator  and  checked  for  integrity  and  size
distribution  in  a  2100  Bioanalyzer.  Libraries  were  then  prepared  by  the  CNIC  Genomics  Unit
(NEBNext  Ultra  DNA Library  Prep;  New  England  Biolabs)  following  manufacturer's  instructions.
Sequencing was performed in an Illumina HiSeq 2500 platform. Mutation analysis was performed as
previously described (Pérez-Durán, 2012).
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Oligonucleotide Sequence (5'-3')
Apobec3
Forward GTC TTC CAT AGC CTG CTC ACA
Reverse TAG CTG ACT GGT GTG GTT CC
Aurkaip1
Forward ACT TGT CAC TTC CGC AGT CC
Reverse CCA TCC CCA AGT CAG GTG TG
Ccdc17
Forward TCT TTT CTG TCC AGT CCG CC
Reverse ACA AAT GGG CAG AGT CAG GG
Cd52
Forward TAC TGC CGC ACA CAT GAC TC
Reverse TGA GGT GGG AAG CCA AAC AT
Cd68
Forward AGG GGC TGG TAG GTT GAT TG
Reverse GGA GTC AGG ACT GGA TTT GAC
Cd69
Forward TCT AAA GGT TTT GAG ACC CCC
Reverse TGA  AGC CTC ATC AAC GCA CT
Clec2d
Forward GGC TCC TGA CCT TGA AAT GC
Reverse AGG CAA CTT CTG CCA CTA TGC
Coro1a
Forward AGG GCT CTG GGG TTC TAC TT
Reverse GGA AAT GAC CAC GGG GGT TT
Hist1h1c
Forward CTC TAT CGG CGT ACT GCC AC
Reverse ATC GAG TCC CTT GCA ACC TT
Il4i
Forward ATT CCC GAG GGA GGT GAG TG
Reverse GGT AGC TTC TCT CCG TCA CAC
Maz
Forward GTC AAC AAA GAA CCC CTC CCT
Reverse CAC CTG TCC CCT GAG TTG TG
Trex1
Forward GCC TAA CAG GTT TGA TTG TCC T
Reverse TAG GCT GAG CAC TCC CAG TC
Table 4 | Primers used for PCR-Seq.
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Gene expression profiling by RNA-seq
Germinal  center (CD19+FAS+GL7+) and resting (CD19+FAS+GL7-) B cells  were sorted from Peyer's
patches of littermate 12 weeks old WT C57BL/6 mice. Three biological replicates were analyzed, each
composed of a pool of 5 female mice. RNA was purified from pellets of 2-2.5x10⁴ cells and DNAse I
treatment applied to avoid DNA contamination (Qiagen RNAeasy MiniKit). RNA quality was assessed
with the 2100 Bioanalyzer showing high RNA purity and integrity. Sequencing libraries were prepared
by CNIC Genomic Unit following manufacturer's protocol (NEB NEXT Ultra RNAseq Library Prep
Kit, New England Biolabs) from 100ng RNA per replicate and sequenced in an Illumina HiSeq 2500
platform.
Computational analysis
a. Pipeline to identify and annotate AID-induced mutations
Raw reads were demultiplexed by CASAVA (Illumina) to generate a fastq file that was aligned to mouse
genome (NCBIm37 v61 Feb 2011) with  Novoalign (Novocraft) (command line options:  -o SAM -F
ILM1.8 -H -r None -q 2). Samfiles were proccessed with  samtools (Li et al.,  2009) to generate a
sorted bamfile (samtools view and samtools sort commands) that was piped to a custom Perl script
for the  analysis  of  AID mutations.  The script  depends on the  ENSEMBL Perl  API:  core  database,
functional genomics, comparative genomics and variation data APIs. Briefly, the software analyzes the
regions of interest in the bamfile, annotates hotspots, localizes and suppresses annotated SNP positions
(Sanger Mouse Genomes Project SNP and Indel Release v2) and reports relevant information about
AID activity.  Details on parameters, filters and input/output files can be found in Table 5. 
AID targets were identified as those genes accumulating significantly more C→T transition mutations
in  Ung-/-Msh2-/- than  in  Aicda-/- mice  (FDR  ≤0.05,  One-tail  Fisher  test  and  Benjamini-Hochberg
correction).
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Mutation frequencies were calculated as follows:
Total mut . freq .=Total number of mutations
Total sequenced length
Mut . freq .C/G=
(Mutated cytosines+Mutated guanines )
(Seq lengthcytosines+Seqlength guanines)
Mut . freq .WR C ( Y) / (R )G YW=
(Mutated cytosinesWR C(Y )+Mutated guanines(R )GYW )
(Seq length cytosinesWR C(Y )+Seq lengthguanines(R)G YW)
(Only cytosines in WRC(Y) and guanines in (R)GYW were considered to calculate mutation frequency
at hotspots).
Parameter Defines Details
--reffile Input file (required) Indexed reference genome in fasta format.
--bamfile Input file (required) Sorted bamfile (alignment of reads to the reference genome).
--posfile Input file (required) Bedfile containing  the  genomic  coordinates  of  the  genomic
regions to be analysed: chr, start, end, name, strand.
--hsfile Input file (required) Text file  containing  Perl  regular  expressions*  matching  the
motif of each of the hotspots to be analysed.
--snpfile Input file (required) Text file containing the name of the mouse strains that should
be considered for SNP removal.
--snpfile Input file (required) Bcf file with information relative to the SNP calling of mouse
strains as retrieved from the MGP.
--qbcut Filter (optional) Defines the base calling quality threshold for a nucleotide read
to be considered for the analysis. Default is Q20 PHRED score
--qmcut Filter (optional) Defines  the  mapping  quality  threshold  for  a  read  to  be
considered for the analysis. Default is inactive.
--outfile Output file (required) Textfile containing the final report.
--ohs Output file (optional) Defines whether the SNPs found in the regions analysed should
be reported to an output file.
--osnps Output file (optional) Defines whether identified hotspots should be reported to an
output file.
--time Technical report Time and memory usage.
--help Help Display information about software usage.
Table 5 | Parameters, input and output files of our custom Perl software.
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b. Sequence context of mutated cytosines
The sequence context of  mutated cytosines (C→T transition frequency ≥ 4x10 -3) was analyzed in a
window of 10 nucleotides using an in-house built Python script. LOGO representation was done using
WebLogo3 (http://weblogo.threeplusone.com/create.cgi)  and  percentage  of  each  nucleotide  in  each
position surrounding the mutated cytosine was calculated by a custom Perl  script.  Enrichment for
adenosine,  guanine,  cytosine  or  thymine  was  tested  against  the  sequence  context  of  all  cytosines
present in the 1588 regions analyzed in this study (one-tailed t-test + Bonferroni correction).
c. Gene expression profiling by RNA-Seq
After demultiplexing by CASAVA, read quality was assessed by FastQC and sequencing adaptors were 
removed from sequence reads by cutadapt (Martin, 2011). The resulting reads were aligned to and 
quantified on the mouse transcriptome (NCBIm38 v75 Feb 2014) using RSEM (Li and Dewey, 2011) 
with the following parameters: -p 3 --time --output-genome-bam --sampling-for-bam 
--bowtie-e 60 --bowtie-m 30 --bowtie-chunkmbs 512 --fragment-length-mean 180 
--fragment-length-sd 50.
Data  were  then  processed  with  a  differential  expression  analysis  pipeline  that  used  Bioconductor
package EdgeR (Robinson et al., 2010) for normalization and differential expression testing. Transcript
quantification was performed at the gene level, and only those genes bearing  ≥ 3 counts per million
were considered for differential expression analysis. Genes were considered differentially expressed at a
q-value ≤ 0.05 (Benjamini-Hoschberg FDR).
d. Transcription rate analysis (GRO-Seq)
Reads were mapped to the mouse genome (mm9/NCBI37) using  bowtie2  (Langmead and Salzberg,
2012) and uniquely mapped, non-redundant reads were kept. Reads mapping in +/-1Kb from TSS were
quantified and summarized at the gene level using HTSeq.
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e. Pol II and SPT5 recruitment
Quantification of RNAP II and SPT5 recruitment was extracted from (Pavri et al., 2010) (Table S3A in
their manuscript).
f. Superenhancers analysis
Data was extracted from the catalog of  superenhancers that  overlap with gene bodies identified in
germinal center B cells as published in (Meng et al., 2014) (TableS3 in their manuscript).
g. Med12 binding and epigenetic marks analysis
Sequencing data (fastq files) from Med12 and H3K4me1, H3K36me3, H3K79me2 epigenetic marks
ChIP-Seq  experiments  was  aligned  to  the  mouse  genome (NCBIm37 v61  Feb  2011)  using  bowtie
(Langmead  et  al.,  2009) (command  line  options:  --best  -m1 -n2  -p2).  Alignment  files  were
processed by samtools to generate a sorted bamfile. Peak calling was done using MACS2 (Zhang et al.,
2008) following the optimal parameters for a histone modification status profiling as reported by the
creators of the tool (callpeak function with command line options:  -q 0.01 -g 1.87e9 –nomodel –
nolambda) (Feng et al., 2011). Mapping of annotated peaks to genes was done using GREAT (Mc Lean,
2010) with the following parameters: Species assembly: Mouse NCBI build 37 (UCSC mm9, Jul/2007);
Background  regions: Whole  genome;  Association  rule: Basal  plus  extension  (Proximal:  5Kb
upstream, 1Kb downstream; plus Distal: up to 1000Kb); Curated regulatory domains were not included
for the analysis.
To remove background noise from data representation, percentage of positive targets and non-targets
for a given mark was referred to the percentage of positive regions in the whole genome before plotting.
For  instance,  75,6%  AID  targets  and  50%  non-targets  showed  Med12  binding  with  36,4%  of  the
genome bearing a positive signal. Thus, percentage of AID targets binding Med12 was represented as
39,2% and percentage of non-targets binding Med12 as 13,6%. Nonetheless, statistics were calculated
using original numbers.
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h. Convergent transcription analysis (GRO-Seq)
Convergent transcription data analysis was performed as described in Meng et al., 2014.  In brief, reads
were  mapped  to  the  mouse  genome  (mm9/NCBI37)  using  bowtie2  and  uniquely  mapped,  non-
redundant reads were kept. HOMER (Heinz et al., 2010) was used with default parameters to identify
transcribed regions from both strands and bedtools (intersect function) (Quinlan, 2002) to find and
annotate  “Convergent  transcription (ConvT) regions” (regions where a greater  of  100pb sense  and
antisense transcription overlap occurs).
i. Machine learning to predict AID targets
The conditional inference tree for the classification was built using ctree function from party R package
(Hothorn et al., 2006; Libbrecht and Noble, 2015) with default parameters. Genes with a background
mutation  frequency  above  5x10-4 were  excluded  to  avoid  artifacts.  The resulting  1339  genes  were
divided into two groups: AID target (272; 20% of total) and non-target (1067; 80% of total) genes and
the following variables were fed into the model:  expression,  transcription rate,  RNAP II and SPT5
recruitment  (quantitative,  continuous);  Med12  recruitment,  H3K4me1  recruitment,  H3K36me3
recruitment,  H3K79me2  recruitment,  regulation  by  superenhancers  and  occurrence  of  convergent
transcription (qualitative, discrete). All variables were assigned equal weights to fit the model.
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Software Version
Bedtools 2.24
BioPerl 1.6.924
Bowtie 1.1.1
Bowtie2 2.2.4
CASAVA 1.8
CIRCOS 0.69-5
Cutadapt 1.9
Debian GNU/linux (x86-64) 7 (Wheezy) and 8 (Jessie) 
ENSEMBL Perl API ensembl65
FastQC 0.10.1
GNU bash 4.2 and 4.3.30
GREAT 3.0.0
HOMER 4.6
HTSeq (python-htseq) 0.5.4
Novoalign 2.08.01
MACS2 2.1.0.20140616
Perl 5.20.2
Python 2.7.9
R 3.1.1
R package: edgeR 3.16.5
R package: gplots 3.0.1
R package: limma 3.30.13
R package: party 1.2-3
R package: pheatmap 1.0.8
RSEM 1.2.25
sratoolkit 2.8.1.3
Weblogo 3
Table 6 | Software versions used for computational analysis.
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j. Annotation of AID targets
Annotation of AID targets was performed based on public data on sequencing of human diffuse large B
cell lymphoma, Burkitt lymphoma and follicular lymphoma tumors (Lohr et al., 2012; Love et al., 2012;
Miranda et al., 2014; Morin et al., 2013; Okosun et al., 2014; Zhang et al., 2013).
Raw data availability
Sequencing data generated for this thesis are available through the Gene Expression Omnibus: targeted
DNA deep sequencing (GSE102944); RNA-Seq (GSE98086).
The rest of the datasets analyzed are publicly available through the Gene Expression Omnibus and/or
Sequence Read Archive:  GRO-Seq (GSE62296): Germinal Center B cells (SRR1611832, SRR1611833,
SRR1611834), Naïve B cells (SRR1611829, SRR1611830, SRR1611831);  ChIP-Seq of Pol II and SPT5
(GSE24178);  ChIP-Seq  data  of  epigenetic  marks:  Med12  (SRX347810),  H3K4me1  (SRX347815),
H3K36me3 (SRX185869), H3K79me2 (SRX185843).
Code availability
Source code  developed for  the  analysis  described  in  this  thesis  will  be  provided  upon  reasonable
request.
Statistical analysis 
Statistical analyses were performed with stats R package v3.1.1. Error bars in figures represent standard
error of the mean (SEM). Student's t-test was applied to continuous data and Fisher test was used to
assess differences between categorical variables. P-values were corrected for multiple hypothesis testing
by  Benjamini-Hochberg  or  Bonferroni  method  where  appropriate.  Differences  were  considered
statistically significant at p ≤ 0.05 or q ≤ 0.05.
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IV. results
Results
1. Development of a custom protocol to detect AID-induced mutations
While AID is crucial for the humoral immune response, its activity poses a risk to genome integrity
through the bystander deamination of cytosine residues in non-Ig genes. Thus, it is fundamental to
understand the mechanisms that drive AID target specificity.  However, this issue remains unresolved,
mostly due to the technical challenge to reliably detect AID-mediated mutagenesis. There are two main
reasons  that  have  classically  hampered  the  discovery of  AID targets:  first,  AID-induced mutations
occur at very low frequencies (ranging from 10-2-10-3 -in the case of the Ig locus- to 10-4 or lower -in off-
targets-); second, they are non-clonal (different cells carry different mutations) which obscures their
faithful identification. Therefore, the detection of mutations derived from AID activity requires high
fidelity and high depth (i.e. reading each nucleotide a high number of times) sequencing of candidate
genes. Until now, only a relatively small number of genes has been directly assayed for AID mutations
(Liu et al., 2008; Pasqualucci et al., 1998, 2001; Shen et al., 1998). These studies were performed by PCR
amplification of individual genes, cloning and Sanger sequencing of single colonies, a time-consuming
approach that is not suitable to evaluate large collections of genes. On the other hand, genome-wide
studies of AID specificity have made use of high-throughput analysis of AID binding, which does not
warrant AID activity, or AID-induced DSBs or TCs, which involve complex processing of the initial
deamination by AID  (Chiarle  et  al.,  2011;  Klein et  al.,  2011;  Meng et  al.,  2014;  Qian et  al.,  2014;
Staszewski  et  al.,  2011;  Yamane  et  al.,  2011).  In  this  work  we  propose  to  directly  measure  AID
mutagenic activity in a wide representation of the B cell genome by next generation sequencing (NGS).
Our lab previously showed that NGS of PCR products (PCR-Seq) can increase sequencing depth by a
thousand  fold  when  compared  to  Sanger  sequencing  and  permits  the  detection  of  AID-induced
mutations in the IgH locus (Pérez-Durán et al., 2012). Here, we coupled the power of NGS to a target
enrichment  protocol  that  provided  the  high  depth and high  sensitivity  necessary  to evaluate  AID
mutagenic activity in a very large collection of genes. 
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1.1. Design of a custom RNA bait capture library
To explore the scope of AID-induced mutations at a high-throughput scale, we made use of a target
enrichment protocol and designed a library of biotinylated RNA probes to capture a collection of 1588
gene  fragments  (corresponding  to  1375  different  genes)  as  a  representation  of  the  B  cell  genome
(Annex I; Figure 5). Gene selection included three different groups. The first group accounts for 85% of
all  genes and was randomly selected from within genes annotated to be protein coding in AmiGO
database.  Bioinformatics  analysis  were  performed to  ensure  even  representation  of  chromosomal
location and unbiased biological function in this set of genes. The second group accounts for 13% of
the capture library and includes all genes that had already been tested for AID activity in the literature
(Gordon et al., 2003; Müschen et al., 2000; Pasqualucci et al., 2001; Pavri et al., 2010; Robbiani et al.,
2009; Shen et al., 1998) and IgH probes (JH4, Sμ and Eμ regions) as positive controls. The third group
contains a small  set  of  genes related to cancer development,  and comprises 2% of  all  genes in the
library. Since  AID  activity  in  Ig  genes  has  been  reported  to  concentrate  in  the  vicinity  of  the
transcriptional start site (TSS) (Besmer et al., 2006; Peters and Storb, 1996; Storb, 2014), probes were
designed to capture the first 500bp downstream of the TSS of each of the 1375 genes. As various genes
contained more than one predicted TSS, the library includes a total of 1588 different genomic regions
(Figure  6A,B).  This  library  design  enables  the  capture  of  about  0.8Mb  of  genomic  sequence  and
coupled to high depth sequencing will theoretically allow reading each nucleotide at a depth ≥ 2000x.
Figure 5 | Groups of genes included in the custom capture library.
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1.2. Validation of the target enrichment protocol 
To test the efficiency of the target enrichment protocol we performed real-time qPCR to measure the
relative DNA abundance of genes included (Noxa and  Pcna) and not included (Ostn) in our capture
library before and after enrichment. Equivalent amounts of DNA were used for each amplification and
cycle  threshold  values  (Ct)  were  measured  in  all  the  samples.  Ct is  defined  as  the  number  of
amplification cycles that results in a fluorescent signal above the detection threshold and is inversely
proportional to the amount of DNA in the sample. Therefore, we would expect those genes included in
our capture library to have lower Ct values after enrichment than before, and vice versa for those genes
not  included.  Indeed,  we found that  in the case of  Noxa  and  Pcna,  enriched fractions consistently
amplified 11 cycles earlier (ΔCt = Ctinput  – Ctenriched  = 11) than input fractions (Table 7). This means that
the  capture  protocol  yielded, approximately,  a  2000  fold  enrichment  (2ΔCT  =  2048)  (Figure  6C).
Conversely,  Ostn amplified 11 cycles later in the enriched fraction than in the input fraction (ΔC t =
Ctinput – Ctenriched = -11) (Table 7) revealing a depletion of approximately 2000 fold (2ΔCT = 1/2048) (Figure
6C).  Notably,  a  2000  fold  enrichment  of  the  target  regions  implies  an  equivalent  increase  in  the
sensitivity  of  the  system to detect  AID-induced mutations.  Thus,  we can conclude that  our  target
enrichment  approach  allows  efficient  enrichment  of  targets  and  provides  improved  sensitivity  to
analyze AID mutagenic activity.
Ct value
Noxa Pcna Ostn
Experiment 1
Enriched 18 16 32
Input 29 27 24
Experiment 2
Enriched 18 16 36
Input 29 27 24
Table 7 | Cycle threshold values in post-enrichment and input fractions. Each Ct value represents the mean of
two independent technical replicates (standard deviation equals zero in all cases).
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Figure 6 |  Target enrichment protocol allows efficient enrichment of selected genes. (A and  B) Schematic
representation of the DNA capture approach. (A) Biotinylated RNA baits are designed to capture 500bp from the
Transcription Start Site (TSS) of a collection of 1375 genes. DNA-RNA hybrids are purified by a magnetic field.
After denaturalization of the duplex, DNA is amplified by PCR and deep-sequenced (B) Before capture, regions of
interest constitute a small proportion of the sample, (left); after capture, they are highly enriched and represent a
major fraction of the sample (right) (C) Genomic DNA corresponding to genes included (green bars) and not
included  (red  bar)  in  the  SureSelect  library  was  quantified  by  qRT-PCR  before  and  after  DNA  capture
enrichment. Graph represents fold depletion or enrichment calculated as 2 (CTinput – CT enriched fraction). Mean of two
independent experiments is represented.
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1.3. Development of a bioinformatics pipeline to analyze AID mutational activity
To perform the mutation analysis of the sequences obtained with our target enrichment and high depth
sequencing protocol,  we developed a custom bioinformatics  pipeline that  gathers,  summarizes  and
reports information for AID activity in a per TSS manner (Figure 7). Briefly, the pipeline includes two
major steps: 1) alignment of sequences to the reference genome; 2) processing of the alignments to
reliably detect AID induced mutations and summarize and report data comprehensively. Our pipeline
uses Novoalign for the alignment of reads for a number of reasons: it takes into account base calling
quality for the alignment; it has built-in adapter and base quality trimming; it permits the alignment of
reads with INDELS; it can align mismatches that cover up to 50% of the read length; and it scores
among the lowest in terms of incorrectly mapped reads and among the highest in terms of proportion
of reads aligned (Hatem et al., 2013; Li and Homer, 2010). Details on the fine-tuning of the aligner can
be found in materials and methods section. Here, we will focus on the second step. A custom analytic
software was developed with the aim of  getting a modular and versatile tool for the detection and
annotation of mutations from NGS genome-wide data. The software is written in Perl and heavily relies
on ENSEMBL Perl API1. This enables code reuse and quick adaptability to potential new requirements.
The pipeline workflow operates as follows (Figure 7): first, sequences stored in a fastq file are aligned to
the reference genome by Novoalign;  second, the samfile containing the alignments is  processed by
samtools  (Li et al., 2009) to generate a sorted bamfile;  third, the sorted bamfile is piped to our Perl
software for the analysis and classification of mutations. In brief, the software connects to ENSEMBL
database and downloads the sequence of the regions of interest, finds hotspots in those regions and
annotates them. Then, it does a pileup2 of the alignments and processes them base by base. At this
point,  genomic  positions where  SNPs  have  been identified by the  Sanger  Mouse  Genomes Project
(Keane et al., 2011) in the selected mouse strains are removed from the analysis. Nucleotide reads that
do not pass the quality thresholds are filtered out as well. When the analysis of a genomic region is
finished, the software creates a summary containing both technical parameters related to sequencing
and information about mutations and prints it to an output file. It also annotates all hotspots found and
all genomic positions removed from the analysis due to known SNPs.
1  Application Programming Interface, a standard set of functions, protocols and tools used to create software.
2  Summary of the alignment at the nucleotide level, including: genomic coordinates of the reference 
nucleotide, number of reads covering the site, the specific nucleotides read and their base calling qualities.
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Figure 7 | Schematic representation of the custom bioinformatics pipeline developed for the analysis of AID
mutations. After demultiplexing, reads are aligned to the mouse genome; alignments are processed and fed to a
custom Perl script that removes SNPs, finds and annotates hotspots, filters sequencing reads by base and mapping
quality  and  generates  a  comprehensive  report  that  includes  relevant  sequencing  technical  parameters  and
information about mutations.
The final report generated by the software is a plain text tabbed file containing one row per TSS and 84
columns  with  the  following  information:  1)  Gene  information. Genomic  coordinates,  strand,
ENSEMBL  ID  and  gene  name;  2)  Sequencing  technical  information. Number  of  reads,  average
depth3, total sequenced length4, percentage of nucleotides covered by more than 300 reads, percentage
of  nucleotides  with  more  than  90% of  reads  passing  the  established  base  calling  quality  filter;  3)
Mutation  information. a)  Total  mutations:  total  number  of  mutations,  number  of  each  of  the  4³
possible mutations, number of mutations at C/G pairs, number of transitions and transversions at C/G
pairs,  number  of  mutations  at  A/T  pairs  and  frequencies  for  all  of  the  previously  mentioned
parameters.  b)  Mutations  at  hotspots:  total  number  of  mutations,  total  number  of  transitions  and
transversions and frequencies for WRC(Y) and (R)GYW hotspots. 
3  Number of times a given genomic region has been read on average.
4  Total sequence volume covering a particular genome region.
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Additionally, this pipeline can generate two additional files: 1) Hotspots file: reports information about
the hotspots identified by the software at the gene level. First line contains ENSEMBL identifier, gene
name, coordinates and number of hotspots in tabbed columns. Second line includes the DNA sequence
of  the  region  analyzed.  Subsequent  lines  (one  per  identified  hotspot)  contain  coordinates  of  the
genomic position where the hotspot starts, position of the hotspot relative to the region being analyzed
and  type(s)  of  hotspot(s)  found  in  that  position.  2) SNPs  file:  vcf* file  that  contains  detailed
information about the SNPs identified by the MGP in our regions of interest for the mouse strains
selected. 
In  conclusion,  we  built  a  custom  bioinformatic  pipeline  to  mine  high-throughput  NGS  data  and
analyze AID mutational activity.
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2. Identification and characterization of AID targets in Germinal Center B 
lymphocytes
2.1. Capture-based deep sequencing allows high throughput identification of AID targets
To investigate AID mutational activity in the B cell genome, we made use of a mouse model deficient
for UNG and MSH2, key components of the BER and MMR pathways. In their absence, AID induced
U:G mismatches remain unprocessed and are replicated over, thus leaving a mutational signature of
C→T and G→A transitions that reveals the footprint of AID deamination events on DNA (Methot and
Di Noia, 2017; Rada et al., 2004). We used GC B cells from Peyer’s patches, secondary lymphoid organs
that form part of the gut-associated lymphoid tissue (GALT). Peyer’s patches act as an immune sensor
of the small intestine, with lymphoid cells undergoing chronic stimulation very likely due to antigens
present in the gut environment (González-Fernández and Milstein, 1993). GCs develop spontaneously
in mouse Peyer’s patches in the absence of immunization, with high rates of SHM accumulating in Ig
genes  (González-Fernández and Milstein,  1993).  GC (CD19+FAS+GL7+)  B  cells  were  purified from
Peyer’s patches of Ung-/-Msh2-/- and from Aicda-/- mice as negative controls. Genomic DNA was isolated,
subjected to target enrichment and deep-sequenced (Figure 8). This approach allowed an extremely
high sequencing quality5 and depth, with each nucleotide being read ~2300 times on average (Figures
8, 9; Table 8). In two independent experiments we found a set of 291 genomic regions (corresponding
to 275 different genes) that were consistently mutated in  Ung-/-Msh2-/- GC B cells when compared to
Aicda-/- GC B cells (FDR ≤ 0.05; Figure 10; Annex II). Moreover, we found a strong correlation between
the mutation frequencies of the 1588 regions measured in the two biological  replicates (R² = 0.86,
Figure 10C left panel). This correlation is even stronger for AID targets (R² = 0.99,  Figure 10C right
panel). Thus, these results indicate that we have reproducibly found a set of 275 targets that are mutated
by AID. 
5  Sequencing quality refers to the probability of a base call being wrong, the higher quality, the lower 
probability of error.
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Table 8 |  Summary of depth and sequencing parameters of the capture libraries analyzed.   (a) Number of
times each nucleotide of each of the 1588 captured regions was read on average. (b) Total number of bases read
for  the  1588 genomic regions analyzed.  (c)  Average number of  bases read per  captured region.  (d)  Average
proportion of  nucleotides read more than 300 times within each captured region.  (e) Average proportion of
nucleotides covered by more than 90% of reads passing Q20 quality threshold.
Figure 8 |  Schematic representation of the experimental approach.  GC (Cd19+Fas+GL7+) B cells from Peyer’s
patches were isolated by cell sorting and genomic DNA was extracted, sheared and captured with a custom library
of RNA probes. Enriched DNA was subject to NGS to achieve a mean of 2300 reads per nucleotide.
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Figure 9 |  High quality sequencing of captured genes. FastqQC plots showing average base calling quality
along the 60nt reads in the libraries sequenced. A PHRED quality score between 28 and 40 corresponds to a base
calling accuracy between 99,8% and 99,99%.
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We found that the average C/G transition frequency of the 291 targets is close to 6.5x10 -4, more than 4-
fold above the background frequency of 1.5x10-4 detected in control cells (Figure 10D). Interestingly,
mutations concentrate at the SHM hotspots WRC(Y)/(R)GYW (W = A/T; R = A/G; Y = C/T) (Rogozin
and Kolchanov, 1992; Dörner et al., 1998; Rogozin and Diaz, 2004), where mutation frequencies are 8
to 12-fold above background (Figure 10D), reinforcing the idea that the mutations we detected are the
result of AID mediated deamination.
To further  validate  our  results,  we  performed Sanger  sequencing  of  some  of  the  genes  we  found
mutated: Hist1h1b, miR142, Cd19 and Cdk4. Primers were designed to amplify roughly the same region
that we previously analyzed by NGS. We sequenced 50-100Kb (equivalent to 100-200 colonies; Table 9)
per gene and found a significantly higher mutation frequency in Ung-/-Msh2-/- than in control GC B cells
in all the genes analyzed (Figure 10E). 
Gene Genotype Mutations(a) Length (bp)(b) Frequency(c) P-value (d)
Hist1h1b
Ung-/-Msh2-/- 27 51000 5.3 x 10-4
8.7 x 10-8
Aicda-/- 1 52000 1.9 x 10-5
miR142
Ung-/-Msh2-/- 32 53000 6.0 x 10-4
4.3 x 10-8
Aicda-/- 2 52250 3.8 x 10-5
Cd19
Ung-/-Msh2-/- 14 107620 1.3 x 10-4
1.5 x 10-2
Aicda-/- 1 56950 1.8 x 10-5
Cdk4
Ung-/-Msh2-/- 15 110999 1.4 x 10-4
4.3 x 10-2
Aicda-/- 2 54010 3.7 x 10-5
Table  9  |  Mutation  analysis  of  representative  AID  targets  in  Ung-/-Msh2-/- and  Aicda-/- mice  by  Sanger
sequencing.  (a)  Total  number  of  mutations  detected.  (b)  Total  number  of  bases  sequenced.  (c)  Mutation
frequency calculated as (Number of mutations / Number of bases sequenced). (d) Statistical comparison of the
mutation frequency found in Ung-/-Msh2-/- with that of Aicda-/- control mice (one-tail Fisher test).
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Figure 10 |  291 reproducible targets were detected by high-throughput analysis of AID-induced mutations.
(A) Two independent experiments were performed (Annex II) with 457 mutated targets found in Exp1 and 399
in Exp2. An overlap of 291 AID targets was found between Exp1 and Exp2. (B) In silico simulation to quantify the
reliability of the 291 regions reproducibly found mutated in Exp1 and Exp2. Graph represents the experimental
distribution of random overlaps after 1000 iterations. For each iteration, random groups of 457 and 399 genes
were selected from the genes included in the SureSelect capture library, overlapped and the number of coincident
genes reported. The probability to find an overlap of 291 genes by chance is below 1 out of each 10 16 times tested.
Two-tailed  Fisher  test;  P  ~ 10-16.  (C-D)  Comparison  of  mutation frequencies  found in  Exp1 and Exp2. (C)
Mutation frequencies of the 1588 TSS proximal regions analyzed and the 291 targets found in two independent
experiments. (D) Mean transition frequency in total C/G nucleotides and in C/G within WRCY/RGYW hotspots
(W=A/T; R=A/G; Y=C/T) of the 291 AID targets (two-tailed Student's t-test; two independent experiments). (E)
Validation of representative AID targets by Sanger sequencing (one-tail Student's t-test; Table R4). *, P ≤ 0.05; ***,
P ≤ 10-3; ****, P ≤  10-4. Error bars depict SEM.
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Importantly, the collection of targets we identified includes 30 of the 35 previously known AID targets
(Figure 11A), such as  Bcl6,  Pim1,  RhoH,  Pax5 or  Cd83  (Shen et al.,  1998; Pasqualucci et  al.,  1998;
Müschen et al., JEM, 2000; Pasqualucci et al., 2001; Gordon et al., PNAS, 2003; Liu et al., 2008). We also
performed overlap analysis of our identified AID mutational targets with published data on genome-
wide analysis of DNA breaks (DSBs) and chromosome translocations induced by AID (Chiarle et al.,
2011; Klein et al., 2011; Staszewski et al., 2011; Qian et al., 2014;  Meng et al., 2014) (Figure 11B-G).
Only a fraction of the targets in each of these studies was assessed in our capture-based SHM assay
(1375 genes); but all 275 AID targets reported here were assayed in DSB and TC genome-wide studies
(Figure 11B). Only 22 of the translocation sites described by Meng et al were included in our 1375-gene
library. However, from those we found 19 (86%) genes mutated (Figure 11E, G). Likewise, 28 of the
translocation sites  described  by  Klein et  al  were  included in our  library,  21  of  which (75%) were
mutated (Figure 11F, G). In contrast, the fraction of mutated genes found in our study that undergo
either DSBs or  chromosome translocations is  much smaller.  For instance,  only 19 of  the 275 AID
targets identified by us (7%) undergo chromosome translocations according to Meng et al. (Figure 11E,
G). This likely reflects that while most of the DSBs / TCs detected in these studies come from AID-
induced mutations in off-targets, not all AID mutations give raise to DSB / TC events.
We  conclude  that  our  capture-based  deep  sequencing  approach  has  allowed  the  discovery  of  an
unprecedented, massive collection of AID targets.
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Figure 11 | Overlap analysis of the 291 targets discovered in this study and previously published data on AID-
induced mutations, translocations and double strand breaks. (A)  Overlap between the targets discovered in
this  study  and  previously  reported  AID  targets.  (B-F)  Venn  diagrams  showing  overlaps  between  the  genes
included in our capture library (SureSelect captured genes, n=1375), AID targets identified in this study (n=275)
and genes  undergoing  DSB or  TCs according to  the  indicated  studies.  (G) Percentage  of  genes  undergoing
DSB/TCs according to the indicated studies within the AID targets described in this study (SHM +; n=275) and
percentage of SHM+ genes within DSB/TC+ genes (see Materials and methods for further details).
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2.2. Analysis of the local specificity of AID
To gain  insights  into  the  local  sequence  preference  of  AID,  we  first  analyzed  the  mean  mutation
frequency at individual WRCY/RGYW hotspots across all 291 AID targets and found a wide range of
mutability, with AACT and AGCT as the top mutated hotspots in both strands of DNA (Figure 12). As
these results were obtained in the combined absence of UNG and MSH2, we think this may reflect an
intrinsic preference for AID to deaminate cytosine residues lying within these motifs. Interestingly, this
result  is  consistent  with  previously  published studies.  For  instance,  using heterologous and  ex vivo
systems to test SHM, our lab previously found AGCT as the most mutated hotspot in a transgene and
in the IgH Sμ region (Pérez-Durán, et al., 2012). In addition, Yeap and colleagues identified AGCT as
the most robust SHM hotspot in the absence of antigen selection in an in vivo model (Yeap et al., 2015).
This indicates that AGCT is a strong hotspot for AID local specificity. Next, we performed an unbiased
analysis of the sequence context of mutated cytosines in the 291 AID targets. We found that A, G and T
nucleotides  were  the  preferred  nucleotides  at  -2,  -1  and +1  positions,  respectively,  but  we  further
uncovered a significant preference for T at +3 (Figure 13A). Indeed, cytosines lying at the AGCTNT
motif were significantly more mutated than those in AGCTNV (where V is A, C or G) or than other
WRCY/RGYW hotspots  (Figure 13B, C).  To analyze how frequently  this novel  hotspot  is  mutated
during SHM, we calculated the percentage of cytosines lying within the AGCTNT context bearing 1 or
more mutations. Throughout the AID target sequences covered by our capture library (roughly 145Kb
in 291 different regions) AGCTNT hotspot is found 134 times and we found mutations in 104 of them
(78%). For the sake of comparison, we performed the same analysis for AGCTNV (254/605, 42% of
mutated cytosines) and for two non-hotspot  4-nucleotide motifs,  CTCA (146/673, 22% of mutated
cytosines) and GGCA (229/1480, 16% of  mutated cytosines),  and found that AGCTNT is mutated
more frequently than AGCTNV or any of the non-hotspot sequences (Figure 13D). We did not find a
difference  in  mutation  frequency  or  in  the  proportion  of  sequences  mutated  between  sense  and
antisense  strands (AGCTNT vs  ANAGCT,  Figure  13C),  suggesting that  the  preference for  AID to
mutate cytosines within the AGCTNT motif is not dependent on the DNA strand.
Together,  these  results  show that  AGCTNT is  a  novel  and the  most  highly  mutated  AID hotspot
identified so far. 
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Figure 12 |  Mutation analysis at  WRCY/RGYW hotspots  in  Ung-/-Msh2-/- GC B cells.  Plots  show mutated
individual hotspots (WRCY, left; RGYW, right). Each dot represents an individual cytosine (C) or guanine (G)
within a WRCY/RGYW motif found mutated at least once. Each position in the X axis corresponds to a different
gene, and the Y axis shows mutation frequency at the underlined C or G of each individual hotspot within a gene.
Mean mutation frequency is indicated and depicted with a red line. Number of mutated hotspots is indicated.
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Figure 13 |  AGCTNT is a novel AID mutational hotspot. (A) Logo representation of the sequence context of
mutated cytosines (mutation frequency ≥ 4x10-3). Statistically significant enrichment of nucleotides surrounding
the mutated C is indicated (One-tail  Fisher test and Bonferroni correction; *,  FDR  ≤ 10-3;  see Materials  and
methods for details), and numbers indicate percentages.  (B) Mean mutation frequency of cytosines within the
indicated motifs (dark blue bar, newly identified hotspot; gray bar, control motif for newly identified hotspot;
light blue bars, WRCY hotspots; red bars, random four-nucleotide motifs; two-tailed Mann-Whitney test; *, P ≤
0.05; error bars depict SEM).  (C) Mutation analysis of AGCTNT and AGCTNV motifs. Within each plot, each
dot represents an individual AGCTNT/AGCTNV motif found mutated at least once. Each position in the X axis
corresponds to a different gene, and the Y axis shows mutation frequency of each individual hotspot within a
gene.  Mean  mutation  frequency  is  indicated  and  depicted  with  a  red  line.  Number  of  mutated  hotspots  is
indicated. (D) Percentage of mutated cytosines within AGCTNT and AGCTNV hotspot motifs and CTCA and
GGCA non-hotspot motifs (Fisher test; ****, P ≤ 10-13). 
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 2.3.- Molecular characterization of AID targets
The uniquely large set of AID-mutated genes identified in this study allows, for the first time, a high
throughput examination of the molecular features that associate to SHM and the evaluation of their
potential role defining AID target specificity. Since AID activity in the Ig loci has been classically linked
to  transcription,  we  performed  a  comprehensive  analysis  of  transcription-related  features  of  AID
targets, including steady-state transcription levels, transcription rate, epigenetic marks and regulatory
sequences.
2.3.1. AID targets are highly transcribed
Given the link between AID activity and transcription (Betz et al., 1994; Chaudhuri et al., 2003; Fukita
et al., 1998; Peters and Storb, 1996; Pham et al., 2003; Ramiro et al., 2003; reviewed in Storb, 2014) we
evaluated  the  transcriptional  state  of  the  1375  genes  included  in  our  capture  library.  Whole
transcriptome  sequencing  (RNA-Seq)  was  performed  in  sorted GC  (CD19+FAS+GL7+)  and  naïve
(CD19+FAS-GL7-)  B cells  from Peyer's  patches  of  WT mice  littermates.  We carried out  differential
expression (DE) analysis in GC versus naïve B cells and identified 8868 genes that are DE in the two
populations (FDR ≤ 0.05) (Figure 14A). This is consistent with previously published RNA-Seq data on
lymph node GC vs naïve B cells (Kuchen et al., 2010) where a similar number of DE genes was reported
and a big proportion of them (~90%) match the DE genes identified by our study (data not shown). In
our experiment, approximately half of the DE genes were upregulated (4412 genes; 49.7%) and the
other half were downregulated (4470 genes; 50.3%) in GC versus naïve B cells (Figure 14A,B). From the
4412 genes significantly upregulated in GC B cells, 407 were included in our capture library and thus
assayed for mutations. Notably, approximately 33% of them (133/407) are mutated by AID, suggesting
that GC specific genes are frequently affected by AID off-targeting. However, this group of genes only
accounts for 48% of the 275 AID targets we identified. This means that AID off-site activity is not
restricted to genes specifically activated during the GC reaction, but also affects other transcriptionally
active genes. Indeed, the remaining 52% AID targets are well expressed both in naïve and activated
states. In agreement with these results, we found that AID targets are significantly more expressed than
non-targets and that this difference is even larger for highly mutated targets (Figure 14C).
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Next,  we  analyzed  publicly  available  data  on  Global  Run-On  Sequencing  (GRO-Seq)  assays  from
mouse GC B cells to estimate the transcription rate of AID targets and non-targets (see Materials and
Methods  for  details).  In contrast  to  RNA-Seq,  which quantifies  RNA steady state  levels,  GRO-Seq
quantitatively  measures  nascent  RNA  transcripts  at  the  genome-wide  scale  by  a  pulse  and  chase
approach.  With this  technique,  modified NTPs  are  incorporated  during  transcriptional  elongation,
which are then captured allowing specific sequencing of newly synthesized mRNA. Thus, GRO-Seq
provides a snapshot of the total number of engaged transcriptional complexes in the cell, and allows the
quantification of the rate at which a particular gene is transcribed in a fashion that is independent of
the stability of the resulting mRNA. In line with the results obtained from RNA-Seq data, we found that
AID targets are transcribed at significantly higher rates than non-targets,  and that the difference is
larger when we compare highly mutated to non-mutated genes (Figure 14D).
In conclusion, these results indicate that AID targets are highly transcribed genes. 
2.3.2. AID targets recruit high levels of RNAP II and SPT5
A few years ago, the Nussenzweig lab reported that AID interacts with SPT5 (Pavri et al., 2010) which
facilitates the association between AID and RNAP II.  They proposed that  AID takes  advantage  of
RNAP II stalling to gain access to ssDNA and that the concomitant decrease in the elongation rate
provides increased time of residence for AID and favors its mutagenic activity. To further explore the
link between AID induced mutation and RNAP II / SPT5 recruitment, we analyzed publicly available
ChIP-Seq data from splenic LPS+IL4 activated B cells. Since this ex vivo setting differs from the in vivo
context in which we identified AID targets,  we first compared the transcription levels of the genes
included in our capture library in LPS+IL4 activated B cells  and in GC B cells.  We found a good
correlation between the two expression profiles, so we reasoned that RNAP II and SPT5 binding data
from LPS+IL4 could be well extrapolated to the GC B cells used in our study (Figure 15A). Thus, we
integrated LPS+IL4 ChIP-Seq data with  our  collection of  captured genes and found a  significantly
higher binding density of RNAP II and SPT5 to AID targets than to non-targets.  Furthermore, we
detected the highest binding of RNAP II and SPT5 in highly mutated genes (Figure 15B, C). This agrees
with our data on expression and transcription rate of AID target genes (Figure 14C, D). Hence, AID
targets highly transcribed genes with high density binding of RNAP II and SPT5. 
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Figure  14  |  AID targets  are  highly  transcribed. (A) Heatmap  representation  of  the  differential  expression
analysis  of  Peyer’s  patch  GC  and  naïve  B  cells  by  RNA-Seq.  Three  biological  replicates  were  analyzed  per
condition (n=5 each); genes were considered as differentially expressed at FDR ≤ 0.05 (see Materials and methods
for details) (B) Volcano plot representation of the differential expression analysis depicted in panel A. Green dots,
genes significantly upregulated in GC vs naïve B cells (n=4412); red dots, genes significantly downregulated in GC
vs naïve B cells (n=4470); Grey dots, unchanged genes (n=2638). (C) Expression level of highly mutated (top 20%
mutated genes, C→T transition frequency > 3x10-4), mutated (rest of mutated) and non-mutated genes in Peyer’s
patch GC B cells as measured by RNA-Seq. (D) Transcription rate of highly mutated, mutated and non-mutated
genes in GC B cells from lymph nodes as measured by GRO-Seq. TPM, Transcripts Per Million.
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2.3.3. AID targets are enriched in marks associated to active enhancers and transcription elongation
Mediator  is  a  large  protein  complex  that  is  generally  required  for  transcription  by  RNAP  II  in
eukaryotes. The Mediator complex interacts with RNAP II and enhances its recruitment stabilizing
transcription complexes at  gene promoters  (Soutourina, 2018; Taatjes,  2010). The main function of
Mediator is exerted at enhancers, where it transduces signals from transcription activators to control
transcription initiation. Mediator forms a complex with cohesin to promote DNA loops that connect
enhancers  and gene promoters  (Kagey et  al.,  2010).  Thus,  we measured MED12 (a  subunit  of  the
mediator complex) binding as a marker of active enhancers in B cells. ChIP-Seq data from LPS+IL4
activated B cells revealed that MED12 recruitment is ~3 times more frequent in AID targets than in
non-targets (Figure 16). This suggests that Mediator binding to gene enhancers can favor AID activity,
very  likely  by  aiding  to  the  recruitment  of  RNAP  II  to  gene  promoters  and  thus  facilitating
transcriptional activation.
Figure  15  |  AID targets  show  high  density  binding  of  RNAP  II  and  SPT5. (A) Correlation  between  the
expression profiles of the 1375 genes included in SureSelect capture library in Peyer’s patch GC B cells (X axis,
this study) and LPS+IL4 activated B cells (Y axis, Pérez-García et al.,,  2017) as measured by RNA-Seq. TPM,
Transcripts Per Million. (B) Recruitment of RNAP II and (C) SPT5 to AID targets and non-targets measured in
in vitro activated splenic B cells by ChIP-Seq. RPKM, Reads Per Kilobase per Million reads mapped.
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Epigenetics also plays a pivotal role in the regulation of gene expression. Epigenetic modifications are
reversible changes of chromatin structure that do not affect the primary sequence of DNA, but regulate
transcriptional activation or repression. They can directly affect DNA (DNA methylation) or DNA-
associated proteins (covalent  modification of  histone proteins).  Here,  we evaluated the presence of
epigenetic marks in AID targets and non-targets. We analyzed publicly available datasets on ChIP-Seq
experiments measuring marks related to active transcription and transcription elongation in B cells
(Kieffer-Kwon  et  al.,  2013;  ENCODE/LICR  project).  Specifically,  we  looked  at  the  following
modifications at histone H3: monomethylation of lysine four (H3K4me1, mark of active promoters),
trimethylation  of  lysine  thirty-six  (H3K36me3,  mark  of  elongation)  and  dimethylation  at  lysine
seventy-nine (H3K79me2, mark of elongation). Interestingly, we found a significant increase in the
proportion of AID targets that bear epigenetic marks of active elongation (H3K36me3 and H3K79me2)
when compared to non-targets (Figure 16). These results are in accordance with previously published
data  reporting  the  occurrence  of  specific  epigenetic  marks  in  genes  affected  by  AID-mediated
translocations, where authors propose that epigenetic features mediate AID recruitment to off-target
sequences (Wang et al., 2014)
In conclusion, AID targets are enriched in marks of active enhancers and transcriptional elongation.
Figure  16 |  AID targets  are  enriched in  marks associated to  transcription and transcription elongation.
Transcription and transcription elongation marks in AID targets and non-targets by ChIP-Seq analysis of in vitro
activated splenic B cells (MED12, H3K4me1, H3K36me3, H3K79me2).
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2.3.4.- AID targets are regulated by superenhancers and frequently undergo convergent transcription
Superenhancers (SE) are clusters of enhancers that recruit lineage specific transcription factors and can
establish long range interactions, thus regulating both proximal and distal loci (Hnisz et al., 2013). SE
have been recently linked to AID off-targeting,  because they initiate  antisense transcription within
sense transcribed genes, which provokes the collapse of the transcription machinery due to convergent
transcription (ConvT).  This  may contribute  to  AID targeting in three  different  ways:  first,  ConvT
results in RNAP II stalling, which can lead to AID recruitment (Pavri et al., 2010);  second, ConvT
generates ssDNA substrates which are amenable to AID action (Meng et al., 2014; Qian et al., 2014);
third, ConvT contributes to the recruitment of the RNA exosome which helps AID access ssDNA (Basu
et  al.,  2011; Pefanis et  al.,  2014). In light  of  these findings,  we wondered whether the AID targets
identified in this work are regulated by SE or undergo ConvT. With that aim, we integrated the data on
SE  and  ConvT  published  in  Meng  et  al.,  2014  and  Qian  et  al.,  2014  with  our  mutational  data.
Interestingly, we found that primary AID targeting, as measured by AID mutations in the absence of
repair, focuses preferentially in the vicinity of superenhancers (Figure 17A) and in regions subject to
convergent transcription (Figure 17B) (Meng et al., 2014; Qian et al., 2014).
Figure 17 |  AID targets are regulated by superenhancers and frequently undergo convergent transcription.
(A) Proportion of highly mutated, mutated and non-mutated genes regulated by superenhancers in GC B cells
(see  Materials  and Methods  for  details).  (B) GRO-Seq analysis  of  convergent  transcription (ConvT)  in AID
targets and non-targets from GC splenic B cells obtained from SRBC-immunized mice.
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Together, the results  presented in this chapter show that several transcription-associated events are
linked to AID activity, and thus provide proof for this previously reported idea  (Meng et al., 2017;
Nambu et al., 2003; Pavri et al.,  2010; Qian et al.,  2014; Storb, 2014; Wang et al.,  2014)  in a broad
collection of targets (Figure 18). However, our data also indicate that AID targeting cannot be defined
by any of these features alone. 
Figure 18 |  Molecular features of AID targets. Circos plot representation of the AID targets identified in this
study and their associated molecular features. The outer ring shows chromosome location and is followed by C→T
transition  frequency  in  Ung-/-Msh2-/- (red)  and  Aicda-/- (grey)  GC  B  cells;  mRNA  expression  (dark  green);
Transcription  rate  (light  green);  RNAP  II  (dark  blue)  and  SPT5  (light  blue)  binding;  Med12  (dark  red),
H3K36me3 (dark orange), H3K79me2 (light orange) marks; Regulation by superenhancers (blue) and ocurrence
of convergent transcription (purple). 
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3. Prediction of AID targets in Germinal Center B lymphocytes
Given our finding that there are several features that associate to SHM (Figure 18), we reasoned that,
conceivably,  a  combination  of  them  could  be  used  to  predict  AID  targeting.  To  approach  this
hypothesis, we made use of a supervised machine learning algorithm known as recursive partitioning
(Tom Mitchell,  1997;  Trevor Hastie,  Robert  Tibshirani,  Jerome Friedman, 2009;  see Materials  and
Methods for details). In brief, the algorithm uses a training dataset 6 to generate a classification tree that
splits  data  into  different  nodes  based  on  a  collection  of  variables.  This  partitioning  allows  the
identification of the variables that better define each of the initial  groups to be classified. There are
some  advantages  to  using  recursive  partitioning  trees:  they  are  non-parametric  and  allow  the
incorporation of categorical data; they are robust with regards to outliers in the training data and they
are very easy to interpret visually (Chapter 3, Tom Mitchell, 1997; Chapters 9-10, Trevor Hastie, Robert
Tibshirani, Jerome Friedman, 2009). However, there are also some drawbacks that need to be taken
into account:  they cannot  make predictions beyond the  upper  and lower  limits  established by the
training data and they tend to overfit (Chapter 3, Tom Mitchell, 1997; Chapters 9-10, Trevor Hastie,
Robert  Tibshirani,  Jerome Friedman,  2009;  Libbrecht  and Noble,  2015).  A good prediction model
learns patterns from the training data and is able to generalize them on new data. Overfitting occurs
when the model learns patterns that are too specific of the training data and cannot be extrapolated to
make reliable predictions.
The recursive partitioning algorithm was trained with a dataset composed of two different groups , AID
target (272) and non-target genes (1067). For each of the genes we included the 10 variables measured
in chapter 2.3: gene expression, transcription rate, binding of transcription cofactors (RNAP II, SPT5,
MED12) and epigenetic marks (H3K36me3, H3K79me2, H3K4me1), regulation by SE and occurrence
of ConvT. To control for overfitting we used tree pruning (Chapter 3, Tom Mitchell, 1997; Chapters 9-
10, Trevor Hastie, Robert Tibshirani, Jerome Friedman, 2009). This technique removes the nodes of the
tree that are less relevant for the classification and reduces the complexity of the final classifiers. If the
model  is  initially overfitted,  tree  pruning will  produce  a different  classification tree  with improved
prediction accuracy. Notably, identical trees were produced before and after pruning, which indicates
that our prediction model was not initially overfitted. The outcome of the machine learning approach
6  The training dataset is the information used by the algorithm to fit the parameters of the classification model,
in other words, the set of examples from which the algorithm “learns”.
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revealed that the combination of high-density RNAP II and SPT5 binding predicts AID targeting with
a 77% probability (P < 0.001;  Figure 19). This combination of features is found in 2.3% of the genes
(~430 genes) in the whole genome (Figure 19B; AnnexIII). Other combinations bear some predictive
power as well  but are much less efficient classifying AID targets.  Conversely, low RNAP II binding
combined with low gene expression predicted the absence of mutation in 95% of the genes (Figure 19).
Figure 19 | Molecular features of AID predict mutability. (A) Recursive partitioning tree model classifies AID
targets based on different molecular features:  mRNA expression, RNAP II and SPT5 recruitment, and presence of
H3K79me2  epigenetic  mark  (see  Materials  and  Methods  for  details).  Each  node  splits  the  genes  into  two
significantly different groups based on a particular feature. Numbers within the branches indicate the thresholds
used to make the groups; P-values of each decision are included below the parameter measured in each node. (B)
Bar graph depicting the proportion of SureSelect genes (1339 genes, closed bars) or of total genes in the mouse
genome (17858 genes; open bars) that meet the thresholds established in each node.  (C) Simplified schematic
representation of the machine-learning approach used for AID target prediction.
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To experimentally validate the accuracy of the prediction model, we randomly picked a collection of
genes (not included in our capture library) with high-density RNAP II and SPT5 binding (Figure 20A)
and analyzed their mutation profiles by PCR-Seq. We found that 11/12 of the analyzed genes were
significantly  mutated,  with  mutations focusing  at  AID mutational  hotspots  (Figure  20B; Table  10).
Indeed, two of those genes (Hist1h1c  and Clec2d) were mutated at the range of the top 20% mutated
genes at frequencies similar to those found in Pax5 or RhoH (Table 10; Annex II). Thus, we have built a
powerful predictive tool for AID activity that identified high RNAP II and SPT5 binding as the best
predictors of AID specificity.
Figure 20 |  Experimental  validation of the  machine-learning model  by  PCR-Seq.  (A)  Box plot  represents
genome-wide data of RNAP II and SPT5 recruitment in in vitro activated B cells. Black dots and squares depict
the 12 genes selected for the validation of the model prediction. RPKM, Reads Per Kilobase per Million reads
mapped.  (B) Validation of representative genes predicted to be mutated by the model by PCR-Seq (Table R5).
Two-tailed Student's t-test, ****P ≤ 10-4..
Table 10 | List of genes selected for machine learning validation. (a) Transition (TS) mutation frequency at C/G
nucleotides calculated as (Total TS mutations in C + Total TS mutations in G) / (Total sequenced C + Total
sequenced G) (b) Transition mutation frequency at cytosines contained in WRCY hotspots calculated as (Total
TS mutations in WRCY) / (Total sequenced C in WRCY) (c) (c) Transition mutation frequency at guanines
containted in RGYW hotspots calculated as (Total TS mutations in RGYW) / (Total sequenced RGYW).
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Gene POLII (RPKM) SPT5 (RPKM) FDR
Apobec3 26.17 10.67 36.54 27.69 210.08 130.38 392.08 271.37 0.56
Aurkaip1 16.74 7.88 13.88 8.77 75.31 11.13 21.58 18.90
Ccdc17 16.10 7.46 6.28 5.73 13.48 11.91 14.91 12.15
Cd52 26.43 9.32 11.54 5.81 56.15 10.19 38.29 8.21 0
Cd68 40.33 20.30 7.43 6.98 16.24 10.99 13.08 9.17
Cd69 7.76 17.26 4.64 3.95 11.56 10.35 13.17 10.39
Clec2d 22.32 19.53 51.11 4.39 532.38 9.70 257.45 7.19 0
Coro1a 44.71 15.77 7.81 6.47 14.89 11.90 31.95 10.13
Hist1h1c 84.00 69.40 60.99 8.38 412.43 11.42 460.45 10.10 0
Il4i1 54.63 7.14 27.22 6.73 135.76 15.75 58.41 16.92
Maz 16.97 7.76 5.99 5.44 14.47 8.20 11.60 9.14
Trex1 65.81 26.68 7.07 6.26 15.74 11.94 15.19 11.84
TS freq. at C/G (x10 -5)(a) WRCY TS freq. (x10 -5)(b) RGYW TS freq. (x10 -5)(c)
Ung-/-Msh2-/- Aicda-/- Ung-/-Msh2-/- Aicda-/- Ung-/-Msh2-/- Aicda-/-
4.01x10-151
3.26x10-9
2.58x10-7
7.98x10-13
3.28x10-30
1.38x10-8
4.19x10-4
1.58x10-32
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4. Analysis of the role of the Base Excision Repair (BER) and Mismatch Repair 
(MMR) pathways in the resolution of AID-induced deaminations
BER and MMR act  downstream of  AID-induced U:G mismatches  so  that  UNG is  critical  for  the
generation of transversions at C:G pairs while MSH2 facilitates the introduction of mutations at A:T
pairs (Frey et al., 1998; Methot and Di Noia, 2017; Phung et al., 1998; Rada et al., 1998, 2002, 2004).
UNG and MSH2 can also  promote  conventional,  faithful  repair  of  AID-induced U:G mismatches
(Pérez-Durán et al., 2012 Roa et al., 2010); Liu et al., 2008).  Indeed, our lab previously reported that
the local sequence context can confer specificity to the resolution of AID-induced lesions by UNG,
directing  it  towards  an  error-free  or  error-prone  repair  outcome.  More  specifically,  AACT,  TACT,
AGTA, AGTT, GGTA and GGTT motifs were shown to drive faithful repair by UNG while AGCT,
AGCT and AGCA promoted error-prone repair by UNG in IgH Sμ region (Pérez-Durán et al., 2012). 
Figure  21  |  BER  and  MMR  back  up  each  other  to  error-free  repair  AID-induced  lesions. (A)  Mutation
frequency of AACT, TACT, AGTA, AGTT, GGTA and GGTT hotspots in IgH Sμ region. Number of each hotspot
is indicated between parenthesis.  (B and C) Total mutation frequency of AID targets in  Ung+/-Msh2+/-  ,  Ung-/-
Msh2+/-  ,Ung+/-Msh2-/-  GC B cells compared with that of  Ung-/-Msh2-/-  GC B cells. Mutation frequency found in
Aicda-/- GC B cells was substracted before plotting. Two-tailed Student's t-test, *, P ≤ 0.05. Error bars depict SEM.
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To  explore  the  contribution  of  BER  and  MMR  to  AID  mutagenic  activity  from  a  more  general
perspective, we purified GC (CD19+FAS+GL7+) B cells from Peyer’s patches of single-deficient  Ung+/-
Msh2-/- and  Ung-/-Msh2+/- mice  and  from  control  Ung+/-Msh2+/- mice;  isolated  genomic  DNA  and
performed target enrichment followed by deep-sequencing. Next, we carried out mutation analysis of
the  1588  TSS-proximal  regions  included  in  our  capture  library.  Unfortunately,  our  genome-wide
approach  provided  us  with  limited  resolution  to  evaluate  the  impact  of  UNG loss  at  the  level  of
individual hotspot sequences in AID off-targets. It is interesting though, that when we focused on IgH
Sμ region, which accumulates mutations at one order of magnitude higher than off-targets, we did find
a trend that exactly reproduces the results  published in Pérez-Durán et al.,  2012 (Figure 21A).  We
compared the  mutation  frequency  of  the  291 AID target  regions identified in this  study in  Ung+/-
Msh2+/-,  Ung+/-Msh2-/-,  Ung-/-Msh2+/-  and Ung-/-Msh2-/- cells (Figure 21B,C; Annex II).  We found similar
average mutation frequencies in B cells deficient for UNG alone, MSH2 alone or proficient for both,
while  AID targets  harboured  significantly  more  mutations  in  the  combined absence  of  UNG and
MSH2 (Figure 21B,C). Indeed, only a small proportion (~6%) of the genes mutated in Ung-/-Msh2-/- cells
harbour a detectable mutation load in single knockout and double heterozygous cells (Figure 22A,
Table  11;  Annex II).  Moreover,  we find that  classical  AID off-targets,  such as  Bcl6 or  Pim1,  while
mutated in all 4 genotypes, harbour a significantly bigger load of mutations in Ung-/-Msh2-/- cells than in
Ung+/-Msh2-/-,  Ung-/-Msh2+/- or  Ung+/-Msh2+/- cells (Figure 22B). Together, these data indicate that BER
and MMR backup each other to faithfully repair most AID-induced lesions in GC B cells. 
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Figure  22  |  BER  and  MMR  pathways  faithfully  repair  most  AID-induced  deaminations. (A)  Heatmap
representation of AID targets in Ung+/-Msh2+/-, Ung-/-Msh2+/-, Ung+/-Msh2-/- and Ung-/-Msh2-/- GC B  cells. Mutation
frequency found in Aicda-/- GC B cells was substracted before plotting. (B) Mutation frequency of representative
genes in Ung+/-Msh2+/-, Ung-/-Msh2+/-, Ung+/-Msh2-/-, Ung-/-Msh2-/- and Aicda-/- GC B cells.
Gene name
Acot 7 Dusp6 Ildr2
Actb Dyrk3 Pim1
Bcl6 Galnt1 Prdx1
Cd19 IgH Eμ Rps6
Cd83 IgH Jh4 Srsf10
Cdk4 IgH Sμ Tmsb4x
Table 11 | List of the 18 AID targets mutated in repair-proficient germinal center B cells.
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5. Analysis of the contribution of AID off-targeting to the development of 
Germinal Center derived malignancies
We have shown here that AID off-targeting occurs widely in the B cell genome during the GC reaction,
and while MMR together with BER takes care of faithfully repairing many of these lesions, they leave
behind a proportion of them, resulting in the accumulation of mutations in non-Ig genes. This poses an
evident  risk  to  genome  integrity  and  can  have  an  impact  in  the  initiation  and/or  progression  of
oncogenic transformation. Genetic mouse models have shown that AID is responsible for chromosome
translocations relevant for the etiology of lymphoma (Kovalchuk et al., 2007; Pasqualucci et al., 2008;
Ramiro  et  al.,  2004,  2006,  Robbiani  et  al.,  2008,  2009).  However,  the  implication  of  AID-induced
mutations in the malignant transformation of B cells remains object of study. We thus assessed the
contribution of AID off-target mutations to B-cell  derived malignancies by making use of available
sequencing data on human lymphoma tumors. We found that AID targets are significantly enriched in
genes mutated in human B cell lymphoma (see materials and methods section for details) (Figure 23). 
Figure 23 | AID targets are recurrently mutated in human lymphomas. (A)  AID targets are enriched in genes
frequently mutated in human lymphomas (“lymphoma genes”). Percentage of lymphoma genes within AID target
and non-target genes. Annotation was done from public data on human lymphoma sequencing (see Materials and
methods for details; Two-tailed Fisher test, ****, P≤ 10-4.  (B) Wordcloud representation of the lymphoma genes
found to be mutated by AID in this study. Word size is proportional to mutation frequency.
Indeed, 21/275 (7.6%) of our set of AID target genes are mutated in diffuse large B cell lymphoma
(DLBCL) (Figure 24; Annex IV), a highly prevalent, aggressive form of the disease (Shaffer and Staudt,
2012). In agreement with previous reports, these 21 genes include Bcl6, RhoH, Pim1, Ebf1, Eif4a2 and
Pax5 (Liu et al., 2008; Pasqualucci et al., 2001; Shen et al., 1998). Additionally, we identified 9 novel
genes mutated in human DLBCL that accumulate AID-induced mutations (Figure 24; Annex IV): Btg2,
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Ciita,  Eef1a1,  Gna13,  Irf8,  Lyn,  Mef2b,  Rims1 and Tnfaip3.  Alterations in most  of  these  genes  are
relevant  for lymphomagenesis:  Gna13 codes for a small  GTPase  whose loss  in GC B cells  impairs
apoptosis  and promotes  lymphoma  (Healy  et  al.,  2016);  Btg2 is  an  antiproliferative  gene  and well
known tumor suppressor  (Mao et al.,  2014) involved in B-cell differentiation  (Tijchon et al., 2016);
Ciita is a frequent gene fusion partner in many lymphoid cancers and its alteration reduces patient
survival  (Steidl  et  al.,  2011), most likely by suppressing antigen presentation and allowing immune
evasion  (Green et al., 2015);  Irf8 frequently translocates to IgH and drives DLBCL  (Bouamar et al.,
2013);  Lyn is a proto-oncogene  (Ingley, 2012; Tauzin et al., 2008) coding for a kinase that acts as a
negative regulator of the BCR signalling  (Chan et al., 1997; Hibbs et al., 1995);  Tnfaip3 deregulation
constituvely  activates  NFKB  signalling  and  has  been  reported  as  a  tumor  supressor  in  Hodgkin
(Schmitz et al., 2009) and Non-Hodgkin lymphoma (Compagno et al., 2009); and Mef2b encodes an
acetyltransferase whose overexpression increases cell  migration and favours epithelial-mesenchymal
transition (Pon et al., 2015). On the other hand, the contribution to lymphoma of Eef1a1, a translation
elongation factor, and Rims1, a member of the Ras superfamily of genes that regulates exocytosis, has
not been thoroughly demonstrated. However, given the fact that they play key functions in the cell and
appear frequently mutated in human lymphoma, their involvement in disease does not seem a far-
fetched possibility.
Figure 24 | Genes frequently mutated in human DLBCL are targeted by AID. Mutation frequency in total C/G
nucleotides and C/G nucleotides within WRCY/RGYW hotspots of the 21 genes frequently mutated in human
DLBCL  and  targeted  by  AID  in  Ung-/-Msh2-/-  and  Aicda-/-  mouse  GC  B  cells  (mean  of  two  independent
experiments, see Material and methods for details).
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In addition to the functional relevance of the above-mentioned AID target genes, it is remarkable that
we found many instances where the exact same mutations described in human lymphoma tumours
were also found in our study in non-transformed mouse GC B cells (Figure 25; Table 12). For instance,
we found a C→G transversion in Gna13 that changes a tyrosine in residue 89 to a stop codon or a G→A
transition affecting a tryptophan in residue 85 of Tnfaip3 that truncates the protein as well (see Table 12
for a complete list of mutations). Interestingly, many of these mutations frequently lie within hotspot
sequences (Figure 25,  highlighted by asterisks), suggesting that they may have originated from AID
activity in human tumors,  and affect  amino acid residues that  are evolutionarily well  conserved in
mammals, which highlights their importance for protein function. 
Table 12 |  Mutations found in  Ung-/-Msh2-/- mice that have been identified in cohorts of human lymphoma
patients. (a)  Total  net  mutation  frequency  calculated  as:  (Number  of  mutations  /  Number  of  bases
sequenced)UngMsh2 dKO – (Number of mutations / Number of bases sequenced)AID KO
[1] Bruno et al., 2014; [2] Compagno et al., 2009; [3] Fabbri et al., 2013; [4] Morin et al., 2011; [5] Pasqualucci et 
al., 2014; [6] Schmitz et al., 2009; [7] Zhang et al., 2013;[8] International Cancer Genome Consortium (DFKZ. 
Germany).
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Gene Position nt change aa change Pathology Reference
Btg2 1:135975497 C → A A45T | A45E 4 DLBCL [1]
Btg2 1:135975530 G→T R34I 3.6 NHL [8]
Btg2 1:135975535 G→T E32D 14 NHL [8]
Btg2 1:135975590 C→T A14V 4 NHL [8]
Gna13 11:109224379 C→T S31F 35 DLBCL [1]
Gna13 11:109224450 T→C L38P 6.1 DLBCL [8]
Gna13 11:109224554 C→G Y89STOP 7.1 NHL [8]
Tnfaip3 10:18731328 G→A W85STOP 6 Hodgkin [2]
Tnfaip3 10:18731338 A→T K82STOP 6 FL [3]
Tnfaip3 10:18731530 G→C A18P 31 DLBCL [4]
Tnfaip3 10:18731575 G→C E3STOP 5.6 DLBCL [4]
Pim1 17:29628092 C→T , C→G L2F | L2V 136 FL [1] [3] [5]
Pim1 17:29628109 C→G N7K 555 NHL [6]
Pim1 17:29628113 C→T L9F 9.3 DLBCL [7]
Pim1 17:29628117 C→G A10T 38.8 DLBCL [7]
Pim1 17:29628146 C→G L20V 147 NHL [6]
Pim1 17:29628156 C→G , C→T T23R | T23I 35.1 FL [3]
Pim1 17:29628160 G→C K24N 313 FL [3]
Pim1 17:29628162 C→G L25V 11.6 NHL [1]
Pim1 17:29628270 G→A , G→C G28D | G28A 166 DLBCL. FL [3] [6] [7]
Pim1 17:29628275 G→A E30K 11.9 NHL [6]
Pim1 17:29628284 C→T P33S 970 FL [3]
Pim1 17:29628298 G→C Q37H 63.6 NHL [1]
Pim1 17:29628301 C→A Y38STOP 58.5 DLBCL [3]
Pim1 17:29628302 C→T Q39STOP 64.1 DLBCL. FL [3] [7]
Mut. freq. (x10-4)(a)
Results
Together these results suggest that off-target AID mutagenic activity can contribute to GC-associated
lymphomagenesis.
Figure 25 | Mutation profiles of representative DLBCL genes. Per nucleotide analysis of the mutation frequency
of representative DLBCL genes in Ung-/-Msh2-/- mouse GC B cells. Blue bars indicate mutations identical to those
found  in  human  lymphoma  tumor  samples  (Table  R6);  asterisks  indicate  mutations  occurring  in  a  WRCY
hotspot. The diagrams below the graphs represent the complete gene (not to scale), and blue boxes indicate the
region depicted above. Mutation frequency found in each nucleotide in Aicda-/-  GC B cells was substracted before
plotting.
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V. discussion
Discussion
1. Development of a capture-based NGS approach to detect AID-induced 
mutations
In this thesis work, we studied the specificity of AID targeting at a high-throughput scope. With that
aim, we developed a novel  strategy based on Next Generation Sequencing (NGS) to analyze AID-
induced mutations in the genome of germinal center B lymphocytes. It is important to note that AID-
induced mutations are particularly challenging to detect, since they occur at a very low frequency (10 -2-
10-3 in Ig genes; at least one order of magnitude lower in off-targets) and do not show clonal recurrence,
with different cells carrying different mutations. Thus, it  is critical that the sequencing approach to
detect AID-induced mutations: 1) allows high depth, i.e. each nucleotide must be read a large number
of times; 2) has a low sequencing error rate, i.e. below the mutation frequency introduced by AID. To
accomplish  these  goals,  we  designed  a  protocol  that  couples  target  enrichment  to  NGS.  Target
enrichment effectively reduces the total length of DNA that is subject to sequencing; thus, for the same
total volume of sequences obtained, target enrichment allows a great increase in the number of times
each nucleotide is read. In our case, we captured 500bp from the TSS of a selection of ~1600 genomic
locations, covering a total of 0.8Mb, approximately 1/3000th of the mouse genome. Accordingly, this
target enrichment approach yielded roughly a 2000 fold enrichment of the target DNA regions and a
consistent  sequencing depth of ~2300x,  i.e.  each nucleotide was read approximately 2300 times on
average. Importantly, this increases by more that 20 fold the sequencing depth achieved by previous
studies based on conventional Sanger sequencing (Liu et al., 2008). In contrast, sequencing the whole
mouse exome or genome at 2300x depth would have meant producing a sequence volume of ~1.5Tb
and ~6Tb respectively, a largely unaffordable setup. Therefore, with our experiment we have covered a
reasonably broad length sequence with affordable means. 
Regarding sequencing background, our protocol involves several PCR steps during target enrichment
and library preparation that can introduce unspecific mutational noise. We found however, that the
major source of error stems from the inherent chemistry of the sequencer, which cannot be modified.
To control for sequencing background noise and false positive signals, i) we have used AID deficient
mice to get an estimation of the sequencing error; and ii) we have developed a custom bioinformatics
pipeline that  allowed us to discard genomic variation derived from mixed genetic backgrounds. In
addition, computational noise (errors coming from base calling and/or sequence alignments) was also
strictly  controlled  by  filtering  data  based  on  base  calling  and  mapping  qualities.  Although  the
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background noise of the NGS setup presented here is much higher than that of Sanger sequencing, the
huge increase  in read depth and the  genome-wide scope provided by our  capture-based approach
largely compensates for this loss of sensitivity. Indeed, this approach has allowed, for the first time, the
evaluation of AID off-target mutagenesis in more than 1500 different genomic locations. As a reference,
this  is  ~15  times  larger  than  the  largest  study  published  to  date.  Remarkably,  our  capture-based
approach can be easily extended to analyze broader collections of genes and our bioinformatics pipeline
would allow the analysis of AID-induced mutations up to a whole-genome level. 
2. Discovery of a large catalogue of AID mutational targets
Up  to  date,  only  a  limited  number  of  genes  had  been  directly  interrogated  for  AID-mediated
mutagenesis (Shen et al., 1998; Pasqualucci et al., 1998; Müschen et al., 2000; Pasqualucci et al., 2001;
Gordon et al., 2003; Liu et al., 2008; Robbiani et al., 2009; Pavri et al., 2010). Instead, genome-wide AID
specificity has been inferred from high throughput analysis of AID binding (Yamane et al., 2011) or
AID-induced DSBs or TCs (Chiarle et al., 2011; Klein et al., 2011; Staszewski et al., 2011, Meng et al.,
2014; Qian et al., 2014). The Casellas lab performed a ChIP-Seq experiment of AID in in vitro LPS+IL4
activated B cells and reported AID binding to ~5900 genes (~12000 genomic locations) (Yamane et al.,
2011), although serious concerns have been raised on different aspects of this study (Hogenbirk et al.,
2012). Regardless of these issues, at best ChIP-Seq studies would provide information of AID binding,
but  not  necessarily activity.  On the other hand, the generation of DSB or TCs involves a complex
processing of the initial lesion induced by AID that occurs only in a fraction of the deamination events.
Therefore, measuring DSBs or TCs as a surrogate of AID activity will oversee all the lesions that are
fixed as mutations, either by replication or after BER/MMR activities.
In contrast, the use of a mouse model deficient for BER and MMR provides a clean, unbiased view of
the primary deamination events produced by AID. Thus, we identified the largest collection of AID
mutational targets -275 genes- to date, expanding in more than 10 times the number of previously
known targets. Several evidences support the reliability of these data. First, the mutation frequencies
measured in AID targets are well above background signal. On average, AID targets showed a mutation
frequency 4x higher than background in the Ung-/-Msh2-/- setting. Second, we found hotspot focusing, a
hallmark of AID activity. In hotspots, mutation frequencies peaked to up to an 8-12 fold increase over
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background. Third, AID targets are highly reproducible, as supported by the good correlation found
between two biological replicates (R² = 0.99). Fourth, we validated some of the newly discovered targets
by conventional Sanger sequencing. Finally,  we confirmed the vast majority of previously identified
AID targets (Shen et al., 1998; Pasqualucci et al., 1998; Müschen et al., 2000; Pasqualucci et al., 2001;
Gordon et al., 2003; Liu et al., 2008; Robbiani et al., 2009; Pavri et al., 2010). In addition, integration of
our mutational targets with DSB/TC data (Chiarle et al., 2011; Klein et al., 2011; Staszewski et al., 2011;
Qian et al., 2014; Meng et al., 2014) revealed that while not all deaminations produced by AID give
raise to DSB/TCs, most of the events identified in these studies originate from AID activity.
3. AGCTNT as a novel hotspot for AID activity
We took advantage of the large collection of AID targets identified here to systematically evaluate the
intrinsic local  sequence preference of  AID. Analysis  of  classic  AID hotspots revealed that  they are
highly sensitive to genomic location, as shown by the wide range of mutation frequencies observed for
the  same hotspot  within  the  same gene  and between different  genes  (Figure  12).  Consistent  with
previous findings (Pérez-Durán et al., 2012; Yeap et al., 2015), we identified AGCT as the most mutated
hotspot within the classical WRCY/RGYW motifs. However, we decided to explore the possibility that
a wider sequence context could also influence the efficiency of AID targeting and analyzed a window of
±10 nucleotides from mutated cytosines. Thus, it  is  important to note here that we focused on the
mutated  cytosine  for  our  hotspot  search,  while  the  classic  WRCY/RGYW  hostpots  were  defined
considering the whole motif as a possible target. We found that the +4 nucleotide position from the
mutated  cytosine  fine-tunes  AID local  specificity.  Specifically,  we  found  that  AGCTNT is  a  novel
hotspot for AID activity and that cytosines lying within this motif are significantly more mutated than
those lying within AGCTNV. Furthermore, 78% of the AGCTNT motifs identified in AID targets are
mutated, as compared to 42% of AGCTNV motifs. Interestingly, AGCTNT motif is enriched in IgH Sμ
region, where we identified a total of 6 AGCTNT motifs, three times more than expected by chance.
Remarkably, AGCTNT was mutated in 100% of the instances mentioned above. Last, this motif has
also been identified in murine IgH Sγ2a,  Sγ2a and Sγ3 consensus tandem repeats.  Together, these
findings suggest that AGCTNT could be relevant for CSR. Regarding its potential  role in AID off-
targeting,  even  if  the  occurrence  of  this  novel  hotspot  is  more  restricted  than  that  of  classic
WRCY/RGYW hotspots (1/1024 bp versus 1/256 bp), it seems unlikely that it suffices to define AID
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off-target specificity. In addition, AGCTNT appears at the random expected frequency in off-targets
(not shown), which would suggest that it does not contribute to the recruitment of AID to these loci.
Thus, we  propose that,  similar  to  the  classic  WRCY/RGYW  hotspots,  AGCTNT  defines  a  local
preference for AID deaminating activity once it has been targeted to a particular locus. In this respect,
the accumulation and frequent mutation of AGCTNT hotspots in Ig switch regions suggests that AID
mediated deamination in these motifs could be a major event for the initiation of CSR. Equivalently,
AGCTNT may contribute  to  AID-induced deamination  in  off-targets.  We therefore  speculate  that
although the primary targeting of AID is not defined by the sequence context alone, once AID gains
access  to  ssDNA,  specific  sequence  contexts  can  confer  local  specificity  for  SHM.  However,  the
mechanisms by which AID is recruited to Ig and non-Ig loci remain to be defined, as we will discuss in
the next chapter.
4. Molecular characterization of AID targets
In  this  study we  have  performed  a  comprehensive  characterization  of  the  molecular  features  that
associate  to  off-target  SHM.  Given that  active  transcription  is  a  well-known requirement  for  AID
activity, we first analyzed the transcriptional profiles of GC and resting B cells. As expected, we found
diverging transcriptional programs in both subsets. It is interesting that approximately one third of the
genes specifically upregulated during the GC reaction are mutated by AID. Nevertheless,  they only
account for about half of total AID targets, the other half being genes highly expressed both in the
naïve and activated states. This indicates that AID off-target activity is not exclusively directed to GC
specific genes, but to a wider set of highly expressed loci. Of interest, we observed some instances of
highly  expressed  genes  that  were  not  mutated  by  AID.  These  results  support  the  idea  that  active
transcription is an absolute requirement for AID activity but argue that AID specificity is not driven by
transcription levels. On the other hand, we also observed a few AID targets which were apparently
expressed at very low levels or not expressed at all. Since this is a very small proportion of all detected
AID targets, we think it may reflect a technical issue with the RNA-Seq data or annotation; this should
be  experimentally  tested  by  an  alternative  measurement  of  mRNA  levels.  We  also  analyzed
transcription rate, i.e. the number of engaged transcriptional complexes per gene, and found that AID
targets are transcribed at higher rates than non-targets, reinforcing the notion that AID preferentially
targets highly transcribed loci.
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A number of genetic screenings have shown AID binding to different components of the transcription
machinery, which would facilitate the association of AID with transcribed switch regions and modulate
CSR. Some examples would be the 14-3-3 adaptor proteins (Xu et al., 2010), PTBP2 protein (Nowak et
al.,  2011), the RNA exosome  (Basu et al.,  2011), RNA polymerase II  (Nambu et al.,  2003) and the
elongation  factor  SPT5  (Pavri  et  al.,  2010).  Based  on  the  position  of  hypermutation  relative  to
transcription  start  sites,  Storb  proposed  that  RNAP  II  pausing  could  be  linked  to  mutation
(Peters&Storb, 1996). Further, a genome-wide study of RNAP II and SPT5 in activated B cells showed a
strong correlation between RNAP II and SPT5 genome occupancy (Pavri et al.,, 2010). In this study,
authors  proposed  that  SPT5 facilitates  the  interaction  between AID and RNAP II  and pointed  to
polymerase  stalling  as  a  mechanism  by  which  AID  would  get  access  to  ssDNA,  with  decreased
elongation rates providing more time for AID to deaminate the target sequence (Pavri et al., 2010). To
explore  the  contribution  of  RNAP  II  and  SPT5  binding  to  AID  off-targeting,  we  analyzed  their
recruitment to the AID targets identified in our study. In line with our findings on transcription, we
observed that AID targets bind high levels of RNAP II and SPT5, suggesting that their binding to off-
targets is relevant for AID recruitment to these loci. It is interesting that, on average, genes included in
the “highly mutated” group accumulated significantly higher levels of RNAP II and SPT5 than those in
the “mutated” or “non-mutated” groups, which suggests a direct correlation between the binding of
these transcription cofactors and the accumulation of AID-induced mutations. However, at the gene
level this correlation was poor, so we must be cautious in the interpretation of these results.
Epigenetic  modifications  have  been  suggested  to  contribute  to  AID  targeting  to  Ig  (reviewed  in
Sheppard et al., 2018) and non-Ig loci (Wang et al., 2014). Wang et al compared AID-induced TCs in B
cells and mouse embrionary fibroblasts upon AID overexpression and identified some genes similarly
transcribed in both experimental systems that were only mutated in B cells. Moreover, they found a
common set of distinctive epigenetic features associated to these genes in B cells but not in MEFs.
These data led them hypothesize that epigenetic modifications are mediators of AID recruitment to off-
target sites in a fashion that is not dependent on the transcription of the target gene. Here we have
analyzed  the  presence  of  epigenetic  marks  associated  to  active  transcription  and  transcription
elongation in AID targets. Consistent with the findings by Wang and colleagues, we observed that AID
targets are enriched in H3K36me3 and H3K79me2 marks. However, given the correlative nature of this
observation, we can only suggest that these epigenetic marks define a chromatin accessibility status that
likely favors AID activity.
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Recent studies have linked AID off-targeting to super-enhancer (SE) regulated loci (Qian et al., 2014;
Meng et al., 2014). SE are regulatory clusters where chromatin accessibility and transcriptional activity
are  much  higher  than  at  other  transcriptional  active  sites  (Whyte  et  al.,  2013).  Further,  they  can
establish long-range interactions and play an important  role in cell  specific processes  (Hnisz et  al.,
2013, 2015; Whyte et al., 2013). SE have been related to AID targeting at two different levels. On one
hand, they have been proposed to establish regulatory clusters that  drive “networks of  cooperating
elements” that generate “the proper conditions for AID promiscuous activity” (Qian et al., 2014). On
the  other  hand,  SE  initiate  antisense  transcription  within  sense  transcribed  genes  (convergent
transcription).  This phenomenon contributes to RNAP II stalling and exosome recruitment,  which
contribute to AID recruitment and activity (Meng et al., 2014). In agreement with these hypothesis, we
found that AID targets are frequently regulated by SE, and that primary AID targeting often occurs in
regions undergoing convergent transcription. We also observed that highly mutated genes were more
frequently regulated by SE than mutated and non-mutated genes.  It  is  important to underline that
although ConvT arises from SE, not all genes regulated by SE necessarily undergo ConvT. However, we
found that all AID off-targets regulated by SE also underwent ConvT, which suggests that, together, SE
regulation and ConvT may favor a microenvironment suitable for AID activity. Following Meng and
Qian hypotheses we would speculate that: i) SE would provide improved chromatin accessibility to AID
by  increasing  transcription  and  potentially  coordinate  regulated  networks  of  B  cell  specific
transcription factors that could contribute to AID off-targeting; ii) ConvT would lead to Pol II stalling
and exosome recruitment, which in turn favor AID activity at off-targets.
AID activity occurs at much higher levels on Ig genes than on off-targets. Although this preferential
targeting has been known for years, the mechanisms underlying are not completely understood. Several
features have been proposed to make the Ig loci  privileged for SHM, including specific enhancers
(Buerstedde  et  al.,  2014),  regulatory  regions  (Rouaud et  al.,  2013),  epigenetic  marks  (reviewed  in
Sheppard et al., 2018) or transcriptional-related mechanisms, such as RNAP II stalling (reviewed in
Storb, 2014), exosome recruitment (Basu et al., 2011) or SE regulation (Qian et al., 2014; Meng et al.,
2014).  Remarkably, some of these features are also present in AID off-targets. This raises the question
of  whether  AID  off-targeting  may  be  driven  by  the  same  Ig-like  features  and  only  quantitative
differences  account  for  the  widely  differing  mutation  frequencies  in  Ig  versus  non-Ig  targets,  or
alternatively, if off-targets are made accessible to AID activity by distinct molecular features. In this
respect, ConvT is the only phenomenon linked to AID targeting that has been observed in off-targets
116
Discussion
but not in Ig genes, although this may be due to technical reasons (Meng et al., 2014). The finding that
IgH Sμ is >7 times more mutated than the most highly mutated off-targets in Ung-/-Msh2-/-  GC B cells
suggests that AID primary targeting to Ig genes is much more frequent than to off-targets and that BER
and MMR mediated processing of AID-induced lesions does not account for the different mutation
frequencies found at on and off-targets. Indeed, we observed that AID-mediated deaminations were
repaired to a similar extent in IgH Sμ and in off-targets (~70-80% of lesions faithfully repaired). Thus,
we believe that a combination of known and unknown Ig specific features may explain AID preference
for Ig loci. Similarly, we think that AID off-targeting is not random, but also defined by a specific set of
features.  In this regard, we found that several mechanisms linked to transcription contribute to AID
off-targeting, but none of them alone suffices to define AID specificity. We envision that AID off-target
specificity is  driven by a complex combination of  factors,  including DNA repair pathways,  specific
sequence  contexts,  chromatin  accessibility,  transcriptional  cofactors  and  other  transcriptional  and
architectural regulatory mechanisms. In this regard, we think a thorough analysis of the dynamics of
genome compartmentalization and loci interactions during the GC reaction would help complete the
picture and probably establish a definitive link between transcription and the definition of AID target
specificity. 
5. Machine learning approach to predict AID off-targeting
Here, we have integrated our mutation data with the collection of molecular features described above to
feed a machine learning algorithm. According to the classification tree generated by our model, the
combined binding of  SPT5 and RNAP II  at  high density  is  the  best  predictor  for AID mutability,
although other transcription-associated traits, such as high expression levels or presence of H3K79me2
mark, bear some predictive power as well. Further, we have performed experimental validation of the
model by randomly picking 12 genes predicted as targets and sequencing them. It is important to note
that  none  of  those  genes  was  initially  included in  our  capture  library.  Notably,  11/12  (91%)  were
actually mutated, suggesting that the accuracy of the model is even higher than expected. Indeed, two
of  those  genes  were  mutated  at  the  range of  the  top 20% mutated  AID targets.  Theoretically,  our
machine learning approach could be improved by using other classic  machine learning algorithms,
such  as  random  forests  or  support  vector  machines,  which  are  less  prone  to  overfitting,  or  deep
learning, which is more accurate than classic machine learning methods. However, we do not think the
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use of these models would have a major impact on our predictions, i) because the recursive partitioning
model we used was not overfitted; ii) because deep learning requires extremely large training datasets
to be properly trained and outperform classic machine learning approaches.  Instead, we believe that
incorporating new parameters to the prediction, such as 3D genome organization information or data
on binding of other transcriptional cofactors, could indeed be very useful to fine-tune the predictions
and contribute to better delimit the extent of AID off-target activity in the B cell genome. 
A first attempt to predict AID off-targeting was published a few years ago but the prediction model
lacked experimental validation (Duke et al., 2013). In addition, the moderate number of AID targets
known at that time limited the prediction power of the approach. A total of 83 genes, which had been
previously assayed for AID mutations in  Ung-/-Msh2-/- B cells (Liu et al., 2008), was used to train the
model. This collection of genes was divided in three different groups: A (15 highly significant mutated
genes), B (21 mutated genes) and C (47 non-mutated genes). According to their classification tree, a
total of 6073 genes were predicted to be AID targets, of which 1896 genes were predicted to be highly
mutated (group A). To get an estimation of the prediction efficiency of the model, we compared their
predicted set of AID targets with collections of genes that bear AID-induced DSB/TC (Staszewski et al.,
2011;  Chiarle et al., 2011;  Qian et al., 2014;  Meng et al., 2014). We only found a minor fraction of the
genes  that  undergo  DSB/TCs  within  their  most  reliable  set  of  predicted  targets  (group  A):   10%
(Staszewski et al., 2011) and 19% (Qian et al., 2014) of reported DSBs; and 22% (Klein et al., 2011); 18%
(Chiarle et al., 2011) and 16% (Meng et al., 2014) of reported TCs. This suggests that the efficiency of
the prediction model was far from optimal. Similarly, only a small portion of the 275 AID targets that
we experimentally identified in GC B cells were predicted by their model: 14% (39/275) if we compare
to group A; 16% (44/275) if we compare to their complete set of predicted genes (groups A+B).
 
Thus, to the best of our knowledge, the machine learning approach presented in this thesis constitutes
the first instance of a tool that successfully predicts the potential of a gene to be targeted by AID. There
are roughly 430 genes predicted to be AID off-targets by our machine learning model, including many
cancer drivers and genes recurrently mutated in human lymphoma. Therefore, we think this collection
of  potential  off-targets constitutes  a good starting point  to guide new SHM studies  both from the
perspective of AID biology and in the context of carcinogenesis.
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6. Role of BER and MMR in the resolution of AID-induced deaminations
With regards to the fate of AID-induced lesions, BER and MMR have been long known to broaden the
diversity of SHM with an apparent perverted recruitment of error prone polymerases, and to do so in a
cooperative manner (Di Noia and Neuberger, 2007; Methot and Di Noia, 2017; Rada et al., 2004). The
mechanisms responsible for the error-free versus error-prone activity of UNG and MSH2 are far from
understood, and both local sequence and gene-specific contexts may play a role in defining the fate of
the U:G resolution (Liu  et  al.,  2008; Pérez-Durán  et  al.,  2012). Pérez-Durán et  al.  showed that  the
sequence context infuences the outcome of AID activity on the IgH locus, with particular hotspots
favouring error-free or error-prone repair of U:G mismatches. On the other hand, Liu et al. examined a
collection of 118 genes that are highly expressed in GC B cells by Sanger sequencing and identified 23
highly  mutated  genes  (~20%)  in  a  repair  proficient  background  (Aicda+/+ vs  Aicda-/- GC  B  cells).
Further, they sequenced 83 genes from B cells  deficient for UNG and MSH2, and found 36 (43%)
significantly mutated. Analysis of individual off-targets in WT,  Ung-/-,  Msh2-/- and  Ung-/-Msh2-/- GC B
cells revealed that different genes behaved differently: although statistical significance was precluded by
the  limited  number  of  mutations  detected,  authors  observed  differential  trends  when  comparing
mutation frequencies in the four mentioned genotypes. These data led them to the hypothesis that the
B cell genome is protected at two different levels: 1) by the selective targeting of AID (since they found
~40% genes targeted by AID); 2) by a balance between error-free and error-prone repair, which would
be defined by gene-specific features.
Interestingly, our data demonstrates that the fate of the majority of off-target lesions induced by AID is
to undergo faithful repair by BER and MMR and that both pathways can backup each other in this task.
It is worth mentioning here that all the 10 AID off-targets analyzed in Liu et al. in the repair-deficient
setting showed a consistent tendency to accumulate more mutations in the absence of BER and MMR
than in any of the other genotypes, which is concordant with our results. Further, they found a higher
proportion of mutated genes in the repair-deficient (43%) than in the repair proficient background
(20%). 
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Given the major repair function of BER and MMR, our experimental approach did not provide enough
resolution to evaluate individual  hotspots in AID off-targets in  Ung-/-Msh2+/-, Ung+/-Msh2-/-  or Ung+/-
Msh2+/- GC B cells. However, we did find a trend that reproduces the results published by Pérez-Durán
et al when we analyzed  AACT, TACT, AGTT, AGTA, GGTA and GGTT  hotspots in IgH Sμ (which
accumulates at least one order of magnitude more muations than off-targets) of Ung+/-Msh2+/- and Ung-/-
Msh2+/- B cells.
We also observed that the error-free repair of AID off-targets by BER/MMR is not absolute. Indeed, a
minor fraction of the mutations escaped repair and we identified a collection of genes (18; ~6.5% of
total  AID  targets)  consistently  mutated  regardless  of  the  genotype  analyzed.  This  finding  can  be
interpreted from different perspectives. On one hand, as suggested by Liu et al., 2008, it is possible that
different genes possess different specific qualities that tip the scales towards a higher or lower level of
repair. Alternatively, since these 18 genes correspond to the most mutated AID off-targets, it seems
reasonable to speculate that the repair pathways might be overwhelmed by an excessive mutation load.
While further investigation will be required to ascertain this issue, our data suggests that faithful repair
of off-target mutations is the prevalent outcome of the BER and MMR pathways, with different genes
being repaired with different efficiencies.
7. AID off-targeting and lymphomagenesis
As we have discussed above, AID mistargeting to non-Ig loci is a frequent event during the GC reaction
and affects a large number of genes. Despite most AID-induced lesions being faithfully repaired by the
BER and MMR pathways, there is a fraction that remains unrepaired and could contribute to genome
instability  and  carcinogenesis.  We  found  that  the  AID  off-targets  identified  in  this  study  are
significantly enriched in genes that are recurrently mutated in human lymphoma tumors, which may
suggest  a  contribution  of  AID-induced  mutations  to  lymphomagenesis.  More  specifically,  our
collection of targets included 21 genes that are usually mutated in human DLBCL. Of these, 9 were
revealed as AID targets for the first time in this study. Although many of these 21 genes are well-known
tumor suppressors (Gna13, Btg2, Tnfaip3, etc) or proto-oncogenes (Bcl6, Lyn, Pim1, etc), it remains
possible that some of the mutations observed in human lymphomas, although of AID origin, are mere
passengers.  Regardless  of  oncogenic  relevance,  it  is  remarkable  that  even  though  our  study  was
120
Discussion
performed in non-transformed cells we could detect AID mutations in the exact same residues that
have been recurrently found mutated in human lymphomas. Thus, our results yield a novel perspective
on the contribution of AID activity to B cell transformation through the introduction of mutations.
Regarding the carcinogenic process, we would speculate that a minor fraction of unrepaired mutations
in pro-lymphomagenic genes could be enough to provide cell growth advantage and account for the
predominance of AID-mediated mutations found in lymphomas. However, there is extensive evidence
of the relevance of repair deficiencies in the development of cancer, with Msh2 probably being one of
the most notable examples (reviewed in Baretti and Le, 2018). In addition, polymorphisms in Ung have
been associated with cancer, although they are much less frequent than mutations in Msh2 (reviewed in
Wallace et al., 2012). Therefore, we cannot completely rule out the possibility that the repair pathways
are somehow crippled in the lymphomagenesis context, thus allowing AID-induced lesions to escape
repair. 
8. Concluding remarks and future prospects
We envision that the advent of new sequencer chemistries and the evolving reduction in the costs of
sequencing will soon allow the whole-genome evaluation of AID off-site mutational activity. In the
meanwhile, we believe that the catalog of AID targets provided by our study constitutes a very valuable
resource  for  the  field.  Together  with  the  experimental  and  in  silico strategies  developed  here,  the
discovery of this large collection of AID targets will help tackle relevant research questions, such as the
evaluation of novel molecular mechanisms involved in AID targeting, the prediction of new targets or
the assessment of cancer-associated mutations. Furthermore, our capture-based approach can be easily
translated  to  the  human setting.  In  this  regard,  it  would  be  of  immediate  interest  to  perform an
exhaustive profiling of AID off-target activity in human memory B cells.  Optimally, the analysis  of
paired tumor-healthy samples from the same donor would help clarify not only what is the extent of
AID mistargeting in a repair proficient background, but also what is the precise contribution of AID
mutations to lymphomagenesis or other malignancies. We think approaches similar to ours would be
very interesting to broaden our knowledge on the biology of AID in humans and its contribution to
disease.
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Conclusions
1.  We  have  developed  a  capture-based  NGS  approach  that  allows  the  detection  of  AID-induced
mutations at a high-throughput level.
2. We have identified the largest collection of AID off-targets to date, composed by 275 different genes.
3. We have identified AGCTNT as a new hotspot for AID activity.
4. AID targets are highly transcribed loci that bind high levels of the transcription cofactors RNAP II
and SPT5 and bear epigenetic marks associated to active transcription and transcription elongation.
5. AID targets are frequently regulated by superenhancers and undergo convergent transcription.
6. We have developed and validated a machine learning algorithm that predicts AID off-targeting.
7. BER and MMR pathways backup each other to faithfully repair AID-induced deaminations.
8. AID-induced mutations are recurrently found in human lymphomas.
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Conclusiones
1.  Hemos  desarrollado  un  protocolo  de  captura  seguido  de  secuenciación  masiva  que  permite  la
detección de mutaciones inducidas por AID a gran escala.
2. Hemos identificado la colección de dianas de AID más amplia hasta la fecha, compuesta por 275
genes distintos.
3. AGCTNT es un nuevo “punto caliente” (hotspot) para la actividad de AID.
4.  Las  dianas  de  AID  son  loci altamente  transcritos  que  unen  niveles  elevados  de  los  cofactores
transcripcionales ARN polimerasa II y SPT5 y presentan marcas epigenéticas asociadas a transcripción
activa y elongación transcripcional.
5. Las dianas de AID están reguladas por súper activadores transcripcionales y sufren transcripción
covergente frecuentemente.
6. Hemos desarrollado y validado experimentalmente un modelo de aprendizaje automático (machine
learning) capaz de predecir nuevas dianas de AID.
7. Las vías de reparación por escisión de bases (base excision repair) y de desapareamiento de bases
(mismatch repair) se respaldan mutuamente para reparar de forma fiel la mayor parte de las lesiones
inducidas por AID.
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annex
Annex I. Genes included in SureSelect capture library
Gene Origin Status Gene Origin Status
0610007P08Rik A Non-mutated Ebf1 A Mutated
Ada A Mutated Eif4a2 A Mutated
Agxt2l2 A Non-mutated Erh A Mutated
Aicda A Mutated Ets1 A Mutated
Alk A Non-mutated Ezh2 A Non-mutated
Anxa2 A Non-mutated Fas A Mutated
Atm A Non-mutated Fcgr2b A Non-mutated
B2m A Mutated Fchsd2 A Mutated
Bcar3 A Non-mutated Fen1 A Mutated
Bcl11a A Mutated Fgfr3 A Non-mutated
Bcl2 A Non-mutated Fh1 A Non-mutated
Bcl2l11 A Non-mutated Fli1 A Mutated
Bcl6 A Mutated Fnbp1 A Mutated
Birc5 A Non-mutated Fosb A Non-mutated
Blimp1 A Non-mutated Gadd45b A Mutated
Blk A Mutated Gas5 A Mutated
Blnk A Non-mutated Grap A Mutated
Brg1 A Non-mutated H2afx A Mutated
Btg1 A Mutated H3f3b A Mutated
Btg2 A Mutated Hdac1 A Mutated
Canx A Non-mutated Hdgf A Mutated
Card11 A Non-mutated Hivep3 A Non-mutated
Casp3 A Non-mutated Hnrnpa2b1 A Mutated
Cbf A Non-mutated Hnrnpf A Mutated
Ccnb2 A Non-mutated Id3 A Mutated
Ccnd1 A Non-mutated Igf1 A Non-mutated
Ccnd2 A Non-mutated Igj A Mutated
Ccnd3 A Non-mutated Igsf8 A Non-mutated
Cd19 A Mutated Ikzf1 A Mutated
Cd22 A Mutated Il21r A Mutated
Cd37 A Mutated Il4ra A Mutated
Cd40 A Non-mutated Irf4 A Mutated
Cd40 A Non-mutated Jak2 A Non-mutated
Cd53 A Mutated Kpna2 A Mutated
Cd79a A Mutated Kras A Non-mutated
Cd79b A Mutated Ksr1 A Non-mutated
Cd82 A Non-mutated Lbr A Non-mutated
Cd83 A Mutated Lcp1 A Non-mutated
Cdc20 A Non-mutated Lmo2 A Non-mutated
Cdc37 A Non-mutated Lmo4 A Non-mutated
Cenpa A Non-mutated Lrmp A Mutated
Chd2 A Mutated Ltb A Mutated
Ciita A Mutated Lyl1 A Non-mutated
Cks2 A Non-mutated Lyn A Mutated
Crip1 A Non-mutated Maf A Non-mutated
Ctsh A Non-mutated Man1a A Mutated
Cyth1 A Mutated Mbd4 A Non-mutated
Dad1 A Non-mutated Mef2b A Mutated
Dock10 A Non-mutated Mef2c A Non-mutated
Ebf1 A Mutated Mid1 A Non-mutated
Gene Origin Status Gene Origin Status
Mir142 A Mutated Snx29 A Non-mutated
Mll1 A Non-mutated Snx5 A Mutated
Ms4a1 A Mutated Sorcs2 A Non-mutated
Msh6 A Mutated Sp110 A Non-mutated
Mybl2 A Non-mutated Spib A Mutated
Myc A Mutated Srsf10 A Mutated
Mycn A Non-mutated St6gal1 A Mutated
Ncl A Mutated Stmn1 A Non-mutated
Nedd8 A Non-mutated Syk A Mutated
Npm1 A Non-mutated Tapbp A Mutated
Nr5a1 A Non-mutated Tcea1 A Mutated
Nras A Non-mutated Tcl1 A Non-mutated
Odc1 A Non-mutated Tex14 A Mutated
Pax5 A Mutated Tff1 A Non-mutated
Pcna A Mutated Tkt A Non-mutated
Pebp4 A Non-mutated Top1 A Mutated
Pgk1 A Non-mutated Tpt1 A Non-mutated
Phip A Mutated Trp53 A Non-mutated
Pik3ap1 A Mutated Txn1 A Non-mutated
Pim1 A Mutated Tyms A Non-mutated
Pold4 A Mutated Ubac2 A Mutated
Polm A Non-mutated Ung A Non-mutated
Pou2af1 A Mutated Usf1 A Non-mutated
Ppp1r16b A Mutated Yes1 A Non-mutated
Prdx1 A Mutated Akap13 B Non-mutated
Prkcd A Non-mutated Apc B Non-mutated
Ptma A Mutated Axl B Non-mutated
Ptprc A Mutated Csf1r B Non-mutated
Rac2 A Non-mutated Ctnnb1 B Non-mutated
Rad51 A Mutated Ddost B Non-mutated
Raf1 A Non-mutated Fes B Non-mutated
Ran A Non-mutated Fgfr2 B Non-mutated
Ranbp1 A Mutated Gip B Non-mutated
Rapgef1 A Non-mutated Gli2 B Non-mutated
Rasa3 A Non-mutated Gnas B Non-mutated
Rassf2 A Non-mutated Irs2 B Non-mutated
Rbm39 A Mutated Lmo1 B Mutated
Rel A Mutated Mas1 B Non-mutated
Rela A Non-mutated Mcf2 B Non-mutated
Rev3l A Mutated Mos B Non-mutated
Rfc2 A Mutated Mre11a B Non-mutated
Rhoh A Mutated Mycl1 B Non-mutated
Rpia A Mutated Nfkb2 B Mutated
Rpl3 A Mutated Ntrk1 B Non-mutated
Rps12 A Mutated Prkcz B Non-mutated
Sema4d A Non-mutated Runx1 B Non-mutated
Set A Non-mutated Sis B Non-mutated
Sfi1 A Non-mutated Tal1 B Non-mutated
Sh3bp5 A Mutated Tal2 B Non-mutated
Slbp A Mutated Tiam1 B Non-mutated
Gene Origin Status Gene Origin Status
Tlx1 B Non-mutated Agtpbp1 C Non-mutated
Tnfaip3 B Mutated Aifm1 C Non-mutated
Tsc2 B Non-mutated Aire C Non-mutated
1810030J14Rik C Non-mutated Akap2 C Non-mutated
1810065E05Rik C Mutated Akap8 C Mutated
2010107E04Rik C Non-mutated Akt1 C Non-mutated
2200002D01Rik C Non-mutated Akt2 C Non-mutated
2210415F13Rik C Non-mutated Alcam C Non-mutated
Aanat C Non-mutated Alpk3 C Non-mutated
Aatf C Non-mutated Als2cl C Non-mutated
Aatk C Mutated Amd1 C Non-mutated
Abca1 C Non-mutated Ank3 C Non-mutated
Abi1 C Non-mutated Anxa5 C Non-mutated
Abi2 C Non-mutated Anxa6 C Non-mutated
Abl1 C Non-mutated Anxa7 C Non-mutated
Abl1 C Non-mutated Aoah C Non-mutated
Abl2 C Mutated Apex1 C Mutated
Ablim1 C Mutated Apip C Non-mutated
Ablim2 C Non-mutated Apoa1 C Non-mutated
Abr C Non-mutated Apoa4 C Non-mutated
Abt1 C Non-mutated Apobec1 C Mutated
Acaca C Non-mutated Apobec2 C Non-mutated
Acacb C Non-mutated Apoc3 C Non-mutated
Acer1 C Non-mutated Apoe C Mutated
Acnat1 C Non-mutated Aptx C Non-mutated
Acot1 C Non-mutated Aqp2 C Non-mutated
Acot3 C Non-mutated Aqp8 C Non-mutated
Acot7 C Mutated Arhgap31 C Non-mutated
Acr C Non-mutated Arl4a C Non-mutated
Acsl6 C Non-mutated Arpp21 C Non-mutated
Acsm1 C Non-mutated Arrb1 C Non-mutated
Acss1 C Non-mutated Art2a-ps C Non-mutated
Actb C Mutated Ascl3 C Non-mutated
Acvr1 C Non-mutated Asf1b C Non-mutated
Adamts20 C Non-mutated Aspn C Non-mutated
Adamts9 C Non-mutated Atf5 C Mutated
Adamtsl4 C Non-mutated Atg13 C Non-mutated
Adar C Mutated Atp12a C Non-mutated
Adc C Non-mutated Atp4a C Non-mutated
Adcy9 C Non-mutated Atp5b C Mutated
Adcyap1 C Non-mutated Atp5e C Mutated
Adh1 C Non-mutated Atp5j2 C Non-mutated
Adipoq C Non-mutated Atp5o C Mutated
Adora2b C Non-mutated Atpif1 C Non-mutated
Adss C Non-mutated Atr C Non-mutated
Aebp1 C Non-mutated Atrnl1 C Non-mutated
Aes C Non-mutated Atrx C Non-mutated
Aff2 C Non-mutated Atxn1 C Non-mutated
Agk C Mutated Atxn2 C Non-mutated
Agr2 C Non-mutated Aurka C Non-mutated
Gene Origin Status Gene Origin Status
Aurkb C Non-mutated Calm1 C Mutated
Avil C Non-mutated Camk1d C Non-mutated
Avp C Non-mutated Capn2 C Non-mutated
Azi2 C Non-mutated Capn3 C Non-mutated
B4galt1 C Non-mutated Car1 C Non-mutated
Bad C Mutated Car2 C Non-mutated
Bak1 C Non-mutated Car4 C Non-mutated
Barx2 C Non-mutated Carf C Non-mutated
Bax C Non-mutated Casc3 C Non-mutated
Baz2a C Non-mutated Casp1 C Non-mutated
Bbs4 C Non-mutated Casr C Non-mutated
Bcam C Non-mutated Cat C Mutated
Bcap31 C Non-mutated Cav2 C Non-mutated
Bcat1 C Non-mutated Cbll1 C Non-mutated
Bcl11b C Non-mutated Cbr2 C Non-mutated
Bcl3 C Non-mutated Cbx1 C Non-mutated
Bcl6b C Non-mutated Cby1 C Non-mutated
Bco2 C Non-mutated Ccdc56 C Non-mutated
Bcr C Non-mutated Cckar C Non-mutated
Best2 C Non-mutated Ccl1 C Non-mutated
Bgn C Non-mutated Ccl28 C Non-mutated
Bid C Mutated Ccnb1ip1 C Non-mutated
Bmf C Non-mutated Ccne1 C Non-mutated
Bmi1 C Non-mutated Ccne2 C Mutated
Bmp2k C Mutated Ccr1 C Non-mutated
Bnip3 C Non-mutated Ccr7 C Non-mutated
Bop1 C Non-mutated Ccrn4l C Non-mutated
Brca1 C Mutated Cd1d1 C Non-mutated
Brca2 C Non-mutated Cd1d2 C Non-mutated
Brf1 C Non-mutated Cd209b C Non-mutated
Brms1 C Non-mutated Cd24a C Mutated
Brsk1 C Non-mutated Cd27 C Non-mutated
Btg4 C Non-mutated Cd28 C Non-mutated
Btrc C Non-mutated Cd300lf C Non-mutated
Bub1 C Non-mutated Cd36 C Non-mutated
Bub1b C Non-mutated Cd3e C Non-mutated
Bub3 C Non-mutated Cd40lg C Non-mutated
C1d C Non-mutated Cd48 C Mutated
C2cd3 C Mutated Cd5 C Non-mutated
C3 C Non-mutated Cd74 C Mutated
Cabp4 C Non-mutated Cd9 C Non-mutated
Cacna1a C Non-mutated Cdc42bpa C Non-mutated
Cacna1e C Non-mutated Cdc42ep1 C Non-mutated
Cacna1s C Non-mutated Cdh1 C Non-mutated
Cacnb2 C Non-mutated Cdh4 C Non-mutated
Cacnb3 C Non-mutated Cdk1 C Non-mutated
Cacng4 C Mutated Cdk11b C Mutated
Cadm1 C Non-mutated Cdk4 C Mutated
Cadps2 C Non-mutated Cdk5 C Non-mutated
Calca C Non-mutated Cdkn1a C Non-mutated
Gene Origin Status Gene Origin Status
Cdkn1b C Non-mutated Creb1 C Non-mutated
Cdkn2a C Non-mutated Crebbp C Non-mutated
Cdkn2b C Non-mutated Crem C Non-mutated
Cdkn2c C Non-mutated Crip3 C Non-mutated
Cdt1 C Non-mutated Crlf1 C Non-mutated
Cebpa C Non-mutated Cry2 C Non-mutated
Cebpb C Non-mutated Csf1 C Non-mutated
Cebpd C Non-mutated Csf2 C Non-mutated
Cebpe C Non-mutated Csk C Mutated
Cebpg C Non-mutated Csnk1d C Mutated
Cela1 C Non-mutated Csrnp2 C Non-mutated
Cela2a C Non-mutated Ctbp2 C Non-mutated
Celf1 C Non-mutated Ctcf C Non-mutated
Celf2 C Non-mutated Ctcf C Non-mutated
Celf3 C Non-mutated Ctgf C Non-mutated
Celf4 C Non-mutated Ctnna3 C Non-mutated
Cenpf C Non-mutated Ctnnd1 C Non-mutated
Cenpk C Non-mutated Ctsd C Non-mutated
Cetn1 C Non-mutated Ctse C Non-mutated
Chd1 C Non-mutated Ctsg C Non-mutated
Chd7 C Non-mutated Ctss C Non-mutated
Chek1 C Mutated Cxadr C Non-mutated
Chek2 C Non-mutated Cybrd1 C Non-mutated
Chrna1 C Non-mutated Cycs C Non-mutated
Chrna6 C Non-mutated Cyfip1 C Non-mutated
Chrnb2 C Non-mutated Cyp11b1 C Non-mutated
Cirbp C Non-mutated Cyp11b2 C Non-mutated
Cish C Non-mutated Cyp1a1 C Non-mutated
Ckmt1 C Non-mutated Cyp2c55 C Non-mutated
Clca1 C Non-mutated Cyp39a1 C Non-mutated
Clcn1 C Non-mutated Cyth3 C Non-mutated
Clcn2 C Non-mutated Dand5 C Non-mutated
Clcnka C Non-mutated Dao C Non-mutated
Cldn1 C Non-mutated Dap3 C Non-mutated
Clk1 C Mutated Daxx C Mutated
Cln6 C Non-mutated Dbh C Non-mutated
Cnbp C Mutated Dbi C Non-mutated
Cnga2 C Non-mutated Dcn C Non-mutated
Col1a1 C Non-mutated Dctn3 C Non-mutated
Col5a3 C Non-mutated Ddb2 C Mutated
Cox10 C Non-mutated Ddit3 C Non-mutated
Cox4i1 C Mutated Ddr1 C Non-mutated
Cox6a1 C Mutated Ddx20 C Mutated
Cox6b1 C Non-mutated Ddx5 C Mutated
Cox6c C Non-mutated Deaf1 C Non-mutated
Cox8a C Mutated Dedd C Non-mutated
Cpa1 C Non-mutated Def8 C Non-mutated
Cpeb1 C Non-mutated Dffa C Non-mutated
Cradd C Mutated Dgat2 C Non-mutated
Crcp C Non-mutated Dgki C Non-mutated
Gene Origin Status Gene Origin Status
Dgkz C Non-mutated Eif3b C Non-mutated
Dguok C Non-mutated Eif3d C Mutated
Dhrs4 C Non-mutated Eif5a C Mutated
Dicer1 C Non-mutated Elane C Non-mutated
Dlc1 C Non-mutated Elf1 C Non-mutated
Dld C Non-mutated Elf4 C Non-mutated
Dmap1 C Non-mutated Elf5 C Non-mutated
Dmc1 C Non-mutated Elk1 C Non-mutated
Dnaja1 C Non-mutated Ell C Mutated
Dnajb11 C Non-mutated Eln C Non-mutated
Dnd1 C Non-mutated Elp2 C Non-mutated
Dnmt1 C Mutated Enox1 C Non-mutated
Dnmt3a C Non-mutated Enox2 C Non-mutated
Dnmt3l C Non-mutated Epb4.1l5 C Non-mutated
Dntt C Non-mutated Epcam C Non-mutated
Doc2a C Non-mutated Epgn C Non-mutated
Dock7 C Non-mutated Ephb2 C Non-mutated
Dok1 C Mutated Ephx1 C Non-mutated
Dpf1 C Non-mutated Erap1 C Non-mutated
Drd5 C Non-mutated Erbb2 C Non-mutated
Dsg4 C Mutated Erbb3 C Non-mutated
Dsp C Non-mutated Ercc1 C Non-mutated
Dtx2 C Non-mutated Ercc2 C Non-mutated
Dub1 C Non-mutated Ercc4 C Non-mutated
Dub1a C Non-mutated Ercc5 C Non-mutated
Duox2 C Non-mutated Ereg C Non-mutated
Dusp22 C Non-mutated Eri1 C Mutated
Dusp6 C Mutated Esam C Non-mutated
Dyrk3 C Mutated Esrra C Non-mutated
E2f1 C Mutated Esrrb C Non-mutated
E2f2 C Mutated Esrrg C Non-mutated
E2f4 C Non-mutated Etnk2 C Non-mutated
E2f7 C Non-mutated Etv4 C Non-mutated
E4f1 C Mutated Etv6 C Non-mutated
Ear2 C Non-mutated Exo1 C Non-mutated
Ebf3 C Non-mutated Ezr C Non-mutated
Ebf4 C Non-mutated Fabp2 C Non-mutated
Ect2 C Non-mutated Fabp5 C Non-mutated
Eda C Non-mutated Fabp7 C Non-mutated
Edil3 C Non-mutated Faf1 C Non-mutated
Eef1a1 C Mutated Faim C Non-mutated
Egf C Non-mutated Fancc C Non-mutated
Egf7 C Non-mutated Fancd2 C Non-mutated
Egfr C Non-mutated Fancg C Non-mutated
Egr2 C Non-mutated Far1 C Non-mutated
Ehhadh C Non-mutated Fasl C Non-mutated
Ehmt2 C Non-mutated Fau C Non-mutated
Eif2a C Mutated Fbl C Non-mutated
Eif2ak4 C Non-mutated Fbxl12 C Non-mutated
Eif3a C Mutated Fbxo11 C Non-mutated
Gene Origin Status Gene Origin Status
Fbxo5 C Non-mutated Gas1 C Non-mutated
Fbxo8 C Non-mutated Gas7 C Non-mutated
Fcgr1 C Non-mutated Gata2 C Non-mutated
Fcgr3 C Non-mutated Gata3 C Non-mutated
Ferd3l C Non-mutated Gata4 C Non-mutated
Ffar1 C Non-mutated Gata6 C Non-mutated
Fgd4 C Non-mutated Gck C Non-mutated
Fgf1 C Non-mutated Gdap1 C Non-mutated
Fgf2 C Non-mutated Gdf5 C Non-mutated
Fgf3 C Non-mutated Gdf7 C Non-mutated
Fgf4 C Non-mutated Gdi2 C Mutated
Fgf6 C Non-mutated Ghr C Non-mutated
Fgf7 C Non-mutated Ghrhr C Non-mutated
Fgfr1 C Non-mutated Gigyf1 C Non-mutated
Fgfr1 C Non-mutated Gins1 C Non-mutated
Figf C Non-mutated Gja1 C Non-mutated
Flt4 C Non-mutated Gja10 C Non-mutated
Fntb C Non-mutated Gjc2 C Non-mutated
Fos C Non-mutated Gkap1 C Non-mutated
Fosl1 C Non-mutated Glis1 C Non-mutated
Fosl2 C Non-mutated Gls C Non-mutated
Foxa1 C Non-mutated Gm1821 C Non-mutated
Foxc1 C Non-mutated Gm5409 C Non-mutated
Foxc2 C Non-mutated Gna12 C Non-mutated
Foxd1 C Non-mutated Gna13 C Mutated
Foxe3 C Non-mutated Gnao1 C Non-mutated
Foxf2 C Non-mutated Gng2 C Non-mutated
Foxg1 C Non-mutated Gnpat C Non-mutated
Foxj1 C Non-mutated Got1 C Non-mutated
Foxl2 C Non-mutated Gpat2 C Non-mutated
Foxo3 C Non-mutated Gpd1 C Non-mutated
Foxo4 C Mutated Gphn C Non-mutated
Foxp1 C Non-mutated Gpnmb C Non-mutated
Foxp3 C Non-mutated Gpr12 C Non-mutated
Fpr1 C Non-mutated Gpx1 C Non-mutated
Frat1 C Non-mutated Gpx2 C Non-mutated
Frem1 C Non-mutated Grik2 C Non-mutated
Fscn2 C Non-mutated Grip1 C Non-mutated
Fth1 C Mutated Grlf1 C Non-mutated
Ftl1 C Mutated Grn C Non-mutated
Fyb C Non-mutated Grsf1 C Non-mutated
Fyn C Non-mutated Gsdma3 C Non-mutated
Gab3 C Non-mutated Gsdmd C Non-mutated
Gabrg1 C Non-mutated Gsk3b C Non-mutated
Gadd45a C Non-mutated Gss C Non-mutated
Gadd45g C Mutated Gsta3 C Mutated
Gale C Non-mutated Gstk1 C Non-mutated
Galnt1 C Mutated Gstp1 C Non-mutated
Gamt C Non-mutated Guca2a C Non-mutated
Gap43 C Non-mutated Gucy1a2 C Non-mutated
Gene Origin Status Gene Origin Status
Gucy1a3 C Non-mutated Id2 C Non-mutated
Gulo C Non-mutated Id4 C Non-mutated
Gyk C Non-mutated Ifitm1 C Non-mutated
Gykl1 C Non-mutated Ifnar1 C Non-mutated
Gypa C Non-mutated Ifnar2 C Non-mutated
Gzmb C Non-mutated Igf2 C Non-mutated
H2-Aa C Non-mutated Igfp3 C Non-mutated
H2-Bl C Non-mutated Ighg1 C Non-mutated
H47 C Mutated Ighg2b C Non-mutated
H60c C Non-mutated Ighg2c C Non-mutated
Hba-a1 C Non-mutated Ighm C Non-mutated
Hck C Non-mutated Igsf5 C Non-mutated
Hdac2 C Non-mutated Igsf9 C Non-mutated
Hdac3 C Non-mutated Ikbkb C Non-mutated
Hdac6 C Non-mutated Ikbkg C Non-mutated
Hdac7 C Non-mutated Ikzf2 C Non-mutated
Hdac9 C Mutated Il17c C Non-mutated
Hdc C Non-mutated Il19 C Non-mutated
Hectd1 C Non-mutated Il21 C Non-mutated
Hells C Mutated Il25 C Non-mutated
Hif3a C Non-mutated Il2ra C Non-mutated
Hint1 C Non-mutated Il3 C Non-mutated
Hist1h1a C Mutated Il4 C Non-mutated
Hist1h1b C Mutated Il6 C Non-mutated
Hist1h1t C Non-mutated Il7 C Non-mutated
Hlf C Non-mutated Il7r C Non-mutated
Hltf C Non-mutated Ildr2 C Mutated
Hopx C Non-mutated Impact C Non-mutated
Hoxa3 C Non-mutated Ing1 C Non-mutated
Hoxa3 C Non-mutated Insig1 C Non-mutated
Hoxb1 C Non-mutated Ipmk C Mutated
Hoxb5 C Non-mutated Ipo11 C Non-mutated
Hoxd12 C Non-mutated Ipo11 C Non-mutated
Hoxd13 C Non-mutated Ipo7 C Mutated
Hpx C Non-mutated Irf6 C Non-mutated
Hrg C Non-mutated Irg1 C Non-mutated
Hrh1 C Non-mutated Irs1 C Non-mutated
Hsd17b12 C Non-mutated Islr2 C Non-mutated
Hsf4 C Mutated Itch C Non-mutated
Hspa1a C Non-mutated Itga1 C Non-mutated
Hspa1b C Non-mutated Itga2b C Non-mutated
Hspb2 C Non-mutated Itga4 C Mutated
Htr3b C Non-mutated Itga5 C Non-mutated
Htr5a C Non-mutated Itgal C Mutated
Hvcn1 C Mutated Itgam C Non-mutated
Hyal5 C Non-mutated Itgb1bp3 C Non-mutated
Icam1 C Non-mutated Itgb2 C Mutated
Icmt C Non-mutated Itpka C Non-mutated
Icosl C Non-mutated Jag2 C Non-mutated
Id1 C Non-mutated Jak3 C Non-mutated
Gene Origin Status Gene Origin Status
Jmjd6 C Non-mutated Madd C Non-mutated
Jun C Non-mutated Maf C Non-mutated
Junb C Mutated Maoa C Non-mutated
Jund C Non-mutated Map2k1 C Non-mutated
Kcna5 C Non-mutated Mapk1 C Non-mutated
Kcnj8 C Non-mutated Mapk3 C Non-mutated
Kif17 C Non-mutated Mapk7 C Non-mutated
Kif1b C Non-mutated Mapk8ip3 C Non-mutated
Kifap3 C Non-mutated Mapkbp1 C Non-mutated
Kiss1 C Non-mutated Mast2 C Non-mutated
Kiss1r C Non-mutated Mb C Non-mutated
Kit C Non-mutated Mbd2 C Non-mutated
Kitl C Non-mutated Mbd3 C Non-mutated
Klb C Non-mutated Mbl1 C Non-mutated
Klk1 C Non-mutated Mbl2 C Non-mutated
Kpnb1 C Mutated Mcm2 C Mutated
Krt20 C Non-mutated Mcm6 C Mutated
Krt27 C Non-mutated Mcm7 C Mutated
L1cam C Non-mutated Mcpt4 C Non-mutated
Lag3 C Non-mutated Mdfi C Mutated
Lamtor3 C Non-mutated Mdh2 C Mutated
Large C Non-mutated Mdk C Non-mutated
Lass2 C Non-mutated Mdm2 C Non-mutated
Lats2 C Non-mutated Mecp2 C Non-mutated
Lbp C Non-mutated Mef2a C Non-mutated
Lbx1 C Non-mutated Mest C Non-mutated
Lcat C Non-mutated Met C Non-mutated
Lck C Non-mutated Mgst3 C Non-mutated
Lef1 C Non-mutated Mia1 C Non-mutated
Lepr C Non-mutated Mknk1 C Non-mutated
Lepre1 C Non-mutated Mlh1 C Non-mutated
Lgals1 C Non-mutated Mlh3 C Mutated
Lgals4 C Non-mutated Mll3 C Non-mutated
Lifr C Non-mutated Mlst8 C Mutated
Lig4 C Non-mutated Mlx C Non-mutated
Lims1 C Non-mutated Mmp2 C Non-mutated
Lin7a C Non-mutated Mnat1 C Non-mutated
Lipa C Non-mutated Mogat1 C Non-mutated
Lipg C Non-mutated Mogat2 C Non-mutated
Lmbr1 C Non-mutated Mov10l1 C Non-mutated
Lmf1 C Non-mutated Mpdz C Non-mutated
Loxhd1 C Non-mutated Mrpl51 C Mutated
Lpar1 C Non-mutated Ms4a8a C Non-mutated
Lpin2 C Non-mutated Msh2 C Mutated
Lsp1 C Mutated Msh3 C Non-mutated
Lst1 C Non-mutated Msh4 C Non-mutated
Lta C Non-mutated Msh5 C Mutated
Lxn C Non-mutated Mstn C Non-mutated
Ly6e C Mutated Msx1 C Non-mutated
Lyz1 C Non-mutated Msx3 C Non-mutated
Gene Origin Status Gene Origin Status
Mt1 C Non-mutated Noxo1 C Non-mutated
Mtap1a C Non-mutated Npc1l1 C Non-mutated
Mtbp C Non-mutated Npy C Non-mutated
Mthfd1 C Non-mutated Nr3c2 C Non-mutated
Mtor C Mutated Nr4a2 C Non-mutated
Mtss1 C Mutated Ntan1 C Mutated
Myb C Non-mutated Nup160 C Non-mutated
Mybbp1a C Mutated Nup62 C Non-mutated
Mycbp2 C Mutated Nupr1 C Non-mutated
Myh11 C Non-mutated Oit1 C Non-mutated
Myl12b C Non-mutated Oprd1 C Non-mutated
Myo1f C Non-mutated Pafah1b1 C Non-mutated
Myo6 C Non-mutated Pak1 C Non-mutated
Nampt C Non-mutated Parg C Non-mutated
Nanog C Non-mutated Parp1 C Mutated
Nanos2 C Non-mutated Parp2 C Non-mutated
Nat3 C Non-mutated Parp4 C Non-mutated
Ncf1 C Non-mutated Pax2 C Non-mutated
Nckap1 C Non-mutated Pax6 C Non-mutated
Ncoa1 C Non-mutated Paxip1 C Non-mutated
Ncor1 C Non-mutated Pcsk1 C Non-mutated
Ndrg1 C Non-mutated Pdcd1lg2 C Non-mutated
Ndufa2 C Non-mutated Pde6g C Non-mutated
Ndufa3 C Non-mutated Pdgfa C Non-mutated
Ndufa7 C Non-mutated Pdgf C Non-mutated
Nduf9 C Non-mutated Pdgfc C Non-mutated
Nek1 C Non-mutated Pdgfra C Non-mutated
Neurl1a C Non-mutated Pea15b C Non-mutated
Nf1 C Non-mutated Perp C Non-mutated
Nf2 C Non-mutated Pex13 C Mutated
Nfil3 C Non-mutated Pgm1 C Non-mutated
Nfkb1 C Non-mutated Phf21a C Non-mutated
Nfkbid C Non-mutated Phgr1 C Non-mutated
Nfx1 C Non-mutated Pias1 C Mutated
Nfyb C Non-mutated Pick1 C Mutated
Nkx2-2 C Non-mutated Pik3c2b C Non-mutated
Nkx3-1 C Non-mutated Pik3cd C Non-mutated
Nlgn3 C Non-mutated Pim2 C Non-mutated
Nlk C Non-mutated Pin1 C Non-mutated
Nlrc4 C Non-mutated Pip5k1b C Non-mutated
Nmnat1 C Non-mutated Pitx3 C Non-mutated
Nod1 C Non-mutated Pkd1 C Non-mutated
Nod2 C Non-mutated Pkn1 C Non-mutated
Nodal C Non-mutated Pla2g15 C Non-mutated
Nog C Non-mutated Plaa C Non-mutated
Nos3 C Non-mutated Plac8 C Mutated
Notch1 C Non-mutated Plat C Non-mutated
Notch2 C Non-mutated Plcb2 C Mutated
Nox1 C Non-mutated Plch2 C Non-mutated
Noxa1 C Non-mutated Plcl1 C Non-mutated
Gene Origin Status Gene Origin Status
Plk2 C Non-mutated Ptbp2 C Mutated
Plscr3 C Non-mutated Pten C Mutated
Pms2 C Mutated Ptf1a C Non-mutated
Pnliprp2 C Non-mutated Ptk2 C Non-mutated
Pnp C Non-mutated Ptk2b C Non-mutated
Pnpla6 C Non-mutated Ptk7 C Non-mutated
Pola1 C Mutated Ptp4a1 C Non-mutated
Pola2 C Non-mutated Ptpn1 C Non-mutated
Polb C Non-mutated Ptpra C Non-mutated
Pold1 C Mutated Ptprm C Non-mutated
Polg C Non-mutated Ptprt C Non-mutated
Polh C Non-mutated Ptrf C Non-mutated
Polk C Non-mutated Pttg1 C Non-mutated
Polr1b C Non-mutated Pvrl1 C Non-mutated
Pomc C Non-mutated Pycard C Non-mutated
Postn C Non-mutated Qtrtd1 C Non-mutated
Pot1a C Non-mutated Rab27a C Non-mutated
Pot1b C Non-mutated Rab3a C Non-mutated
Pou2f1 C Mutated Rab3c C Non-mutated
Pou2f2 C Mutated Rab4a C Non-mutated
Pou2f3 C Non-mutated Rab5b C Non-mutated
Pou3f2 C Non-mutated Rab5c C Non-mutated
Pou3f3 C Non-mutated Rac1 C Mutated
Pou4f1 C Non-mutated Rac3 C Non-mutated
Pou4f2 C Non-mutated Rad17 C Non-mutated
Pou4f3 C Non-mutated Rad23a C Mutated
Ppard C Mutated Rad23b C Non-mutated
Ppargc1a C Non-mutated Rad51c C Non-mutated
Ppia C Mutated Rad52 C Non-mutated
Ppm1j C Non-mutated Rad54b C Non-mutated
Ppm1l C Non-mutated Rad54b C Non-mutated
Ppp1r15a C Non-mutated Rad54l C Non-mutated
Ppp1r15b C Mutated Rad9 C Mutated
Ppp3ca C Non-mutated Rag1 C Non-mutated
Prdm1 C Non-mutated Rala C Non-mutated
Prdx6 C Non-mutated Ramp1 C Non-mutated
Prkaa1 C Non-mutated Rasgrf1 C Non-mutated
Prkcc C Non-mutated Rb1 C Non-mutated
Prkci C Non-mutated Rb1cc1 C Non-mutated
Prkdc C Non-mutated Rbbp7 C Non-mutated
Prkra C Non-mutated Rbl1 C Non-mutated
Prl4a1 C Non-mutated Rbm15 C Mutated
Prlr C Non-mutated Rbm19 C Mutated
Prss1 C Non-mutated Rbpjl C Non-mutated
Prss3 C Non-mutated Rdx C Non-mutated
Psap C Non-mutated Rec8 C Non-mutated
Psmb4 C Non-mutated Recql4 C Mutated
Psmc3 C Mutated Reg4 C Non-mutated
Psme1 C Non-mutated Rell2 C Non-mutated
Psme2 C Non-mutated Ret C Non-mutated
Gene Origin Status Gene Origin Status
Rev1 C Non-mutated Sprr2a2 C Non-mutated
Rfx3 C Non-mutated Sprr2b C Non-mutated
Rgma C Non-mutated Sra1 C Mutated
Rgmb C Non-mutated Src C Non-mutated
Rgs13 C Mutated Srcin1 C Non-mutated
Rgs9bp C Non-mutated Srf C Non-mutated
Rhoa C Non-mutated Srpk2 C Non-mutated
Rhob C Non-mutated Srrd C Non-mutated
Rictor C Non-mutated Srsf1 C Non-mutated
Rims1 C Mutated Ss18l1 C Non-mutated
Rims2 C Non-mutated Ssbp1 C Non-mutated
Rnaseh1 C Non-mutated Sst C Non-mutated
Rnf11 C Non-mutated Sstr2 C Non-mutated
Rnf130 C Non-mutated Stac C Non-mutated
Rnf2 C Mutated Stap1 C Non-mutated
Ror2 C Non-mutated Star C Non-mutated
Ros1 C Non-mutated Stat3 C Non-mutated
Rpa1 C Mutated Stat4 C Non-mutated
Rpl29 C Mutated Stat5a C Non-mutated
Rpl32 C Mutated Stat5b C Non-mutated
Rpl35 C Mutated Stau1 C Mutated
Rpl4 C Mutated Steap4 C Non-mutated
Rpl41 C Mutated Strap C Non-mutated
Rplp0 C Mutated Stub1 C Non-mutated
Rps14 C Mutated Stx3 C Mutated
Rps5 C Mutated Sumo3 C Non-mutated
Rps6 C Mutated Sv2a C Non-mutated
Rps9 C Mutated Sv2b C Mutated
Rras C Non-mutated Swap70 C Mutated
Rrn3 C Non-mutated Syn1 C Non-mutated
Rsc1a1 C Non-mutated Sync C Non-mutated
Rsu1 C Non-mutated Syngr1 C Non-mutated
Rtel1 C Non-mutated Syngr3 C Non-mutated
Runx1t1 C Mutated Synpo C Non-mutated
Ryr2 C Non-mutated Syp C Non-mutated
S100a16 C Non-mutated Sypl2 C Non-mutated
S100a6 C Non-mutated Sytl1 C Non-mutated
Saa1 C Non-mutated Taf10 C Non-mutated
Saf C Mutated Taf4a C Mutated
Satb2 C Non-mutated Taf7l C Non-mutated
Scai C Non-mutated Taf8 C Non-mutated
Scarf2 C Non-mutated Taf9 C Mutated
Scn1a C Non-mutated Taf9 C Mutated
Scnm1 C Non-mutated Tbp C Non-mutated
Sdc1 C Non-mutated Tbpl1 C Non-mutated
Selenbp1 C Non-mutated Tbpl2 C Non-mutated
Selp C Non-mutated Tcf21 C Non-mutated
Sema3a C Non-mutated Tcf3 C Mutated
Serpinb9 C Non-mutated Tcf4 C Mutated
Serpine1 C Non-mutated Tcf7l2 C Non-mutated
Gene Origin Status Gene Origin Status
Tdrd1 C Non-mutated Traf3ip2 C Non-mutated
Tdrd6 C Non-mutated Traf4 C Non-mutated
Tead2 C Non-mutated Traf6 C Non-mutated
Tek C Non-mutated Trhr2 C Non-mutated
Tekt2 C Non-mutated Trim63 C Non-mutated
Tenc1 C Non-mutated Trp53bp1 C Non-mutated
Tep1 C Non-mutated Trp53bp2 C Non-mutated
Tet2 C Mutated Trpt1 C Non-mutated
Tfap2a C Non-mutated Tsg101 C Non-mutated
Tfap2e C Non-mutated Tspan1 C Non-mutated
Tfap4 C Mutated Ttf1 C Mutated
Tfcp2l1 C Non-mutated Ttll8 C Non-mutated
Tfdp1 C Mutated Tyr C Non-mutated
Tfdp2 C Non-mutated U2af2 C Mutated
Tfe3 C Non-mutated Uba3 C Mutated
Tfeb C Non-mutated Ubb C Mutated
Tfec C Non-mutated Ube2b C Mutated
Tff3 C Non-mutated Ube2n C Mutated
Tgfa C Non-mutated Ube3a C Non-mutated
Tgf1 C Non-mutated Ube4b C Mutated
Tgf2 C Non-mutated Ubox5 C Mutated
Tgf3 C Non-mutated Ubtf C Mutated
Tgfi C Non-mutated Uchl1 C Non-mutated
Tgfr1 C Non-mutated Ucp3 C Non-mutated
Tgif2 C Non-mutated Ufm1 C Non-mutated
T C Non-mutated Ufm1 C Non-mutated
Tra C Non-mutated Uhmk1 C Mutated
Tial1 C Non-mutated Ulbp1 C Non-mutated
Tinf2 C Non-mutated Uncx C Non-mutated
Tk2 C Non-mutated Uqcrh C Non-mutated
Tlr1 C Non-mutated Uqcrq C Non-mutated
Tlr2 C Non-mutated Usp22 C Non-mutated
Tmlhe C Non-mutated Usp8 C Non-mutated
Tmod1 C Non-mutated Vav1 C Mutated
Tmsb4x C Mutated Vav2 C Mutated
Tnf C Mutated Vav3 C Non-mutated
Tnfaip1 C Non-mutated Vcan C Non-mutated
Tnfrsf11b C Non-mutated Vcl C Mutated
Tnfrsf12a C Non-mutated Vdac1 C Mutated
Tnfrsf4 C Non-mutated Vdr C Non-mutated
Tnfsf11 C Non-mutated Vezt C Non-mutated
Tnks2 C Non-mutated Vhl C Non-mutated
Tnn C Non-mutated Vim C Non-mutated
Tnp2 C Non-mutated Vnn3 C Non-mutated
Top2a C Mutated Vrk1 C Non-mutated
Top2b C Non-mutated Vsx1 C Non-mutated
Top3b C Non-mutated Vtn C Non-mutated
Topors C Mutated Vwa1 C Non-mutated
Tpi1 C Non-mutated Vwc2 C Non-mutated
Tpm1 C Non-mutated Wisp2 C Non-mutated
Gene Origin Status
Wnt7b C Non-mutated
Wt1 C Non-mutated
Wwp1 C Non-mutated
Xab2 C Non-mutated
Xbp1 C Mutated
Xiap C Non-mutated
Xpa C Non-mutated
Xpc C Non-mutated
Xrcc6 C Non-mutated
Zbtb7a C Non-mutated
Zc3h15 C Mutated
Zdhhc1 C Non-mutated
Zdhhc8 C Non-mutated
Zeb1 C Non-mutated
Zfand6 C Non-mutated
Zfp467 C Non-mutated
Zfp488 C Non-mutated
Zg16 C Non-mutated
Zglp1 C Non-mutated
Zhx2 C Non-mutated
Zmiz1 C Non-mutated
Zmpste24 C Non-mutated
Zp3 C Non-mutated
Zscan21 C Non-mutated
Annex II. List of the 291 AID targets discovered in Ung-/-Msh2-/- GC B cells.
Transitions at C/G pairs C/G Transition Frequency Total mutation frequency
FDR
Gene Ensembl ID Coordinates C/G transitions C/G sequenced C/G transitions C/G sequenced C/G transitions C/G sequenced Exp1 Exp2 Exp1 Exp2 Exp1 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1
1810065E05Rik ENSMUSG00000013653 11:58234613-58235112 108 578612 123 654456 66 616727 1,28E-03 7,46E-04 1,87E-04 1,88E-04 1,07E-04 4,66E-04 4,07E-04 4,29E-04 4,82E-04 4,14E-04 4,18E-04 4,35E-04 4,10E-04 4,83E-04
Aatk ENSMUSG00000025375 11:119907530-119908029 115 627801 132 689096 70 665980 8,87E-04 1,69E-04 1,83E-04 1,92E-04 1,05E-04 3,63E-04 3,35E-04 3,49E-04 3,80E-04 3,64E-04 3,30E-04 3,70E-04 3,55E-04 3,12E-04
Abl2 ENSMUSG00000026596 1:158488918-158489417 24 127053 29 134774 4 120744 9,98E-04 1,60E-04 1,89E-04 2,15E-04 3,31E-05 5,54E-04 4,58E-04 5,18E-04 5,99E-04 5,21E-04 5,12E-04 4,88E-04 4,77E-04 3,93E-04
Ablim1-1 ENSMUSG00000025085 19:57193000-57193499 158 871990 154 977772 103 917256 5,96E-04 2,13E-02 1,81E-04 1,58E-04 1,12E-04 3,53E-04 3,00E-04 3,03E-04 3,41E-04 3,29E-04 2,82E-04 3,62E-04 3,15E-04 3,15E-04
Acot7-2 ENSMUSG00000028937 4:151560243-151560742 414 600746 779 686292 86 655520 1,81E-57 5,60E-132 6,89E-04 1,14E-03 1,31E-04 5,83E-04 6,28E-04 5,25E-04 1,06E-03 5,30E-04 5,01E-04 6,55E-04 8,77E-04 2,96E-04
Actb ENSMUSG00000029580 5:143667904-143668403 1283 664606 1337 727186 88 706775 6,36E-287 8,41E-278 1,93E-03 1,84E-03 1,25E-04 5,08E-04 4,43E-04 5,85E-04 5,30E-04 5,68E-04 6,63E-04 1,46E-03 1,41E-03 3,40E-04
Ada ENSMUSG00000017697 2:163575414-163575913 142 839004 144 900476 100 867497 9,12E-03 3,03E-02 1,69E-04 1,60E-04 1,15E-04 3,71E-04 2,90E-04 3,53E-04 3,47E-04 3,77E-04 3,40E-04 3,69E-04 3,46E-04 3,39E-04
Adar-2 ENSMUSG00000027951 3:89534640-89535139 158 844603 190 951051 122 906859 1,58E-02 2,15E-03 1,87E-04 2,00E-04 1,35E-04 3,31E-04 3,21E-04 3,48E-04 3,38E-04 3,16E-04 2,92E-04 3,64E-04 3,52E-04 3,15E-04
Agk ENSMUSG00000029916 6:40275477-40275976 128 661157 128 721156 87 712317 2,98E-03 2,00E-02 1,94E-04 1,77E-04 1,22E-04 3,73E-04 3,34E-04 3,28E-04 3,47E-04 3,45E-04 2,94E-04 3,88E-04 3,19E-04 3,27E-04
Aicda ENSMUSG00000040627 6:122503827-122504326 419 622206 336 688299 63 656677 2,98E-68 3,96E-42 6,73E-04 4,88E-04 9,59E-05 4,26E-04 3,31E-04 3,35E-04 3,40E-04 3,67E-04 4,17E-04 6,19E-04 4,89E-04 2,90E-04
Akap8 ENSMUSG00000024045 17:32457599-32458098 271 921841 216 991927 136 937960 4,50E-11 7,25E-04 2,94E-04 2,18E-04 1,45E-04 3,74E-04 3,35E-04 3,62E-04 3,82E-04 3,41E-04 3,18E-04 4,56E-04 3,78E-04 3,18E-04
Apex1 ENSMUSG00000035960 14:51544696-51545195 112 534368 133 634471 70 479669 3,76E-02 3,41E-02 2,10E-04 2,10E-04 1,46E-04 3,60E-04 2,93E-04 3,80E-04 3,55E-04 3,39E-04 3,23E-04 4,14E-04 3,77E-04 4,19E-04
Apobec1 ENSMUSG00000040613 6:122551963-122552462 59 216939 78 243624 28 242037 6,11E-04 7,05E-06 2,72E-04 3,20E-04 1,16E-04 4,01E-04 2,99E-04 3,67E-04 3,49E-04 3,30E-04 3,08E-04 3,97E-04 4,20E-04 3,28E-04
Apoe ENSMUSG00000002985 7:20284016-20284515 217 808907 187 904147 105 862508 6,65E-11 5,24E-05 2,68E-04 2,07E-04 1,22E-04 3,63E-04 3,01E-04 3,53E-04 3,70E-04 3,31E-04 3,16E-04 3,83E-04 4,08E-04 3,06E-04
Atf5-2 ENSMUSG00000038539 7:52071529-52072028 221 661275 272 692644 122 656875 7,03E-07 1,14E-11 3,34E-04 3,93E-04 1,86E-04 4,29E-04 3,24E-04 3,65E-04 3,99E-04 3,79E-04 3,80E-04 5,05E-04 4,96E-04 3,40E-04
Atp5b-1 ENSMUSG00000025393 10:127520363-127520862 245 702451 235 774079 87 734085 4,76E-19 3,08E-14 3,49E-04 3,04E-04 1,19E-04 3,62E-04 3,04E-04 3,39E-04 3,78E-04 3,47E-04 3,21E-04 4,56E-04 4,38E-04 3,10E-04
Atp5e ENSMUSG00000016252 2:174289103-174289602 150 756165 169 826748 109 799734 8,19E-03 3,15E-03 1,98E-04 2,04E-04 1,36E-04 3,83E-04 3,17E-04 3,65E-04 3,94E-04 3,49E-04 3,78E-04 3,93E-04 3,69E-04 3,19E-04
Atp5o ENSMUSG00000022956 16:91931376-91931875 126 627614 160 689116 89 675021 7,13E-03 6,90E-05 2,01E-04 2,32E-04 1,32E-04 9,69E-04 8,26E-04 7,58E-04 5,83E-04 7,95E-04 8,06E-04 8,04E-04 8,53E-04 1,47E-03
B2m ENSMUSG00000060802 2:121973423-121973922 181 865665 399 979732 128 900105 2,76E-03 1,73E-27 2,09E-04 4,07E-04 1,42E-04 4,73E-04 3,27E-04 3,45E-04 3,69E-04 3,78E-04 3,22E-04 3,93E-04 4,93E-04 3,39E-04
Bad ENSMUSG00000024959 19:7016345-7016844 156 951417 208 1053172 119 969598 3,72E-02 1,27E-04 1,64E-04 1,97E-04 1,23E-04 3,70E-04 3,09E-04 3,66E-04 3,49E-04 3,81E-04 2,93E-04 3,73E-04 3,48E-04 3,38E-04
Bcl11a-1 ENSMUSG00000000861 11:23978056-23978555 93 308111 117 348752 52 329931 6,13E-04 1,68E-05 3,02E-04 3,35E-04 1,58E-04 4,14E-04 4,00E-04 4,10E-04 5,15E-04 4,29E-04 4,09E-04 4,51E-04 4,90E-04 4,01E-04
Bcl6 ENSMUSG00000022508 16:23988199-23988698 1404 417740 1939 440223 120 436513 8,99E-289 0,00E+00 3,36E-03 4,40E-03 2,75E-04 9,42E-04 6,94E-04 6,33E-04 5,07E-04 6,47E-04 7,36E-04 1,83E-03 2,27E-03 4,01E-04
Bid ENSMUSG00000004446 6:120866339-120866838 183 754213 284 811723 141 768463 2,85E-02 1,09E-09 2,43E-04 3,50E-04 1,83E-04 3,28E-04 3,61E-04 3,90E-04 3,70E-04 3,72E-04 3,41E-04 3,97E-04 4,89E-04 3,53E-04
Blk ENSMUSG00000014453 14:64035525-64036024 102 527591 106 596350 69 556744 1,18E-02 4,56E-02 1,93E-04 1,78E-04 1,24E-04 3,39E-04 3,31E-04 3,35E-04 4,03E-04 3,48E-04 3,07E-04 3,74E-04 3,53E-04 3,24E-04
Bmp2k ENSMUSG00000034663 5:97426708-97427207 47 139451 62 141754 23 136675 1,58E-02 2,14E-04 3,37E-04 4,37E-04 1,68E-04 3,94E-04 3,85E-04 4,03E-04 3,45E-04 3,89E-04 3,84E-04 5,48E-04 5,49E-04 3,79E-04
Brca1 ENSMUSG00000017146 11:101412770-101413269 152 767386 161 864750 96 817166 2,50E-04 1,23E-03 1,98E-04 1,86E-04 1,17E-04 3,54E-04 3,15E-04 3,65E-04 3,45E-04 3,51E-04 3,24E-04 3,62E-04 3,82E-04 2,96E-04
Btg1 ENSMUSG00000036478 10:96079635-96080134 110 427551 180 467161 60 430699 4,76E-04 3,74E-12 2,57E-04 3,85E-04 1,39E-04 3,74E-04 3,10E-04 3,58E-04 3,48E-04 3,51E-04 3,23E-04 4,07E-04 4,73E-04 3,44E-04
Btg2 ENSMUSG00000020423 1:135975233-135975732 145 666628 159 728119 104 675155 1,79E-02 1,59E-02 2,18E-04 2,18E-04 1,54E-04 3,42E-04 3,00E-04 3,71E-04 3,95E-04 3,52E-04 3,04E-04 3,95E-04 3,76E-04 3,18E-04
C2cd3 ENSMUSG00000047248 7:107520743-107521242 289 760425 198 846933 120 795981 6,74E-18 5,33E-04 3,80E-04 2,34E-04 1,51E-04 3,87E-04 3,27E-04 3,61E-04 3,65E-04 3,57E-04 3,49E-04 4,85E-04 4,04E-04 3,21E-04
Cacng4 ENSMUSG00000020723 11:107655279-107655778 122 555422 110 598492 69 564512 3,74E-04 2,16E-02 2,20E-04 1,84E-04 1,22E-04 3,87E-04 3,45E-04 3,67E-04 4,11E-04 3,76E-04 3,23E-04 3,80E-04 3,46E-04 3,14E-04
Calm1 ENSMUSG00000001175 12:101437751-101438250 218 582011 171 632117 88 605252 4,53E-14 7,73E-06 3,75E-04 2,71E-04 1,45E-04 4,47E-04 3,88E-04 3,67E-04 3,75E-04 3,70E-04 3,46E-04 4,98E-04 4,26E-04 3,16E-04
Cat ENSMUSG00000027187 2:103324811-103325310 149 750450 172 833393 108 790008 8,85E-03 2,59E-03 1,99E-04 2,06E-04 1,37E-04 3,50E-04 3,05E-04 3,76E-04 3,82E-04 3,43E-04 3,17E-04 3,58E-04 3,60E-04 3,15E-04
Ccne2-2 ENSMUSG00000028212 4:11118856-11119355 138 512119 213 558252 98 548934 5,54E-03 1,10E-09 2,69E-04 3,82E-04 1,79E-04 6,62E-04 6,46E-04 7,17E-04 7,24E-04 6,39E-04 6,59E-04 6,70E-04 7,33E-04 6,45E-04
Cd19 ENSMUSG00000030724 7:133557885-133558384 585 590847 1082 636713 80 628528 6,06E-101 1,87E-220 9,90E-04 1,70E-03 1,27E-04 8,39E-04 9,48E-04 7,26E-04 5,96E-04 6,82E-04 5,25E-04 7,99E-04 1,17E-03 3,23E-04
Cd22-1 ENSMUSG00000030577 7:31663548-31664047 210 508233 170 583742 101 552839 3,34E-11 7,25E-04 4,13E-04 2,91E-04 1,83E-04 4,20E-04 4,07E-04 4,21E-04 4,68E-04 4,05E-04 3,96E-04 5,10E-04 4,80E-04 3,92E-04
Cd22-2 ENSMUSG00000030577 7:31664862-31665361 121 594181 117 648737 67 628974 7,86E-05 1,91E-03 2,04E-04 1,80E-04 1,07E-04 3,35E-04 2,87E-04 3,29E-04 3,62E-04 3,40E-04 2,78E-04 3,62E-04 3,51E-04 2,84E-04
Cd24a ENSMUSG00000047139 10:43298975-43299474 430 668120 455 706462 96 690421 1,75E-52 8,83E-54 6,44E-04 6,44E-04 1,39E-04 4,21E-04 3,76E-04 4,08E-04 4,01E-04 4,40E-04 4,13E-04 7,11E-04 6,59E-04 3,97E-04
Cd37 ENSMUSG00000030798 7:52493710-52494209 228 622269 239 693742 76 655705 1,63E-19 8,06E-18 3,66E-04 3,45E-04 1,16E-04 3,31E-04 3,34E-04 3,37E-04 3,65E-04 3,27E-04 3,03E-04 4,90E-04 4,75E-04 3,44E-04
Cd48 ENSMUSG00000015355 1:173612186-173612685 153 469597 217 521041 56 477045 4,50E-11 1,59E-19 3,26E-04 4,16E-04 1,17E-04 3,74E-04 3,15E-04 3,47E-04 3,28E-04 3,46E-04 3,21E-04 4,30E-04 4,73E-04 3,02E-04
Cd53 ENSMUSG00000040747 3:106592568-106593067 149 758706 177 884426 96 842871 1,33E-04 3,20E-05 1,96E-04 2,00E-04 1,14E-04 3,77E-04 3,30E-04 3,48E-04 3,79E-04 3,51E-04 3,13E-04 3,63E-04 3,64E-04 3,06E-04
Cd74 ENSMUSG00000024610 18:60963503-60964002 257 339907 354 398425 15 258186 2,31E-43 1,04E-55 7,56E-04 8,88E-04 5,81E-05 5,66E-04 7,69E-04 9,54E-04 5,41E-04 1,13E-03 5,97E-04 1,60E-03 1,21E-03 4,08E-03
Cd79a ENSMUSG00000003379 7:25682530-25683029 216 364021 269 401722 38 382713 3,39E-32 2,16E-40 5,93E-04 6,70E-04 9,93E-05 3,61E-04 3,13E-04 3,19E-04 3,61E-04 3,42E-04 3,59E-04 5,86E-04 5,84E-04 3,02E-04
Cd79b ENSMUSG00000040592 11:106175344-106175843 391 507479 480 564481 53 538105 1,34E-67 2,94E-81 7,70E-04 8,50E-04 9,85E-05 5,53E-04 4,89E-04 5,34E-04 6,53E-04 5,02E-04 5,03E-04 8,56E-04 8,71E-04 4,49E-04
Cd83 ENSMUSG00000015396 13:43880476-43880975 1044 798791 1150 867530 134 848537 1,85E-185 3,80E-195 1,31E-03 1,33E-03 1,58E-04 5,49E-04 5,38E-04 6,00E-04 5,07E-04 6,56E-04 6,00E-04 1,13E-03 1,15E-03 3,54E-04
Cdk11b ENSMUSG00000029062 4:154998978-154999477 170 846241 187 894894 116 865838 2,53E-03 6,09E-04 2,01E-04 2,09E-04 1,34E-04 3,33E-04 3,17E-04 3,56E-04 3,81E-04 3,40E-04 3,02E-04 4,01E-04 3,48E-04 3,09E-04
Cdk4 ENSMUSG00000006728 10:126500659-126501158 186 616638 223 661600 114 709287 5,15E-07 3,59E-10 3,02E-04 3,37E-04 1,61E-04 7,33E-04 9,87E-04 5,26E-04 1,11E-03 8,69E-04 5,08E-04 6,40E-04 1,03E-03 3,51E-04
Chd2 ENSMUSG00000078671 7:80686133-80686632 198 729975 171 809722 81 760913 1,18E-12 1,17E-06 2,71E-04 2,11E-04 1,06E-04 3,09E-04 2,96E-04 3,41E-04 3,55E-04 3,59E-04 3,21E-04 4,11E-04 3,64E-04 3,18E-04
Chek1 ENSMUSG00000032113 9:36533744-36534243 129 587896 219 655426 86 638564 1,55E-03 7,32E-13 2,19E-04 3,34E-04 1,35E-04 3,57E-04 3,62E-04 3,57E-04 4,12E-04 3,99E-04 3,31E-04 4,08E-04 4,49E-04 3,06E-04
Ciita ENSMUSG00000075404 16:10489874-10490373 286 598029 368 667910 89 635646 9,12E-27 3,45E-37 4,78E-04 5,51E-04 1,40E-04 5,61E-04 3,77E-04 4,20E-04 4,87E-04 4,43E-04 3,90E-04 5,84E-04 6,54E-04 4,04E-04
Ciita-2 ENSMUSG00000022504 16:10488271-10488770 413 938622 350 1053849 107 995011 5,28E-46 4,19E-27 4,40E-04 3,32E-04 1,08E-04 3,27E-04 3,11E-04 3,35E-04 3,81E-04 3,11E-04 3,29E-04 4,91E-04 4,06E-04 3,09E-04
Clk1 ENSMUSG00000026034 1:58480433-58480932 220 688612 263 739819 105 703889 3,08E-10 3,90E-14 3,19E-04 3,55E-04 1,49E-04 3,53E-04 3,33E-04 3,62E-04 3,91E-04 3,80E-04 3,22E-04 4,84E-04 4,66E-04 3,35E-04
Cnbp ENSMUSG00000030057 6:87800601-87801100 153 516603 148 540939 82 518739 1,61E-05 2,37E-04 2,96E-04 2,74E-04 1,58E-04 3,72E-04 3,02E-04 3,49E-04 3,79E-04 3,51E-04 3,17E-04 4,39E-04 4,32E-04 3,11E-04
Cox4i1 ENSMUSG00000031818 8:123192190-123192689 133 610439 149 665493 94 631579 1,24E-02 5,91E-03 2,18E-04 2,24E-04 1,49E-04 4,00E-04 3,38E-04 3,71E-04 4,22E-04 3,90E-04 3,21E-04 4,18E-04 4,02E-04 3,37E-04
Cox6a1 ENSMUSG00000041697 5:115798465-115798964 139 640715 136 668150 94 646443 7,82E-03 3,07E-02 2,17E-04 2,04E-04 1,45E-04 3,38E-04 3,54E-04 3,45E-04 3,81E-04 3,89E-04 3,61E-04 3,97E-04 4,04E-04 3,56E-04
Cox8a ENSMUSG00000035885 19:7291607-7292106 229 841672 242 893226 139 828713 2,81E-05 2,60E-05 2,72E-04 2,71E-04 1,68E-04 7,43E-04 7,21E-04 1,01E-03 8,63E-04 9,99E-04 1,09E-03 7,90E-04 8,26E-04 6,90E-04
Cradd ENSMUSG00000045867 10:94786232-94786731 207 456848 181 526336 130 495059 4,78E-06 4,35E-02 4,53E-04 3,44E-04 2,63E-04 5,40E-04 5,28E-04 5,75E-04 6,10E-04 5,35E-04 5,52E-04 5,86E-04 5,22E-04 5,03E-04
Csk ENSMUSG00000032312 9:57492488-57492987 298 489386 358 544273 65 530077 1,20E-39 3,33E-47 6,09E-04 6,58E-04 1,23E-04 4,92E-04 4,10E-04 4,73E-04 4,68E-04 4,64E-04 4,37E-04 7,64E-04 7,21E-04 3,64E-04
Csnk1d ENSMUSG00000025162 11:120852148-120852647 152 555365 142 585236 103 591508 1,38E-03 2,72E-02 2,74E-04 2,43E-04 1,74E-04 4,01E-04 3,57E-04 3,86E-04 4,09E-04 3,56E-04 3,26E-04 4,17E-04 3,86E-04 3,70E-04
Cyth1 ENSMUSG00000017132 11:118109407-118109906 214 747423 223 763562 101 755887 6,20E-10 1,38E-10 2,86E-04 2,92E-04 1,34E-04 4,02E-04 2,96E-04 3,71E-04 3,95E-04 3,59E-04 3,21E-04 4,84E-04 4,67E-04 3,68E-04
Daxx ENSMUSG00000002307 17:34046443-34046942 137 518202 123 569451 75 537203 3,28E-05 8,57E-03 2,64E-04 2,16E-04 1,40E-04 4,12E-04 3,17E-04 4,13E-04 4,33E-04 3,27E-04 3,58E-04 4,19E-04 3,54E-04 3,39E-04
Ddb2 ENSMUSG00000002109 2:91076724-91077223 166 679079 173 748034 82 688244 3,05E-07 2,39E-06 2,44E-04 2,31E-04 1,19E-04 3,49E-04 3,22E-04 3,88E-04 3,79E-04 3,48E-04 3,07E-04 4,33E-04 3,72E-04 3,08E-04
Ddx20 ENSMUSG00000027905 3:105489990-105490489 182 523935 174 558189 80 531241 8,32E-10 1,96E-07 3,47E-04 3,12E-04 1,51E-04 4,12E-04 3,45E-04 4,27E-04 3,64E-04 3,98E-04 3,13E-04 5,09E-04 4,58E-04 3,29E-04
Ddx5 ENSMUSG00000020719 11:106649309-106649808 272 590855 242 644855 110 596950 2,55E-16 1,41E-09 4,60E-04 3,75E-04 1,84E-04 5,38E-04 5,52E-04 5,23E-04 6,26E-04 5,45E-04 5,20E-04 6,97E-04 6,23E-04 5,63E-04
Dnmt1 ENSMUSG00000004099 9:20756818-20757317 322 641931 188 700547 124 689646 1,82E-23 1,81E-03 5,02E-04 2,68E-04 1,80E-04 4,36E-04 3,78E-04 4,23E-04 4,25E-04 3,77E-04 3,55E-04 6,13E-04 4,42E-04 3,96E-04
Dok1 ENSMUSG00000068335 6:82982966-82983465 138 790501 161 859276 105 807835 4,56E-02 1,05E-02 1,75E-04 1,87E-04 1,30E-04 3,50E-04 3,03E-04 3,53E-04 3,65E-04 3,44E-04 2,83E-04 3,51E-04 3,79E-04 3,10E-04
Ung-/-Msh2-/-Exp1 Ung-/-Msh2-/-Exp2 Aicda-/- Ung-/-Msh2-/- Aicda-/- Ung+/-Msh2+/- Ung+/-Msh2-/- Ung-/-Msh2+/- Ung-/-Msh2-/- Aicda-/-
Transitions at C/G pairs C/G Transition Frequency Total mutation frequency
FDR
Gene Ensembl ID Coordinates C/G transitions C/G sequenced C/G transitions C/G sequenced C/G transitions C/G sequenced Exp1 Exp2 Exp1 Exp2 Exp1 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1
Dsg4 ENSMUSG00000001804 18:20594676-20595175 234 643280 260 741818 194 713232 7,90E-03 2,03E-02 3,64E-04 3,50E-04 2,72E-04 4,35E-04 4,16E-04 4,54E-04 5,35E-04 4,38E-04 3,65E-04 4,57E-04 4,27E-04 4,09E-04
Dusp6 ENSMUSG00000019960 10:98725865-98726364 679 620088 822 691274 82 654408 3,56E-123 5,45E-144 1,10E-03 1,19E-03 1,25E-04 1,04E-03 1,11E-03 7,99E-04 1,27E-03 9,95E-04 5,16E-04 8,49E-04 9,21E-04 3,19E-04
Dyrk3 ENSMUSG00000016526 1:133034312-133034811 729 464930 337 500073 70 436631 1,55E-128 2,52E-34 1,57E-03 6,74E-04 1,60E-04 1,01E-03 1,14E-03 1,32E-03 1,32E-03 1,37E-03 6,26E-04 1,52E-03 8,63E-04 4,82E-04
E2f1 ENSMUSG00000027490 2:154395089-154395588 130 629443 151 667660 93 659209 1,33E-02 1,21E-03 2,07E-04 2,26E-04 1,41E-04 3,41E-04 3,02E-04 3,43E-04 3,87E-04 3,55E-04 2,94E-04 3,87E-04 3,58E-04 3,25E-04
E2f2 ENSMUSG00000018983 4:135728309-135728808 185 454184 169 506415 72 490306 1,14E-13 1,05E-08 4,07E-04 3,34E-04 1,47E-04 4,08E-04 3,43E-04 3,80E-04 4,35E-04 3,48E-04 3,95E-04 5,51E-04 4,74E-04 3,01E-04
E4f1 ENSMUSG00000024137 17:24591757-24592256 205 755753 155 816018 102 735467 9,44E-08 3,36E-02 2,71E-04 1,90E-04 1,39E-04 3,73E-04 3,29E-04 3,54E-04 3,50E-04 3,14E-04 3,51E-04 4,36E-04 3,80E-04 3,48E-04
Ebf1 ENSMUSG00000057098 11:44431636-44432135 233 449050 345 478696 87 464618 1,20E-16 1,43E-34 5,19E-04 7,21E-04 1,87E-04 3,65E-04 3,38E-04 3,79E-04 3,94E-04 4,11E-04 3,58E-04 6,21E-04 6,99E-04 3,53E-04
Eef1a1 ENSMUSG00000037742 9:78329032-78329531 459 715067 512 769746 107 737892 6,90E-54 2,84E-59 6,42E-04 6,65E-04 1,45E-04 2,50E-03 2,36E-03 1,43E-03 2,43E-03 1,82E-03 2,38E-03 1,60E-03 1,91E-03 2,95E-03
Eif2a ENSMUSG00000027810 3:58329743-58330242 146 830559 175 915815 116 890209 3,56E-02 4,44E-03 1,76E-04 1,91E-04 1,30E-04 3,27E-04 3,29E-04 3,61E-04 3,62E-04 3,40E-04 3,01E-04 3,66E-04 3,59E-04 3,35E-04
Eif3a ENSMUSG00000024991 19:60866097-60866596 455 996063 306 1057507 166 1022373 1,68E-32 7,47E-09 4,57E-04 2,89E-04 1,62E-04 3,54E-04 3,52E-04 3,52E-04 3,79E-04 3,63E-04 3,34E-04 5,78E-04 4,27E-04 3,28E-04
Eif3d ENSMUSG00000016554 15:77800755-77801254 243 796707 261 873457 126 820784 1,17E-09 2,25E-09 3,05E-04 2,99E-04 1,54E-04 3,71E-04 3,24E-04 3,65E-04 3,93E-04 3,31E-04 3,61E-04 4,46E-04 4,17E-04 3,52E-04
Eif4a2 ENSMUSG00000022884 16:23107552-23108051 404 957514 414 1038510 135 980345 2,33E-32 2,17E-29 4,22E-04 3,99E-04 1,38E-04 3,12E-04 3,45E-04 3,50E-04 3,52E-04 3,65E-04 3,45E-04 5,09E-04 4,83E-04 3,11E-04
Eif5a-1 ENSMUSG00000078812 11:69733633-69734132 374 742478 368 770568 114 757801 2,89E-33 3,74E-30 5,04E-04 4,78E-04 1,50E-04 4,94E-04 3,01E-04 3,63E-04 3,77E-04 3,59E-04 3,59E-04 5,53E-04 5,45E-04 3,21E-04
Eif5a-3 ENSMUSG00000078812 11:69734088-69734587 236 627743 173 664189 121 668428 1,74E-10 6,64E-03 3,76E-04 2,60E-04 1,81E-04 6,87E-04 5,96E-04 6,78E-04 6,69E-04 6,66E-04 6,61E-04 7,91E-04 6,64E-04 5,69E-04
Eif5a-4 ENSMUSG00000078812 11:69734278-69734777 315 699639 210 758573 107 729400 1,18E-25 3,01E-07 4,50E-04 2,77E-04 1,47E-04 5,43E-04 4,19E-04 4,65E-04 4,70E-04 4,79E-04 4,33E-04 6,90E-04 5,16E-04 4,17E-04
Eif5a-5 ENSMUSG00000078812 11:69734389-69734888 289 721139 206 778918 109 754042 1,27E-20 1,24E-06 4,01E-04 2,64E-04 1,45E-04 5,04E-04 3,85E-04 4,28E-04 4,34E-04 4,41E-04 3,95E-04 6,24E-04 4,59E-04 3,88E-04
Ell ENSMUSG00000070002 8:73063574-73064073 106 492639 112 555718 66 522688 2,23E-03 7,73E-03 2,15E-04 2,02E-04 1,26E-04 3,74E-04 3,05E-04 3,16E-04 4,18E-04 3,34E-04 3,05E-04 3,77E-04 4,13E-04 3,28E-04
Emu NoCode002 12:114665496-114665807 576 394268 609 459225 52 439275 1,03E-123 1,21E-114 1,46E-03 1,33E-03 1,18E-04 7,80E-04 6,68E-04 5,67E-04 7,36E-04 6,56E-04 5,88E-04 8,96E-04 8,51E-04 3,10E-04
Erh ENSMUSG00000021131 12:81744349-81744848 143 659794 192 706210 104 691754 1,22E-02 4,31E-06 2,17E-04 2,72E-04 1,50E-04 4,13E-04 2,96E-04 3,93E-04 4,14E-04 3,81E-04 3,31E-04 4,29E-04 4,27E-04 3,21E-04
Eri1 ENSMUSG00000031527 8:36558088-36558587 99 526061 163 553046 62 536641 7,53E-03 3,74E-10 1,88E-04 2,95E-04 1,16E-04 3,46E-04 3,56E-04 3,69E-04 4,02E-04 3,61E-04 3,04E-04 3,71E-04 4,36E-04 3,20E-04
Ets1 ENSMUSG00000032035 9:32503627-32504126 287 524073 267 586650 90 544529 1,25E-25 1,02E-17 5,48E-04 4,55E-04 1,65E-04 4,24E-04 3,63E-04 3,90E-04 3,71E-04 4,55E-04 3,63E-04 6,23E-04 5,30E-04 3,62E-04
Fas ENSMUSG00000024778 19:34365149-34365648 126 518153 119 551763 53 459575 1,37E-05 4,49E-04 2,43E-04 2,16E-04 1,15E-04 4,24E-04 3,86E-04 4,54E-04 3,94E-04 4,07E-04 3,80E-04 5,23E-04 4,38E-04 3,23E-04
Fchsd2 ENSMUSG00000030691 7:108257289-108257788 476 745466 659 816912 120 776490 6,81E-53 1,45E-83 6,39E-04 8,07E-04 1,55E-04 4,66E-04 4,97E-04 4,03E-04 4,21E-04 4,56E-04 4,87E-04 7,20E-04 8,07E-04 3,57E-04
Fen1 ENSMUSG00000024742 19:10277934-10278433 172 862644 190 976838 117 912862 8,38E-04 1,33E-03 1,99E-04 1,95E-04 1,28E-04 3,14E-04 3,00E-04 3,28E-04 3,91E-04 3,50E-04 3,01E-04 3,68E-04 3,37E-04 3,33E-04
Fli1 ENSMUSG00000016087 9:32348454-32348953 237 862713 258 904025 135 892881 1,19E-07 7,45E-09 2,75E-04 2,85E-04 1,51E-04 6,02E-04 3,11E-04 3,72E-04 3,68E-04 3,76E-04 3,11E-04 4,22E-04 4,47E-04 3,49E-04
Fnbp1-2 ENSMUSG00000075415 2:30997029-30997528 175 492567 169 514751 78 510802 1,02E-09 5,75E-08 3,55E-04 3,28E-04 1,53E-04 4,02E-04 3,41E-04 4,04E-04 4,26E-04 3,91E-04 3,54E-04 5,10E-04 4,37E-04 3,63E-04
Foxo4 ENSMUSG00000042903 X:98449867-98450366 83 564888 93 537789 45 556546 3,78E-03 8,87E-05 1,47E-04 1,73E-04 8,09E-05 3,51E-04 3,17E-04 3,33E-04 3,68E-04 3,69E-04 3,16E-04 3,41E-04 3,39E-04 2,79E-04
Fth1 ENSMUSG00000024661 19:10057193-10057692 157 739271 193 809262 107 746410 5,13E-03 8,72E-05 2,12E-04 2,38E-04 1,43E-04 3,62E-04 2,98E-04 3,46E-04 3,89E-04 3,57E-04 2,84E-04 4,19E-04 3,71E-04 3,37E-04
Ftl1 ENSMUSG00000050708 7:52714757-52715256 92 304615 78 335544 46 315947 1,84E-04 3,06E-02 3,02E-04 2,32E-04 1,46E-04 4,41E-04 4,24E-04 4,21E-04 4,59E-04 4,59E-04 4,51E-04 5,70E-04 4,99E-04 3,58E-04
Gadd45b ENSMUSG00000015312 10:80392836-80393335 464 868383 364 916664 112 892678 1,40E-52 1,49E-29 5,34E-04 3,97E-04 1,25E-04 3,72E-04 3,36E-04 3,79E-04 3,70E-04 4,01E-04 3,29E-04 5,98E-04 4,77E-04 2,83E-04
Gadd45g ENSMUSG00000021453 13:51942044-51942543 114 590842 285 657055 84 619943 3,19E-02 3,94E-23 1,93E-04 4,34E-04 1,35E-04 4,52E-04 3,41E-04 3,48E-04 3,58E-04 3,42E-04 3,13E-04 3,51E-04 5,00E-04 3,16E-04
Galnt1-1 ENSMUSG00000000420 18:24363845-24364344 104 316197 118 337701 40 323734 2,29E-07 1,22E-08 3,29E-04 3,49E-04 1,24E-04 6,08E-04 4,27E-04 4,32E-04 5,13E-04 5,17E-04 5,93E-04 4,64E-04 4,72E-04 2,97E-04
Galnt1-2 ENSMUSG00000000420 18:24364495-24364994 79 359102 145 398682 46 379759 3,97E-03 3,21E-11 2,20E-04 3,64E-04 1,21E-04 3,44E-04 3,31E-04 3,70E-04 3,72E-04 3,28E-04 3,76E-04 3,25E-04 4,68E-04 2,90E-04
Gas5 ENSMUSG00000053332 1:162965297-162965796 577 615634 794 668642 107 628751 2,26E-79 8,85E-120 9,37E-04 1,19E-03 1,70E-04 2,69E-03 2,50E-03 8,57E-04 2,41E-03 1,83E-03 2,55E-03 1,75E-03 2,95E-03 4,36E-03
Gdi2 ENSMUSG00000021218 13:3537321-3537820 253 596124 279 635569 150 606710 6,46E-07 5,23E-08 4,24E-04 4,39E-04 2,47E-04 4,75E-04 4,22E-04 4,90E-04 5,03E-04 5,34E-04 5,15E-04 6,55E-04 6,23E-04 5,17E-04
Gna13 ENSMUSG00000020611 11:109224108-109224607 208 642595 296 684780 101 642910 6,78E-09 1,13E-19 3,24E-04 4,32E-04 1,57E-04 3,66E-04 3,45E-04 3,84E-04 4,33E-04 4,01E-04 3,43E-04 4,99E-04 6,36E-04 3,59E-04
Grap ENSMUSG00000004837 11:61466823-61467322 240 391575 193 439740 54 437463 1,27E-32 2,40E-18 6,13E-04 4,39E-04 1,23E-04 4,10E-04 3,06E-04 3,43E-04 3,46E-04 3,24E-04 3,40E-04 5,80E-04 4,69E-04 3,35E-04
Gsta3 ENSMUSG00000025934 1:21230670-21231169 128 406344 179 480189 92 456338 3,59E-03 5,86E-06 3,15E-04 3,73E-04 2,02E-04 6,00E-04 4,46E-04 4,92E-04 5,72E-04 4,53E-04 4,70E-04 5,04E-04 5,01E-04 4,19E-04
H2afx ENSMUSG00000049932 9:44142798-44143297 523 663628 531 716953 118 697873 9,33E-65 1,07E-59 7,88E-04 7,41E-04 1,69E-04 3,86E-04 3,84E-04 3,60E-04 3,78E-04 4,71E-04 4,38E-04 7,85E-04 7,24E-04 3,51E-04
H3f3b ENSMUSG00000016559 11:115885319-115885818 209 768881 252 840753 116 787845 4,42E-07 5,42E-10 2,72E-04 3,00E-04 1,47E-04 3,67E-04 3,18E-04 4,11E-04 4,66E-04 3,44E-04 3,30E-04 4,33E-04 4,65E-04 3,68E-04
H47 ENSMUSG00000075701 7:73224535-73225034 219 865446 279 939021 118 906324 2,04E-08 5,67E-14 2,53E-04 2,97E-04 1,30E-04 3,45E-04 3,19E-04 3,35E-04 3,59E-04 3,23E-04 2,93E-04 4,00E-04 4,22E-04 2,92E-04
Hdac1 ENSMUSG00000028800 4:129219391-129219890 159 754440 180 805875 111 797257 2,66E-03 3,31E-04 2,11E-04 2,23E-04 1,39E-04 3,69E-04 3,20E-04 3,72E-04 4,24E-04 3,98E-04 3,72E-04 4,09E-04 4,09E-04 3,26E-04
Hdac9 ENSMUSG00000004698 12:35213255-35213754 118 540256 139 587555 69 507953 5,03E-03 5,32E-04 2,18E-04 2,37E-04 1,36E-04 5,75E-04 5,70E-04 5,26E-04 5,96E-04 5,46E-04 5,07E-04 4,92E-04 5,29E-04 4,78E-04
Hdgf ENSMUSG00000004897 3:87710243-87710742 222 680627 193 751993 106 691046 3,79E-10 7,45E-05 3,26E-04 2,57E-04 1,53E-04 3,73E-04 3,38E-04 3,73E-04 3,95E-04 3,53E-04 3,45E-04 4,45E-04 3,91E-04 3,47E-04
Hells ENSMUSG00000025001 19:39005480-39005979 168 557458 221 605650 104 603496 3,14E-05 6,55E-10 3,01E-04 3,65E-04 1,72E-04 3,55E-04 3,62E-04 3,68E-04 4,17E-04 3,54E-04 3,72E-04 4,21E-04 4,71E-04 3,56E-04
Hist1h1a ENSMUSG00000049539 13:23855537-23856036 323 452994 440 491598 66 480903 7,78E-44 1,11E-65 7,13E-04 8,95E-04 1,37E-04 4,63E-04 3,37E-04 3,33E-04 3,59E-04 3,56E-04 3,59E-04 6,84E-04 7,91E-04 3,02E-04
Hist1h1b ENSMUSG00000058773 13:21871924-21872423 576 387884 735 449949 63 426862 6,12E-114 6,37E-137 1,48E-03 1,63E-03 1,48E-04 3,49E-04 3,69E-04 4,25E-04 4,17E-04 4,13E-04 4,47E-04 1,15E-03 1,22E-03 3,33E-04
Hnrnpa2b1-1 ENSMUSG00000004980 6:51419394-51419893 461 842176 382 944784 177 988573 1,24E-39 2,19E-19 5,47E-04 4,04E-04 1,79E-04 3,83E-04 3,59E-04 3,67E-04 3,91E-04 3,98E-04 3,62E-04 5,99E-04 4,92E-04 3,39E-04
Hnrnpf-2 ENSMUSG00000042079 6:117856800-117857299 251 674985 271 724519 83 720551 3,83E-22 4,24E-23 3,72E-04 3,74E-04 1,15E-04 3,96E-04 3,30E-04 3,61E-04 4,53E-04 3,80E-04 3,49E-04 5,29E-04 4,93E-04 3,20E-04
Hnrnpf-3 ENSMUSG00000042079 6:117857822-117858321 334 935765 479 1007257 159 964305 1,51E-15 5,09E-34 3,57E-04 4,76E-04 1,65E-04 3,71E-04 3,47E-04 3,98E-04 3,77E-04 4,07E-04 3,52E-04 4,83E-04 5,30E-04 3,33E-04
Hnrnpf-4 ENSMUSG00000042079 6:117867312-117867811 165 477813 249 521172 71 508346 2,73E-10 2,65E-22 3,45E-04 4,78E-04 1,40E-04 4,41E-04 2,83E-04 3,01E-04 3,54E-04 3,36E-04 3,27E-04 4,44E-04 5,20E-04 3,10E-04
Hsf4 ENSMUSG00000033249 8:107793774-107794273 144 826674 146 932286 98 886188 1,77E-03 2,11E-02 1,74E-04 1,57E-04 1,11E-04 3,01E-04 3,32E-04 3,53E-04 3,32E-04 3,09E-04 3,10E-04 3,72E-04 3,41E-04 3,08E-04
Hvcn1-1 ENSMUSG00000064267 5:122659746-122660245 142 717436 164 793379 104 752454 1,40E-02 4,23E-03 1,98E-04 2,07E-04 1,38E-04 3,61E-04 3,18E-04 3,32E-04 3,89E-04 3,62E-04 3,00E-04 3,72E-04 3,97E-04 3,27E-04
Id3 ENSMUSG00000007872 4:135699737-135700236 271 878340 280 962896 139 943036 3,58E-12 1,57E-10 3,09E-04 2,91E-04 1,47E-04 3,50E-04 3,28E-04 4,47E-04 4,37E-04 3,68E-04 3,29E-04 4,54E-04 4,20E-04 3,00E-04
Igj ENSMUSG00000067149 5:88956423-88956922 239 344459 344 408061 162 357676 1,18E-04 1,78E-10 6,94E-04 8,43E-04 4,53E-04 3,78E-04 5,49E-04 5,93E-04 5,79E-04 6,26E-04 6,64E-04 7,31E-04 8,27E-04 4,79E-04
Ikzf1 ENSMUSG00000018654 11:11586216-11586715 561 644630 607 719160 89 695595 5,50E-91 1,99E-90 8,70E-04 8,44E-04 1,28E-04 3,63E-04 3,36E-04 3,55E-04 3,33E-04 3,43E-04 3,43E-04 7,22E-04 6,89E-04 3,24E-04
Il21r ENSMUSG00000030745 7:132746943-132747442 501 654441 543 723059 104 691656 1,32E-66 5,66E-67 7,66E-04 7,51E-04 1,50E-04 5,37E-04 3,29E-04 4,17E-04 3,51E-04 3,99E-04 4,45E-04 7,12E-04 6,72E-04 3,48E-04
Il4ra ENSMUSG00000030748 7:132695796-132696295 173 681497 386 764757 114 716952 4,21E-04 1,02E-30 2,54E-04 5,05E-04 1,59E-04 3,97E-04 3,00E-04 3,10E-04 3,47E-04 3,46E-04 3,14E-04 4,32E-04 5,56E-04 3,28E-04
Ildr2 ENSMUSG00000040612 1:168184270-168184769 95 282593 107 303801 24 310856 7,82E-12 3,42E-13 3,36E-04 3,52E-04 7,72E-05 1,15E-03 8,72E-04 2,53E-03 1,25E-03 1,45E-03 2,51E-03 1,30E-03 1,33E-03 3,19E-04
Ipmk ENSMUSG00000060733 10:70810541-70811040 110 541434 129 590055 74 604134 2,58E-03 2,56E-04 2,03E-04 2,19E-04 1,22E-04 3,55E-04 3,48E-04 3,97E-04 4,10E-04 3,36E-04 3,49E-04 3,89E-04 3,76E-04 3,12E-04
Ipo7 ENSMUSG00000066232 7:117161939-117162438 165 775158 182 839214 120 792026 1,22E-02 6,89E-03 2,13E-04 2,17E-04 1,52E-04 3,72E-04 3,25E-04 3,22E-04 3,59E-04 3,56E-04 3,57E-04 3,78E-04 3,60E-04 3,35E-04
Irf4 ENSMUSG00000021356 13:30841127-30841626 157 458687 143 527486 68 507831 1,50E-10 5,28E-06 3,42E-04 2,71E-04 1,34E-04 3,69E-04 3,20E-04 3,57E-04 3,91E-04 4,17E-04 3,69E-04 4,69E-04 3,94E-04 2,73E-04
Irf8 ENSMUSG00000041515 8:123260276-123260775 328 550422 456 601283 66 564248 5,67E-43 4,99E-66 5,96E-04 7,58E-04 1,17E-04 3,76E-04 3,38E-04 3,76E-04 3,81E-04 3,40E-04 3,44E-04 6,53E-04 6,73E-04 3,38E-04
Itga4 ENSMUSG00000027009 2:79095583-79096082 164 740245 237 815845 101 788194 6,23E-05 7,88E-12 2,22E-04 2,90E-04 1,28E-04 3,85E-04 3,23E-04 3,66E-04 3,58E-04 5,35E-04 3,61E-04 4,20E-04 4,04E-04 3,19E-04
Itgal ENSMUSG00000030830 7:134439862-134440361 104 563705 138 620692 72 604187 1,19E-02 6,28E-05 1,84E-04 2,22E-04 1,19E-04 3,70E-04 2,94E-04 3,41E-04 3,68E-04 3,14E-04 3,24E-04 3,63E-04 3,43E-04 3,22E-04
Itgb2 ENSMUSG00000000290 10:76993093-76993592 128 536106 127 595348 69 580511 1,10E-05 3,19E-04 2,39E-04 2,13E-04 1,19E-04 3,41E-04 3,00E-04 3,49E-04 4,11E-04 3,41E-04 3,28E-04 3,80E-04 3,95E-04 3,18E-04
Jh4 NoCode003 12:114666194-114666736 11619 822724 14950 920989 97 948760 0,00E+00 0,00E+00 1,41E-02 1,62E-02 1,02E-04 5,34E-03 3,65E-03 2,09E-03 1,78E-03 2,77E-03 3,25E-03 6,47E-03 7,59E-03 2,91E-04
Junb ENSMUSG00000052837 8:87502118-87502617 311 737087 329 796520 112 752693 1,45E-22 3,61E-22 4,22E-04 4,13E-04 1,49E-04 3,94E-04 3,21E-04 3,60E-04 3,96E-04 3,71E-04 4,63E-04 5,53E-04 4,76E-04 3,62E-04
Kpna2 ENSMUSG00000018362 11:106860340-106860839 244 519174 316 561836 96 546553 1,05E-16 4,31E-26 4,70E-04 5,62E-04 1,76E-04 7,87E-04 7,45E-04 7,40E-04 4,73E-04 6,43E-04 4,72E-04 8,67E-04 1,00E-03 4,37E-04
Ung-/-Msh2-/-Exp1 Ung-/-Msh2-/-Exp2 Aicda-/- Ung-/-Msh2-/- Aicda-/- Ung+/-Msh2+/- Ung+/-Msh2-/- Ung-/-Msh2+/- Ung-/-Msh2-/- Aicda-/-
Transitions at C/G pairs C/G Transition Frequency Total mutation frequency
FDR
Gene Ensembl ID Coordinates C/G transitions C/G sequenced C/G transitions C/G sequenced C/G transitions C/G sequenced Exp1 Exp2 Exp1 Exp2 Exp1 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1
Kpnb1 ENSMUSG00000001440 11:97048707-97049206 55 181493 86 198709 22 178540 9,57E-04 6,24E-08 3,03E-04 4,33E-04 1,23E-04 4,96E-04 4,11E-04 4,86E-04 4,05E-04 3,97E-04 5,21E-04 5,11E-04 6,78E-04 4,26E-04
Lmo1 ENSMUSG00000036111 7:116313323-116313822 136 720717 160 822820 100 802471 5,05E-03 1,62E-03 1,89E-04 1,94E-04 1,25E-04 3,36E-04 3,23E-04 3,56E-04 3,81E-04 3,72E-04 3,22E-04 3,96E-04 3,65E-04 3,39E-04
Lrmp ENSMUSG00000030263 6:145070259-145070758 199 696203 261 775233 94 684396 1,22E-08 4,23E-14 2,86E-04 3,37E-04 1,37E-04 3,46E-04 4,97E-04 6,54E-04 3,42E-04 4,14E-04 3,58E-04 7,02E-04 4,52E-04 2,45E-03
Lsp1-1 ENSMUSG00000018819 7:149646775-149647274 125 628466 134 716411 85 672175 4,01E-03 1,37E-02 1,99E-04 1,87E-04 1,26E-04 1,29E-03 7,00E-04 1,43E-03 9,88E-04 1,70E-03 1,61E-03 1,57E-03 1,64E-03 2,29E-03
Ltb ENSMUSG00000024399 17:35331452-35331951 219 634910 501 711874 85 662443 4,38E-15 5,72E-65 3,45E-04 7,04E-04 1,28E-04 4,23E-04 3,40E-04 3,61E-04 3,85E-04 3,78E-04 3,39E-04 4,42E-04 6,49E-04 3,48E-04
Ly6e-1 ENSMUSG00000022587 15:74785481-74785980 284 644773 661 730789 100 690693 2,83E-23 6,66E-94 4,40E-04 9,05E-04 1,45E-04 3,89E-04 3,50E-04 3,69E-04 3,77E-04 4,08E-04 3,26E-04 5,88E-04 8,14E-04 4,00E-04
Ly6e-2 ENSMUSG00000022587 15:74785501-74786000 287 648185 658 734202 103 692343 7,94E-23 2,55E-91 4,43E-04 8,96E-04 1,49E-04 3,92E-04 3,52E-04 3,80E-04 3,78E-04 4,13E-04 3,28E-04 5,85E-04 8,11E-04 3,98E-04
Ly6e-3 ENSMUSG00000022587 15:74785536-74786035 271 643424 480 728497 105 684529 2,70E-19 5,58E-52 4,21E-04 6,59E-04 1,53E-04 3,67E-04 3,34E-04 3,66E-04 3,76E-04 3,98E-04 3,18E-04 5,37E-04 6,53E-04 3,48E-04
Lyn ENSMUSG00000042228 4:3605268-3605767 205 837139 291 913231 117 850871 2,51E-06 1,19E-14 2,45E-04 3,19E-04 1,38E-04 3,51E-04 3,23E-04 3,69E-04 3,75E-04 3,63E-04 3,16E-04 4,11E-04 4,60E-04 3,28E-04
Man1a ENSMUSG00000003746 10:53795103-53795602 371 734648 437 819639 112 784848 4,89E-36 4,63E-42 5,05E-04 5,33E-04 1,43E-04 3,83E-04 3,65E-04 3,74E-04 3,99E-04 3,77E-04 4,38E-04 5,94E-04 5,90E-04 3,44E-04
Mcm2 ENSMUSG00000002870 6:88848275-88848774 324 563045 476 597167 88 574445 1,19E-32 8,59E-61 5,75E-04 7,97E-04 1,53E-04 4,26E-04 2,87E-04 3,43E-04 3,67E-04 3,65E-04 3,54E-04 5,97E-04 7,02E-04 3,24E-04
Mcm6 ENSMUSG00000026355 1:130255734-130256233 251 751486 415 818149 119 796013 8,99E-13 1,97E-36 3,34E-04 5,07E-04 1,49E-04 1,24E-03 1,05E-03 5,92E-04 1,16E-03 9,89E-04 1,09E-03 9,37E-04 1,34E-03 1,95E-03
Mcm7 ENSMUSG00000029730 5:138612591-138613090 182 665798 211 713331 107 689303 1,36E-05 1,86E-07 2,73E-04 2,96E-04 1,55E-04 4,60E-04 4,19E-04 4,30E-04 5,19E-04 4,34E-04 4,35E-04 4,62E-04 4,96E-04 4,27E-04
Mdfi-2 ENSMUSG00000032717 17:47971141-47971640 165 892383 184 944059 120 930634 7,70E-03 1,50E-03 1,85E-04 1,95E-04 1,29E-04 3,37E-04 3,33E-04 4,09E-04 3,74E-04 3,56E-04 3,15E-04 3,62E-04 3,51E-04 3,17E-04
Mdh2 ENSMUSG00000019179 5:136254519-136255018 158 750847 155 841360 105 783547 1,19E-03 3,00E-02 2,10E-04 1,84E-04 1,34E-04 3,53E-04 3,17E-04 3,36E-04 3,79E-04 3,59E-04 3,27E-04 3,84E-04 3,56E-04 3,32E-04
Mef2b ENSMUSG00000079033 8:72676677-72677176 105 215355 155 247435 26 224352 2,89E-12 7,37E-20 4,88E-04 6,26E-04 1,16E-04 4,34E-04 2,84E-04 3,12E-04 3,51E-04 3,38E-04 3,09E-04 5,15E-04 6,69E-04 3,06E-04
Mir142 ENSMUSG00000065420 11:87570366-87570865 828 600466 1212 671624 93 658987 1,55E-161 1,29E-242 1,38E-03 1,80E-03 1,41E-04 4,84E-04 3,81E-04 4,24E-04 3,72E-04 4,76E-04 4,15E-04 1,06E-03 1,30E-03 3,31E-04
Mlh3 ENSMUSG00000021245 12:86611015-86611514 161 923662 188 1019032 124 990252 1,45E-02 2,65E-03 1,74E-04 1,84E-04 1,25E-04 3,39E-04 3,33E-04 3,31E-04 3,99E-04 3,48E-04 3,20E-04 3,76E-04 3,46E-04 3,13E-04
Mlst8 ENSMUSG00000024142 17:24615524-24616023 230 843924 290 909513 118 835142 2,07E-08 8,11E-14 2,73E-04 3,19E-04 1,41E-04 3,62E-04 3,06E-04 3,65E-04 3,96E-04 3,97E-04 3,14E-04 4,23E-04 4,40E-04 3,39E-04
Mrpl51 ENSMUSG00000030335 6:125142218-125142717 132 659742 142 715217 102 702555 3,37E-02 3,79E-02 2,00E-04 1,99E-04 1,45E-04 3,12E-04 2,96E-04 3,56E-04 3,46E-04 3,31E-04 2,91E-04 3,85E-04 3,69E-04 3,44E-04
Ms4a1 ENSMUSG00000024673 19:11340142-11340641 599 908541 833 1020544 123 976298 5,63E-82 8,72E-122 6,59E-04 8,16E-04 1,26E-04 3,51E-04 3,16E-04 3,29E-04 3,47E-04 3,36E-04 3,23E-04 5,66E-04 6,59E-04 3,07E-04
Msh2 ENSMUSG00000024151 17:88071897-88072396 137 510486 118 558651 81 563898 3,29E-05 2,11E-02 2,68E-04 2,11E-04 1,44E-04 3,66E-04 3,50E-04 3,82E-04 3,95E-04 3,63E-04 2,97E-04 4,06E-04 3,39E-04 3,12E-04
Msh5-1 ENSMUSG00000007035 17:35183052-35183551 182 629303 156 681009 85 635597 1,07E-08 2,28E-04 2,89E-04 2,29E-04 1,34E-04 3,58E-04 3,16E-04 3,53E-04 4,01E-04 3,47E-04 2,79E-04 4,28E-04 3,59E-04 3,15E-04
Msh5-2 ENSMUSG00000007035 17:35183169-35183668 126 521555 118 567992 71 523734 3,71E-04 1,30E-02 2,42E-04 2,08E-04 1,36E-04 3,57E-04 3,51E-04 3,77E-04 4,04E-04 3,68E-04 2,95E-04 4,16E-04 3,63E-04 3,27E-04
Msh6 ENSMUSG00000005370 17:88374390-88374889 190 764672 184 817788 128 750411 3,14E-03 3,79E-02 2,48E-04 2,25E-04 1,71E-04 3,97E-04 3,29E-04 3,47E-04 3,89E-04 3,83E-04 3,27E-04 4,25E-04 3,80E-04 3,51E-04
Mtor ENSMUSG00000028991 4:147822691-147823190 97 499716 134 557502 63 529821 7,27E-03 1,27E-05 1,94E-04 2,40E-04 1,19E-04 3,71E-04 3,10E-04 3,16E-04 3,55E-04 3,73E-04 3,42E-04 4,02E-04 4,06E-04 3,15E-04
Mtss1 ENSMUSG00000022353 15:58913082-58913581 216 738806 316 819654 130 795017 6,87E-07 9,62E-17 2,92E-04 3,86E-04 1,64E-04 3,48E-04 3,23E-04 3,74E-04 3,73E-04 3,78E-04 3,76E-04 4,20E-04 4,84E-04 3,61E-04
Mybbp1a ENSMUSG00000040463 11:72254880-72255379 141 555854 154 614681 95 597996 1,47E-03 1,61E-03 2,54E-04 2,51E-04 1,59E-04 3,85E-04 3,09E-04 3,80E-04 3,82E-04 3,45E-04 3,55E-04 3,88E-04 4,54E-04 3,46E-04
Myc ENSMUSG00000022346 15:61816896-61817395 362 480006 459 522364 80 490714 6,61E-44 2,95E-59 7,54E-04 8,79E-04 1,63E-04 4,00E-04 3,39E-04 3,89E-04 4,39E-04 4,61E-04 3,76E-04 7,59E-04 7,97E-04 3,36E-04
Mycbp2 ENSMUSG00000033004 14:103745518-103746017 42 159683 46 164458 14 161191 7,02E-04 2,20E-04 2,63E-04 2,80E-04 8,69E-05 5,32E-04 3,28E-04 3,19E-04 3,87E-04 3,56E-04 3,13E-04 4,12E-04 4,58E-04 2,79E-04
Ncl ENSMUSG00000026234 1:88255531-88256030 287 983500 284 1034488 141 973071 2,46E-11 1,61E-09 2,92E-04 2,75E-04 1,45E-04 3,51E-04 3,14E-04 3,47E-04 3,59E-04 3,77E-04 3,60E-04 4,58E-04 4,28E-04 3,41E-04
Nfkb2-1 ENSMUSG00000025225 19:46379227-46379726 148 747171 164 821171 116 777691 4,49E-02 3,79E-02 1,98E-04 2,00E-04 1,49E-04 3,64E-04 3,25E-04 3,19E-04 3,87E-04 3,80E-04 3,14E-04 3,78E-04 3,62E-04 3,21E-04
Nfkb2-2 ENSMUSG00000025225 19:46380185-46380684 120 560027 121 620957 66 547790 5,96E-04 5,04E-03 2,14E-04 1,95E-04 1,20E-04 3,76E-04 3,42E-04 3,66E-04 4,00E-04 3,77E-04 3,53E-04 4,05E-04 3,85E-04 3,00E-04
Nfkb2-3 ENSMUSG00000025225 19:46380420-46380919 273 621600 151 696165 73 653745 2,18E-29 1,04E-05 4,39E-04 2,17E-04 1,12E-04 3,31E-04 3,23E-04 3,56E-04 3,60E-04 3,68E-04 3,41E-04 5,29E-04 4,03E-04 3,20E-04
Ntan1 ENSMUSG00000022681 16:13819370-13819869 134 679722 129 758918 89 723768 1,87E-03 4,36E-02 1,97E-04 1,70E-04 1,23E-04 3,82E-04 2,85E-04 3,47E-04 3,90E-04 3,62E-04 3,49E-04 3,93E-04 3,28E-04 3,15E-04
Parp1 ENSMUSG00000026496 1:182499106-182499605 151 707486 150 771792 91 742589 1,17E-04 1,72E-03 2,13E-04 1,94E-04 1,23E-04 3,34E-04 3,10E-04 3,87E-04 3,94E-04 3,30E-04 3,38E-04 4,01E-04 3,66E-04 3,10E-04
Pax5 ENSMUSG00000014030 4:44722813-44723312 554 503476 682 551020 64 515254 3,64E-99 5,88E-121 1,10E-03 1,24E-03 1,24E-04 5,42E-04 4,87E-04 5,00E-04 5,41E-04 4,88E-04 4,35E-04 8,81E-04 9,36E-04 4,20E-04
Pcna ENSMUSG00000027342 2:132078417-132078916 146 617312 162 677457 89 656611 1,41E-04 6,24E-05 2,37E-04 2,39E-04 1,36E-04 3,42E-04 2,88E-04 3,17E-04 3,66E-04 3,36E-04 3,25E-04 4,16E-04 3,58E-04 3,13E-04
Pex13 ENSMUSG00000020283 11:23565436-23565935 187 684392 158 749783 106 697002 5,64E-06 2,48E-02 2,73E-04 2,11E-04 1,52E-04 3,85E-04 3,91E-04 3,79E-04 3,87E-04 3,62E-04 3,18E-04 4,51E-04 4,10E-04 3,33E-04
Phip ENSMUSG00000032253 9:82868597-82869096 176 494894 129 511028 63 495442 1,16E-12 2,67E-05 3,56E-04 2,52E-04 1,27E-04 3,60E-04 3,33E-04 3,34E-04 3,72E-04 3,70E-04 3,35E-04 4,89E-04 4,06E-04 3,50E-04
Pias1 ENSMUSG00000032405 9:62828187-62828686 155 556985 282 612404 76 599841 5,35E-08 6,11E-27 2,78E-04 4,60E-04 1,27E-04 8,75E-04 8,13E-04 7,72E-04 7,10E-04 7,04E-04 7,91E-04 7,13E-04 7,31E-04 6,68E-04
Pick1-2 ENSMUSG00000068206 15:79059812-79060311 130 873283 167 967303 100 912093 4,41E-02 1,15E-03 1,49E-04 1,73E-04 1,10E-04 3,46E-04 3,03E-04 3,18E-04 3,79E-04 3,48E-04 3,13E-04 3,46E-04 3,42E-04 3,13E-04
Pik3ap1 ENSMUSG00000025017 19:41459061-41459560 192 797382 167 882959 96 797313 9,03E-08 1,41E-03 2,41E-04 1,89E-04 1,20E-04 2,84E-03 3,30E-03 2,18E-03 3,31E-03 1,63E-03 2,93E-03 2,94E-03 3,05E-03 5,88E-03
Pim1 ENSMUSG00000024014 17:29627990-29628489 2145 614306 2751 657842 98 642524 0,00E+00 0,00E+00 3,49E-03 4,18E-03 1,53E-04 6,56E-04 6,14E-04 7,08E-04 5,19E-04 7,42E-04 8,24E-04 2,71E-03 3,15E-03 3,36E-04
Plac8 ENSMUSG00000029322 5:101000725-101001224 81 340658 136 383491 50 361198 7,70E-03 1,63E-08 2,38E-04 3,55E-04 1,38E-04 3,65E-04 3,10E-04 3,43E-04 4,04E-04 3,41E-04 3,13E-04 3,88E-04 4,36E-04 3,42E-04
Plcb2 ENSMUSG00000040061 2:118553675-118554174 149 910849 170 1020135 103 919968 8,67E-03 4,49E-03 1,64E-04 1,67E-04 1,12E-04 2,38E-03 1,64E-03 2,11E-03 3,01E-03 3,38E-03 1,15E-03 1,77E-03 1,24E-03 5,42E-03
Pms2 ENSMUSG00000079109 5:144670870-144671369 189 709817 157 798404 101 774062 2,36E-08 4,20E-03 2,66E-04 1,97E-04 1,30E-04 3,47E-04 2,81E-04 3,82E-04 3,28E-04 3,32E-04 3,15E-04 4,00E-04 3,37E-04 3,02E-04
Pola1 ENSMUSG00000006678 X:90876995-90877494 282 580875 500 549551 66 571667 5,31E-31 8,85E-86 4,85E-04 9,10E-04 1,15E-04 3,54E-04 3,29E-04 3,44E-04 3,95E-04 3,17E-04 3,67E-04 5,34E-04 7,57E-04 3,49E-04
Pold1 ENSMUSG00000038644 7:51803686-51804185 339 702046 470 793770 110 757641 5,45E-31 4,51E-49 4,83E-04 5,92E-04 1,45E-04 3,55E-04 3,17E-04 3,80E-04 4,20E-04 3,72E-04 3,23E-04 5,72E-04 6,31E-04 3,64E-04
Pold4 ENSMUSG00000024854 19:4231899-4232398 169 610086 201 700534 75 640097 1,01E-09 3,33E-11 2,77E-04 2,87E-04 1,17E-04 4,42E-04 4,16E-04 4,96E-04 5,24E-04 4,41E-04 4,52E-04 5,42E-04 5,26E-04 4,55E-04
Pou2af1 ENSMUSG00000032053 9:51021795-51022294 1438 581980 1399 657671 83 650248 0,00E+00 6,93E-304 2,47E-03 2,13E-03 1,28E-04 4,19E-04 3,91E-04 4,35E-04 3,79E-04 4,42E-04 3,62E-04 1,53E-03 1,34E-03 3,27E-04
Pou2f1-1 ENSMUSG00000026565 1:167864532-167865031 99 492890 97 575689 63 550754 1,63E-03 4,00E-02 2,01E-04 1,68E-04 1,14E-04 3,13E-04 2,87E-04 3,10E-04 3,44E-04 2,99E-04 3,26E-04 3,67E-04 3,08E-04 3,27E-04
Pou2f2 ENSMUSG00000008496 7:25916980-25917479 108 407122 115 452927 70 452772 1,50E-03 3,47E-03 2,65E-04 2,54E-04 1,55E-04 3,67E-04 2,80E-04 3,21E-04 3,69E-04 3,44E-04 3,23E-04 4,09E-04 4,10E-04 3,84E-04
Ppard ENSMUSG00000002250 17:28369699-28370198 138 562238 119 599180 83 585038 3,15E-04 4,36E-02 2,45E-04 1,99E-04 1,42E-04 4,81E-04 4,02E-04 4,03E-04 4,44E-04 4,28E-04 4,17E-04 4,80E-04 4,07E-04 3,31E-04
Ppia ENSMUSG00000071866 11:6315873-6316372 103 409774 109 450054 56 378333 4,14E-03 7,85E-03 2,51E-04 2,42E-04 1,48E-04 3,47E-04 3,03E-04 3,50E-04 4,38E-04 3,76E-04 3,45E-04 4,36E-04 4,24E-04 3,33E-04
Ppp1r15b ENSMUSG00000046062 1:135027743-135028242 156 783542 160 841987 108 807394 4,55E-03 1,38E-02 1,99E-04 1,90E-04 1,34E-04 3,69E-04 3,31E-04 3,66E-04 3,45E-04 3,48E-04 3,18E-04 3,84E-04 3,67E-04 3,51E-04
Ppp1r16b-2 ENSMUSG00000037754 2:158492871-158493370 156 557644 239 619563 109 590836 2,79E-03 3,74E-10 2,80E-04 3,86E-04 1,84E-04 4,26E-04 3,59E-04 3,62E-04 3,84E-04 4,22E-04 3,21E-04 4,47E-04 5,14E-04 3,48E-04
Prdx1 ENSMUSG00000028691 4:116358204-116358703 317 838736 697 935580 158 875549 6,39E-14 2,03E-72 3,78E-04 7,45E-04 1,80E-04 1,17E-03 1,20E-03 7,12E-04 1,42E-03 6,83E-04 1,22E-03 8,06E-04 1,51E-03 5,60E-04
Psmc3 ENSMUSG00000002102 2:90894173-90894672 251 880879 278 980450 112 893512 6,93E-13 2,88E-13 2,85E-04 2,84E-04 1,25E-04 3,37E-04 3,15E-04 3,89E-04 3,86E-04 3,29E-04 3,35E-04 4,49E-04 4,01E-04 3,31E-04
Ptbp2 ENSMUSG00000028134 3:119485807-119486306 219 520503 223 581299 96 557036 3,58E-13 9,30E-11 4,21E-04 3,84E-04 1,72E-04 3,71E-04 3,07E-04 3,71E-04 3,65E-04 3,20E-04 3,18E-04 5,67E-04 5,09E-04 3,52E-04
Pten ENSMUSG00000013663 19:32832067-32832566 142 429732 101 462809 58 450616 2,01E-09 4,28E-03 3,30E-04 2,18E-04 1,29E-04 3,98E-04 3,22E-04 4,28E-04 4,00E-04 3,90E-04 3,09E-04 5,40E-04 4,03E-04 3,27E-04
Ptma ENSMUSG00000026238 1:88423311-88423810 600 584974 862 621012 102 593937 1,04E-86 1,34E-141 1,03E-03 1,39E-03 1,72E-04 4,49E-04 4,14E-04 3,90E-04 3,65E-04 5,22E-04 4,48E-04 9,58E-04 1,19E-03 3,41E-04
Ptprc ENSMUSG00000026395 1:140071383-140071882 173 560187 234 614866 75 584306 3,43E-10 1,83E-17 3,09E-04 3,81E-04 1,28E-04 3,42E-04 3,07E-04 3,49E-04 3,43E-04 3,09E-04 2,93E-04 3,86E-04 4,16E-04 2,99E-04
Rac1 ENSMUSG00000001847 5:144288362-144288861 195 836186 226 911049 117 868552 1,11E-05 2,89E-07 2,33E-04 2,48E-04 1,35E-04 3,86E-04 3,22E-04 3,82E-04 3,82E-04 3,77E-04 3,61E-04 4,07E-04 4,48E-04 3,56E-04
Rad23a ENSMUSG00000003813 8:87364041-87364540 132 486609 162 519096 78 496719 4,86E-04 1,99E-06 2,71E-04 3,12E-04 1,57E-04 3,40E-04 3,15E-04 3,86E-04 3,77E-04 3,53E-04 3,39E-04 4,17E-04 4,42E-04 3,45E-04
Rad51 ENSMUSG00000027323 2:118938553-118939052 194 901196 284 991878 145 903256 1,83E-02 4,89E-08 2,15E-04 2,86E-04 1,61E-04 3,55E-04 3,14E-04 3,69E-04 3,70E-04 3,53E-04 3,33E-04 3,93E-04 4,06E-04 3,36E-04
Rad9 ENSMUSG00000024824 19:4201104-4201603 220 1076714 208 1165317 127 1061661 6,22E-06 1,31E-03 2,04E-04 1,78E-04 1,20E-04 3,45E-04 2,85E-04 3,59E-04 3,72E-04 3,23E-04 3,31E-04 3,62E-04 3,40E-04 3,19E-04
Ranbp1 ENSMUSG00000005732 16:18248288-18248787 170 711915 229 752275 129 728583 2,41E-02 3,43E-06 2,39E-04 3,04E-04 1,77E-04 3,89E-04 3,49E-04 3,57E-04 3,56E-04 3,62E-04 3,33E-04 3,86E-04 4,64E-04 3,69E-04
Rbm15 ENSMUSG00000048109 3:107135708-107136207 232 629055 147 708227 75 683164 1,12E-21 2,50E-05 3,69E-04 2,08E-04 1,10E-04 3,48E-04 3,06E-04 3,46E-04 3,81E-04 3,58E-04 3,03E-04 4,83E-04 3,67E-04 3,14E-04
Ung-/-Msh2-/-Exp1 Ung-/-Msh2-/-Exp2 Aicda-/- Ung-/-Msh2-/- Aicda-/- Ung+/-Msh2+/- Ung+/-Msh2-/- Ung-/-Msh2+/- Ung-/-Msh2-/- Aicda-/-
Transitions at C/G pairs C/G Transition Frequency Total mutation frequency
FDR
Gene Ensembl ID Coordinates C/G transitions C/G sequenced C/G transitions C/G sequenced C/G transitions C/G sequenced Exp1 Exp2 Exp1 Exp2 Exp1 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1
Rbm19 ENSMUSG00000029594 5:120566522-120567021 112 536555 150 604127 76 558948 1,08E-02 6,47E-05 2,09E-04 2,48E-04 1,36E-04 3,76E-04 2,89E-04 3,26E-04 3,74E-04 3,26E-04 3,31E-04 4,20E-04 3,85E-04 3,19E-04
Rbm39 ENSMUSG00000027620 2:156005477-156005976 286 634965 205 689250 93 677920 1,18E-25 1,30E-09 4,50E-04 2,97E-04 1,37E-04 3,91E-04 3,39E-04 3,48E-04 4,14E-04 4,15E-04 3,27E-04 5,57E-04 4,29E-04 3,32E-04
Recql4 ENSMUSG00000033762 15:76540407-76540906 144 581529 128 646820 78 628329 3,31E-06 3,77E-03 2,48E-04 1,98E-04 1,24E-04 3,82E-04 3,26E-04 3,10E-04 3,73E-04 3,52E-04 3,11E-04 4,11E-04 3,65E-04 3,28E-04
Rel ENSMUSG00000020275 11:23670471-23670970 144 603446 168 672273 88 626167 3,61E-04 4,33E-05 2,39E-04 2,50E-04 1,41E-04 3,88E-04 3,50E-04 4,07E-04 3,35E-04 3,54E-04 3,46E-04 4,11E-04 3,94E-04 3,46E-04
Rev3l ENSMUSG00000019841 10:39451966-39452465 103 472492 131 522108 73 483878 3,58E-02 1,61E-03 2,18E-04 2,51E-04 1,51E-04 3,80E-04 3,34E-04 3,48E-04 3,60E-04 3,26E-04 3,68E-04 3,98E-04 3,91E-04 3,02E-04
Rfc2 ENSMUSG00000023104 5:135058560-135059059 159 415540 143 457169 72 425790 2,04E-08 6,93E-05 3,83E-04 3,13E-04 1,69E-04 3,88E-04 3,45E-04 3,51E-04 3,79E-04 3,47E-04 3,16E-04 5,34E-04 4,79E-04 3,42E-04
Rgs13 ENSMUSG00000051079 1:146024003-146024502 108 571740 177 666112 76 606918 1,56E-02 9,56E-08 1,89E-04 2,66E-04 1,25E-04 3,30E-04 3,07E-04 3,27E-04 3,20E-04 2,96E-04 3,06E-04 3,02E-04 3,59E-04 3,30E-04
Rhoh ENSMUSG00000029204 5:66254808-66255307 787 706562 951 773153 248 753845 3,88E-72 5,44E-92 1,11E-03 1,23E-03 3,29E-04 5,33E-04 4,08E-04 4,24E-04 4,27E-04 4,26E-04 3,78E-04 7,88E-04 8,29E-04 4,03E-04
Rims1 ENSMUSG00000041670 1:22812064-22812563 117 589206 136 692194 95 677255 2,80E-02 3,01E-02 1,99E-04 1,96E-04 1,40E-04 3,66E-04 3,56E-04 4,33E-04 4,06E-04 4,79E-04 3,13E-04 3,86E-04 3,79E-04 3,21E-04
Rnf2 ENSMUSG00000026484 1:153347454-153347953 35 140958 36 155865 17 158125 1,23E-02 2,53E-02 2,48E-04 2,31E-04 1,08E-04 4,72E-04 4,61E-04 4,81E-04 4,92E-04 5,05E-04 3,86E-04 5,40E-04 5,04E-04 4,35E-04
Rpa1 ENSMUSG00000000751 11:75161386-75161885 178 738607 153 810620 106 781374 1,15E-05 2,40E-02 2,41E-04 1,89E-04 1,36E-04 3,49E-04 3,03E-04 3,46E-04 3,54E-04 3,62E-04 3,24E-04 3,89E-04 3,68E-04 3,43E-04
Rpia ENSMUSG00000053604 6:70741670-70742169 130 705834 127 754821 90 761126 3,91E-03 2,75E-02 1,84E-04 1,68E-04 1,18E-04 3,62E-04 2,82E-04 2,94E-04 3,98E-04 3,80E-04 3,36E-04 3,76E-04 3,34E-04 3,19E-04
Rpl29 ENSMUSG00000048758 9:106331870-106332369 228 625577 147 670209 85 617428 7,12E-15 2,03E-03 3,64E-04 2,19E-04 1,38E-04 3,27E-04 3,46E-04 3,91E-04 4,16E-04 3,74E-04 3,28E-04 4,81E-04 4,09E-04 3,25E-04
Rpl3 ENSMUSG00000060036 15:79913337-79913836 482 627694 306 689141 93 621963 5,20E-62 5,01E-22 7,68E-04 4,44E-04 1,50E-04 3,54E-04 3,63E-04 3,64E-04 3,59E-04 3,90E-04 3,83E-04 6,71E-04 4,88E-04 3,37E-04
Rpl32 ENSMUSG00000057841 6:115758262-115758761 235 467993 281 496836 71 465442 2,15E-20 1,12E-26 5,02E-04 5,66E-04 1,53E-04 3,70E-04 2,95E-04 3,41E-04 3,58E-04 3,91E-04 3,53E-04 6,01E-04 5,94E-04 3,34E-04
Rpl35 ENSMUSG00000062997 2:38860152-38860651 171 519530 213 550445 82 541086 2,04E-08 3,58E-13 3,29E-04 3,87E-04 1,52E-04 3,55E-04 3,31E-04 3,77E-04 3,63E-04 3,76E-04 3,63E-04 4,59E-04 4,70E-04 3,46E-04
Rpl4 ENSMUSG00000032399 9:64021194-64021693 348 727090 332 819432 90 792082 1,60E-40 9,80E-31 4,79E-04 4,05E-04 1,14E-04 3,25E-04 3,27E-04 3,61E-04 3,49E-04 3,45E-04 4,10E-04 5,08E-04 4,41E-04 2,83E-04
Rpl41 ENSMUSG00000093674 10:127985725-127986224 231 704789 257 774035 108 722845 3,19E-11 4,38E-12 3,28E-04 3,32E-04 1,49E-04 3,81E-04 3,07E-04 3,53E-04 3,86E-04 3,56E-04 3,13E-04 4,63E-04 4,38E-04 3,49E-04
Rplp0 ENSMUSG00000067274 5:116009476-116009975 311 720711 388 773252 126 730965 1,16E-18 8,41E-28 4,32E-04 5,02E-04 1,72E-04 3,93E-04 3,08E-04 3,84E-04 3,98E-04 3,88E-04 2,96E-04 5,69E-04 6,06E-04 3,43E-04
Rps12 ENSMUSG00000061983 10:23506516-23507015 388 564928 525 606055 117 600164 2,34E-37 2,24E-60 6,87E-04 8,66E-04 1,95E-04 3,87E-04 3,28E-04 3,68E-04 3,40E-04 3,69E-04 3,50E-04 6,84E-04 7,59E-04 3,44E-04
Rps14 ENSMUSG00000024608 18:60934250-60934749 512 783590 585 875489 114 766837 8,34E-58 7,73E-63 6,53E-04 6,68E-04 1,49E-04 3,40E-04 3,47E-04 3,57E-04 4,15E-04 3,81E-04 3,62E-04 6,93E-04 6,60E-04 3,21E-04
Rps5 ENSMUSG00000012848 7:13507660-13508159 394 790650 426 881418 111 831430 5,03E-40 2,36E-39 4,98E-04 4,83E-04 1,34E-04 3,96E-04 2,84E-04 3,02E-04 3,34E-04 3,35E-04 3,91E-04 5,31E-04 5,19E-04 2,91E-04
Rps6 ENSMUSG00000028495 4:86502772-86503271 263 697680 232 759107 107 759467 2,80E-18 7,03E-11 3,77E-04 3,06E-04 1,41E-04 4,87E-04 4,64E-04 5,76E-04 5,19E-04 5,19E-04 5,36E-04 6,14E-04 5,78E-04 3,03E-04
Rps9 ENSMUSG00000006333 7:3655643-3656142 1393 786312 1432 859642 1155 822127 3,23E-08 6,92E-05 1,77E-03 1,67E-03 1,40E-03 1,35E-03 1,36E-03 1,32E-03 1,44E-03 1,25E-03 1,26E-03 1,56E-03 1,49E-03 1,31E-03
Rrm1 ENSMUSG00000030978 7:109590209-109590708 137 564554 130 615072 92 615904 1,15E-03 2,83E-02 2,43E-04 2,11E-04 1,49E-04 1,94E-03 1,60E-03 1,85E-03 2,46E-03 1,81E-03 1,78E-03 1,97E-03 1,58E-03 2,45E-03
Rrm2 ENSMUSG00000020649 12:25393119-25393618 182 610935 201 669515 104 626036 7,95E-06 3,47E-06 2,98E-04 3,00E-04 1,66E-04 3,57E-04 3,48E-04 4,89E-04 3,77E-04 3,73E-04 3,14E-04 4,59E-04 5,50E-04 3,46E-04
Runx1t1-2 ENSMUSG00000006586 4:13678444-13678943 111 552085 129 630298 85 604088 3,07E-02 2,03E-02 2,01E-04 2,05E-04 1,41E-04 5,36E-04 4,63E-04 5,62E-04 5,95E-04 5,29E-04 5,35E-04 5,64E-04 6,01E-04 4,55E-04
Safb ENSMUSG00000071054 17:56724405-56724904 124 537299 104 587865 67 555762 6,81E-05 3,55E-02 2,31E-04 1,77E-04 1,21E-04 3,65E-04 3,36E-04 3,77E-04 3,56E-04 3,85E-04 3,05E-04 4,02E-04 3,22E-04 3,19E-04
Serinc3 ENSMUSG00000017707 2:163470380-163470879 158 639032 288 677569 107 680762 1,08E-03 1,96E-19 2,47E-04 4,25E-04 1,57E-04 4,04E-04 3,04E-04 3,73E-04 3,70E-04 3,70E-04 3,44E-04 3,93E-04 5,72E-04 3,67E-04
Sf3b1 ENSMUSG00000025982 1:55083823-55084322 216 956671 226 1029605 132 934345 8,85E-05 2,12E-04 2,26E-04 2,20E-04 1,41E-04 3,62E-04 3,17E-04 3,64E-04 3,96E-04 3,58E-04 3,26E-04 4,01E-04 3,98E-04 3,20E-04
Sh3bp5 ENSMUSG00000021892 14:32248720-32249219 151 485566 172 523489 96 521000 2,50E-04 2,16E-05 3,11E-04 3,29E-04 1,84E-04 4,23E-04 2,95E-04 3,73E-04 3,94E-04 4,41E-04 3,40E-04 4,41E-04 4,47E-04 3,38E-04
Sipa1 ENSMUSG00000056917 19:5663208-5663707 200 664806 131 711958 92 687281 2,58E-10 4,45E-02 3,01E-04 1,84E-04 1,34E-04 3,31E-04 2,95E-04 3,18E-04 3,67E-04 3,45E-04 3,51E-04 4,40E-04 3,17E-04 3,05E-04
Sirt6-2 ENSMUSG00000034748 10:81089854-81090353 143 728703 186 783900 89 760033 5,03E-04 1,25E-07 1,96E-04 2,37E-04 1,17E-04 3,67E-04 3,47E-04 3,50E-04 4,00E-04 3,89E-04 3,11E-04 3,93E-04 4,03E-04 3,19E-04
Slbp ENSMUSG00000004642 5:33994456-33994955 220 676978 214 715314 92 694595 4,84E-13 1,04E-10 3,25E-04 2,99E-04 1,32E-04 3,66E-04 3,11E-04 3,68E-04 3,84E-04 3,45E-04 3,49E-04 4,40E-04 4,24E-04 2,95E-04
Slc30a6 ENSMUSG00000024069 17:74794972-74795471 135 815974 265 906712 102 871918 2,02E-02 1,74E-15 1,65E-04 2,92E-04 1,17E-04 3,41E-04 4,48E-04 3,37E-04 3,68E-04 3,25E-04 2,86E-04 3,40E-04 3,97E-04 3,05E-04
Smu NoCode001 12:114663752-114664475 37333 734739 40702 779929 136 977119 0,00E+00 0,00E+00 5,08E-02 5,22E-02 1,39E-04 6,23E-03 6,14E-03 4,31E-03 3,41E-03 5,42E-03 8,00E-03 2,31E-02 2,39E-02 3,29E-04
Snx5 ENSMUSG00000027423 2:144096139-144096638 157 533761 230 580477 102 559053 6,44E-04 1,33E-10 2,94E-04 3,96E-04 1,82E-04 3,51E-04 3,38E-04 4,44E-04 4,46E-04 4,18E-04 3,54E-04 4,81E-04 5,00E-04 3,70E-04
Sod1 ENSMUSG00000022982 16:90220987-90221486 145 690849 138 772156 93 724434 7,85E-04 3,39E-02 2,10E-04 1,79E-04 1,28E-04 3,39E-04 3,16E-04 3,91E-04 3,98E-04 3,65E-04 3,16E-04 4,12E-04 3,99E-04 3,29E-04
Sp3-2 ENSMUSG00000027109 2:72818004-72818503 95 300119 103 323520 64 300620 3,23E-02 2,97E-02 3,17E-04 3,18E-04 2,13E-04 3,72E-04 4,05E-04 3,62E-04 4,52E-04 4,09E-04 3,39E-04 4,64E-04 4,36E-04 3,67E-04
Spib ENSMUSG00000008193 7:51786942-51787441 115 381443 147 413056 44 404567 1,12E-08 8,78E-13 3,01E-04 3,56E-04 1,09E-04 6,37E-04 5,06E-04 6,68E-04 5,72E-04 6,50E-04 6,56E-04 6,27E-04 7,13E-04 5,73E-04
Sra1 ENSMUSG00000006050 18:36829466-36829965 158 834218 197 920653 107 885311 1,19E-03 7,37E-06 1,89E-04 2,14E-04 1,21E-04 3,73E-04 2,76E-04 3,60E-04 3,36E-04 3,30E-04 2,95E-04 3,63E-04 3,76E-04 3,15E-04
Srsf10 ENSMUSG00000028676 4:135412007-135412506 150 328508 311 354771 45 346103 1,16E-14 2,30E-47 4,57E-04 8,77E-04 1,30E-04 1,05E-03 7,42E-04 1,67E-03 1,56E-03 1,34E-03 2,56E-03 1,17E-03 1,56E-03 4,08E-04
St6gal1-1 ENSMUSG00000022885 16:23224813-23225312 191 690488 261 769742 97 721765 2,10E-08 2,77E-15 2,77E-04 3,39E-04 1,34E-04 3,36E-04 3,09E-04 3,53E-04 3,56E-04 3,68E-04 2,99E-04 4,07E-04 4,50E-04 3,01E-04
St6gal1-2 ENSMUSG00000022885 16:23226094-23226593 224 862113 211 969163 107 909042 3,36E-11 7,61E-07 2,60E-04 2,18E-04 1,18E-04 3,53E-04 3,48E-04 3,25E-04 3,42E-04 3,30E-04 3,67E-04 3,83E-04 3,51E-04 3,29E-04
Stau1 ENSMUSG00000039536 2:166821279-166821778 90 456903 96 484273 57 450848 2,15E-02 2,00E-02 1,97E-04 1,98E-04 1,26E-04 3,64E-04 3,17E-04 4,31E-04 4,69E-04 3,84E-04 3,35E-04 3,88E-04 3,68E-04 3,13E-04
Stx3-2 ENSMUSG00000041488 19:11893394-11893893 167 695033 206 798519 126 688379 4,28E-02 7,06E-03 2,40E-04 2,58E-04 1,83E-04 8,19E-04 6,96E-04 7,37E-04 7,47E-04 7,41E-04 7,64E-04 7,89E-04 7,05E-04 6,31E-04
Sv2b-1 ENSMUSG00000053025 7:82452773-82453272 126 769258 141 861550 100 848988 3,16E-02 3,03E-02 1,64E-04 1,64E-04 1,18E-04 3,33E-04 3,52E-04 3,66E-04 3,56E-04 3,60E-04 3,39E-04 3,57E-04 3,30E-04 3,35E-04
Swap70 ENSMUSG00000031015 7:117365217-117365716 152 438736 245 465057 70 441820 1,55E-07 6,00E-21 3,46E-04 5,27E-04 1,58E-04 3,57E-04 3,35E-04 4,11E-04 3,42E-04 3,74E-04 1,08E-03 5,28E-04 6,09E-04 3,09E-04
Syk ENSMUSG00000021457 13:52692251-52692750 354 761725 360 841588 95 795086 2,34E-37 5,56E-33 4,65E-04 4,28E-04 1,19E-04 4,70E-04 3,38E-04 3,15E-04 3,41E-04 3,54E-04 3,54E-04 4,90E-04 4,42E-04 2,99E-04
Taf4a ENSMUSG00000039117 2:179710852-179711351 30 84085 36 86986 11 81819 1,30E-02 2,26E-03 3,57E-04 4,14E-04 1,34E-04 3,07E-04 3,48E-04 3,27E-04 3,69E-04 4,07E-04 4,02E-04 5,02E-04 5,53E-04 3,74E-04
Taf9-2 ENSMUSG00000052293 13:101421562-101422061 311 715720 182 822626 86 760905 7,40E-33 8,78E-07 4,35E-04 2,21E-04 1,13E-04 3,19E-04 3,04E-04 3,13E-04 3,34E-04 3,42E-04 3,12E-04 4,72E-04 3,64E-04 3,38E-04
Tapbp ENSMUSG00000024308 17:34056423-34056922 247 753754 184 844945 93 799215 3,01E-18 2,93E-06 3,28E-04 2,18E-04 1,16E-04 3,41E-04 3,42E-04 3,80E-04 3,88E-04 3,69E-04 3,33E-04 4,61E-04 3,63E-04 3,26E-04
Tcea1-2 ENSMUSG00000033813 1:4848409-4848908 191 717890 164 850451 89 797762 2,33E-11 1,14E-04 2,66E-04 1,93E-04 1,12E-04 3,53E-04 3,20E-04 3,34E-04 3,40E-04 3,11E-04 3,20E-04 3,76E-04 3,48E-04 3,07E-04
Tcf3 ENSMUSG00000020167 10:79895899-79896398 179 678888 132 695636 86 667711 1,35E-07 1,48E-02 2,64E-04 1,90E-04 1,29E-04 3,53E-04 3,44E-04 3,89E-04 4,81E-04 3,93E-04 4,12E-04 4,54E-04 4,30E-04 3,65E-04
Tcf4-1 ENSMUSG00000053477 18:69504146-69504645 122 641344 155 753715 98 706912 4,15E-02 6,77E-03 1,90E-04 2,06E-04 1,39E-04 3,39E-04 3,21E-04 3,32E-04 3,38E-04 3,05E-04 3,10E-04 3,39E-04 3,16E-04 3,28E-04
Telomerase-vert ENSMUSG00000064796 3:96218257-96218756 167 847739 159 913453 109 860318 1,19E-03 2,74E-02 1,97E-04 1,74E-04 1,27E-04 3,63E-04 3,20E-04 3,57E-04 3,69E-04 3,25E-04 2,98E-04 3,64E-04 3,46E-04 3,03E-04
Tet2 ENSMUSG00000040943 3:133206855-133207354 151 687031 193 760095 106 734090 2,98E-03 1,15E-05 2,20E-04 2,54E-04 1,44E-04 4,13E-04 3,04E-04 4,06E-04 3,79E-04 3,36E-04 3,14E-04 3,90E-04 3,98E-04 2,91E-04
Tex14-1 ENSMUSG00000010342 11:87218567-87219066 70 408369 81 446181 47 420648 4,85E-02 2,22E-02 1,71E-04 1,82E-04 1,12E-04 3,89E-04 4,27E-04 3,57E-04 3,77E-04 3,50E-04 2,73E-04 3,42E-04 3,65E-04 3,12E-04
Tfap4 ENSMUSG00000005718 16:4559221-4559720 123 652623 125 696841 80 646779 9,28E-03 2,49E-02 1,88E-04 1,79E-04 1,24E-04 3,98E-04 3,85E-04 4,61E-04 4,17E-04 4,12E-04 4,03E-04 4,31E-04 3,96E-04 4,00E-04
Tfdp1 ENSMUSG00000038482 8:13339674-13340173 125 409604 196 477394 97 463004 1,44E-02 1,89E-07 3,05E-04 4,11E-04 2,10E-04 4,08E-04 3,67E-04 4,21E-04 3,94E-04 4,27E-04 3,77E-04 4,03E-04 5,00E-04 3,84E-04
Tmsb4x ENSMUSG00000049775 X:163646651-163647150 1326 456363 1389 433376 78 437003 2,98E-280 0,00E+00 2,91E-03 3,21E-03 1,78E-04 5,43E-04 5,74E-04 7,41E-04 5,67E-04 6,65E-04 7,20E-04 1,87E-03 1,99E-03 4,09E-04
Tnf ENSMUSG00000024401 17:35338442-35338941 198 828728 197 940588 87 884605 7,16E-12 9,41E-09 2,39E-04 2,09E-04 9,83E-05 3,26E-04 3,16E-04 3,32E-04 3,45E-04 3,10E-04 2,86E-04 4,05E-04 3,86E-04 2,93E-04
Tnfaip3-1 ENSMUSG00000019850 10:18731270-18731769 206 815638 179 893794 97 856932 1,50E-10 2,25E-05 2,53E-04 2,00E-04 1,13E-04 3,68E-04 3,26E-04 3,32E-04 3,42E-04 3,18E-04 2,98E-04 3,87E-04 3,44E-04 2,85E-04
Tnfaip3-2 ENSMUSG00000019850 10:18734717-18735216 266 789064 206 866245 110 830029 8,51E-17 2,78E-06 3,37E-04 2,38E-04 1,33E-04 4,03E-04 3,32E-04 3,71E-04 3,67E-04 3,75E-04 3,68E-04 4,67E-04 4,06E-04 3,23E-04
Top1 ENSMUSG00000070544 2:160471633-160472132 156 671777 188 732294 101 707823 5,28E-04 7,15E-06 2,32E-04 2,57E-04 1,43E-04 3,51E-04 3,22E-04 3,70E-04 4,13E-04 3,42E-04 3,15E-04 4,16E-04 3,93E-04 3,39E-04
Top2a ENSMUSG00000020914 11:98885004-98885503 185 834544 219 904432 119 852505 3,37E-04 5,06E-06 2,22E-04 2,42E-04 1,40E-04 3,66E-04 3,19E-04 3,76E-04 3,53E-04 3,34E-04 3,03E-04 3,64E-04 3,69E-04 3,15E-04
Topors ENSMUSG00000036822 4:40216375-40216874 144 826069 197 910587 111 872728 2,87E-02 2,91E-05 1,74E-04 2,16E-04 1,27E-04 3,45E-04 3,41E-04 3,50E-04 3,87E-04 3,44E-04 2,92E-04 3,67E-04 3,53E-04 3,05E-04
Tra2b ENSMUSG00000022858 16:22265503-22266002 162 636870 273 687689 120 651574 1,81E-02 3,70E-12 2,54E-04 3,97E-04 1,84E-04 5,30E-04 4,34E-04 4,28E-04 4,93E-04 4,74E-04 4,70E-04 5,46E-04 5,57E-04 4,24E-04
Ung-/-Msh2-/-Exp1 Ung-/-Msh2-/-Exp2 Aicda-/- Ung-/-Msh2-/- Aicda-/- Ung+/-Msh2+/- Ung+/-Msh2-/- Ung-/-Msh2+/- Ung-/-Msh2-/- Aicda-/-
Transitions at C/G pairs C/G Transition Frequency Total mutation frequency
FDR
Gene Ensembl ID Coordinates C/G transitions C/G sequenced C/G transitions C/G sequenced C/G transitions C/G sequenced Exp1 Exp2 Exp1 Exp2 Exp1 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1 Exp2 Exp1
Ttf1 ENSMUSG00000026803 2:28915783-28916282 120 705047 220 773269 91 734424 4,55E-02 3,49E-11 1,70E-04 2,85E-04 1,24E-04 3,61E-04 3,07E-04 3,74E-04 3,54E-04 3,71E-04 3,17E-04 3,77E-04 4,05E-04 3,04E-04
U2af2 ENSMUSG00000030435 7:5013784-5014283 100 355362 114 383400 55 367985 5,74E-04 8,83E-05 2,81E-04 2,97E-04 1,49E-04 3,46E-04 3,08E-04 3,61E-04 4,46E-04 3,86E-04 3,18E-04 4,31E-04 4,24E-04 3,32E-04
Uba3 ENSMUSG00000030061 6:97155137-97155636 107 387904 107 436370 68 421010 1,87E-03 2,00E-02 2,76E-04 2,45E-04 1,62E-04 3,53E-04 3,41E-04 3,42E-04 4,32E-04 3,93E-04 3,79E-04 4,60E-04 3,85E-04 3,38E-04
Ubac2 ENSMUSG00000041765 14:122277828-122278327 211 880732 205 897741 141 875519 9,40E-04 4,49E-03 2,40E-04 2,28E-04 1,61E-04 3,75E-04 3,26E-04 3,29E-04 3,84E-04 3,97E-04 3,67E-04 4,05E-04 3,83E-04 3,51E-04
Ubb ENSMUSG00000019505 11:62365006-62365505 174 664352 169 729561 124 708920 1,99E-03 4,07E-02 2,62E-04 2,32E-04 1,75E-04 4,85E-04 4,31E-04 4,55E-04 4,53E-04 4,47E-04 4,19E-04 4,90E-04 4,83E-04 4,56E-04
Ube2b ENSMUSG00000020390 11:51813469-51813968 182 692159 166 744358 99 702589 2,19E-06 1,04E-03 2,63E-04 2,23E-04 1,41E-04 6,75E-04 6,15E-04 7,05E-04 6,78E-04 6,26E-04 5,91E-04 7,21E-04 6,21E-04 6,21E-04
Ube2n ENSMUSG00000074781 10:94977796-94978295 122 492310 123 528919 60 499865 1,37E-05 8,63E-05 2,48E-04 2,33E-04 1,20E-04 4,17E-04 3,32E-04 3,71E-04 3,67E-04 3,85E-04 3,37E-04 4,09E-04 3,92E-04 3,03E-04
Ube4b ENSMUSG00000028960 4:148800241-148800740 197 841925 224 910180 138 878551 1,19E-03 1,27E-04 2,34E-04 2,46E-04 1,57E-04 3,69E-04 3,17E-04 3,97E-04 4,19E-04 3,59E-04 3,28E-04 4,14E-04 3,86E-04 3,44E-04
Ubox5 ENSMUSG00000027300 2:130455223-130455722 253 899101 270 984227 132 923318 8,57E-10 2,37E-09 2,81E-04 2,74E-04 1,43E-04 4,19E-04 3,07E-04 3,47E-04 3,61E-04 3,41E-04 3,28E-04 4,67E-04 4,19E-04 3,32E-04
Ubtf-1 ENSMUSG00000020923 11:102178102-102178601 176 430099 152 463949 69 426026 7,01E-11 3,57E-06 4,09E-04 3,28E-04 1,62E-04 3,96E-04 2,98E-04 3,53E-04 4,26E-04 3,54E-04 2,90E-04 5,86E-04 5,18E-04 3,68E-04
Ubtf-2 ENSMUSG00000020923 11:102179911-102180410 156 492497 156 539203 78 489902 2,32E-06 5,63E-05 3,17E-04 2,89E-04 1,59E-04 4,71E-04 3,35E-04 3,68E-04 4,40E-04 3,48E-04 3,48E-04 4,70E-04 4,28E-04 3,09E-04
Uhmk1 ENSMUSG00000026667 1:172145025-172145524 215 451892 252 498008 81 463773 5,66E-15 5,50E-18 4,76E-04 5,06E-04 1,75E-04 3,32E-04 5,87E-04 1,08E-03 7,51E-04 8,20E-04 1,29E-03 6,67E-04 7,05E-04 3,71E-04
UPGm13390-2 ENSMUSG00000087656 2:7317326-7317825 273 554140 333 651951 227 620639 2,98E-03 3,91E-04 4,93E-04 5,11E-04 3,66E-04 5,26E-04 5,44E-04 8,12E-04 8,18E-04 5,69E-04 5,26E-04 7,89E-04 8,17E-04 5,34E-04
Vav1 ENSMUSG00000034116 17:57418523-57419022 121 633878 149 678302 80 668214 3,81E-03 4,33E-05 1,91E-04 2,20E-04 1,20E-04 3,52E-04 3,26E-04 3,33E-04 3,48E-04 3,17E-04 3,29E-04 3,30E-04 3,67E-04 3,17E-04
Vav2 ENSMUSG00000009621 2:27281846-27282345 218 515435 228 567378 94 535758 1,16E-12 1,79E-11 4,23E-04 4,02E-04 1,75E-04 3,72E-04 3,51E-04 3,72E-04 4,29E-04 3,45E-04 3,70E-04 5,40E-04 5,26E-04 3,58E-04
Vcl ENSMUSG00000021823 14:21748655-21749154 146 747402 176 825832 98 776499 2,69E-03 1,16E-04 1,95E-04 2,13E-04 1,26E-04 3,84E-04 3,26E-04 3,40E-04 3,60E-04 3,37E-04 2,97E-04 3,69E-04 3,72E-04 3,18E-04
Vdac1 ENSMUSG00000020402 11:52174617-52175116 121 495642 140 533042 79 515183 4,04E-03 4,59E-04 2,44E-04 2,63E-04 1,53E-04 4,25E-04 3,62E-04 3,62E-04 3,79E-04 4,35E-04 3,62E-04 4,30E-04 4,03E-04 3,65E-04
Xbp1 ENSMUSG00000020484 11:5420970-5421469 217 768683 148 817986 104 779896 7,65E-10 4,00E-02 2,82E-04 1,81E-04 1,33E-04 3,80E-04 3,47E-04 3,65E-04 3,84E-04 3,84E-04 3,48E-04 4,57E-04 3,65E-04 3,21E-04
Zc3h15 ENSMUSG00000027091 2:83484735-83485234 118 604885 135 644471 78 626855 6,13E-03 8,61E-04 1,95E-04 2,09E-04 1,24E-04 3,70E-04 3,03E-04 3,76E-04 3,95E-04 3,09E-04 3,32E-04 3,69E-04 3,90E-04 3,25E-04
Zcchc7 ENSMUSG00000035649 4:44769440-44769939 240 1068500 308 1144835 167 1100379 4,07E-04 9,33E-09 2,25E-04 2,69E-04 1,52E-04 3,58E-04 3,37E-04 3,52E-04 3,94E-04 3,66E-04 3,14E-04 4,07E-04 4,67E-04 3,48E-04
Ung-/-Msh2-/-Exp1 Ung-/-Msh2-/-Exp2 Aicda-/- Ung-/-Msh2-/- Aicda-/- Ung+/-Msh2+/- Ung+/-Msh2-/- Ung-/-Msh2+/- Ung-/-Msh2-/- Aicda-/-
Annex III. List of genes predicted to be mutated by AID. Genes included in our SureSelect 
capture library are highlighted in green; genes validated by PCR-Seq are highlighted in orange.
Gene SPT5 (RPKM) RNAP II (RPKM) Gene SPT5 (RPKM) RNAP II (RPKM)
09-002_145561_chr11 19,58 30,48 Ccnd2 10,25 25,29
1110005A03Rik 16,66 14,93 Ccnl1 8,03 9,70
1110065P20Rik 13,31 24,19 Cd37 7,16 24,05
1500012F01Rik 35,41 41,13 Cd52 9,32 26,43
1700001P01Rik 7,60 9,04 Cd68 20,30 40,32
1700008J07Rik 10,69 18,89 Cd69 17,26 7,76
1700040I03Rik 7,61 14,98 Cd74 31,76 64,77
1810009A15Rik 13,67 21,08 Cd83 9,94 28,52
1810035L17Rik 7,40 8,13 Cdt1 8,17 22,76
2010001M09Rik 17,99 37,45 Cfl1 14,13 25,21
2310014L17Rik 12,58 16,44 Chmp2a 10,97 23,77
2310016E02Rik 7,69 16,47 Chrac1 9,43 16,93
2310033P09Rik 9,92 26,87 Cirbp 9,29 16,72
2310039H08Rik 19,79 28,49 Clec2d 19,53 22,32
2700094K13Rik 10,59 16,21 Clic1 7,89 16,22
2810422O20Rik 12,37 6,46 Cnbp 11,13 13,08
2810428I15Rik 8,06 12,52 Coro1a 15,77 44,71
4930404N11Rik 9,38 15,74 D230037D09Rik 8,52 13,99
6230427J02Rik 7,48 20,00 D4Wsu53e 10,78 19,06
9130023H24Rik 7,41 12,93 Dbil5 12,67 19,83
A130010J15Rik 7,70 10,11 Dbp 7,98 11,68
A830007P12Rik 8,66 20,30 Ddit3 9,77 13,62
Abhd11 7,58 15,92 Ddx5 14,25 17,62
Actb 24,97 64,52 Dhps 7,19 16,67
Actg1 8,27 23,97 Dusp2 13,93 26,70
Agxt2l2 11,08 15,67 Eef1b2 7,92 15,72
AI413582 15,87 33,75 Eef2 9,67 29,31
Aldoa 8,96 16,30 Eif1 16,79 30,62
Alkbh1 8,10 7,68 Eif4a1 15,05 29,29
Apex1 12,35 21,37 Eif4a2 18,77 23,05
Apobec3 10,67 26,17 Eif4g2 10,29 11,01
Arf6 11,02 18,95 Eif5 8,32 11,45
Arhgdia 7,75 21,12 Eif5a 14,40 24,19
Atf4 27,82 60,46 Erp29 10,62 16,28
Aup1 9,87 21,55 Exosc6 13,03 22,43
Aurkaip1 7,88 16,74 Fam36a 28,47 33,32
AY074887 8,26 15,96 Fam69b 9,99 18,45
B2m 14,74 23,02 Fau 10,43 25,37
B3galt4 25,22 42,94 Fbxl22 7,77 15,22
B3galt6 7,92 12,87 Fkbp2 14,82 26,69
Banf1 11,85 23,96 Fth1 7,26 22,31
BC031181 9,06 11,25 Ftl1 11,04 21,11
BC056474 8,47 12,46 Fus 8,46 9,50
Bola1 10,56 20,67 Gadd45b 9,28 20,21
Bola2 11,96 25,33 Gadd45g 7,87 52,74
Brd2 17,98 39,92 Gadd45gip1 7,29 12,29
Bzrap1 7,21 9,12 Gas5 44,66 37,62
Calr 11,22 21,11 Gimap1 15,72 25,67
Ccdc17 7,46 16,10 Gimap4 11,70 14,68
Ccdc84 7,78 9,08 Gimap5 13,72 20,50
Gene SPT5 (RPKM) RNAP II (RPKM) Gene SPT5 (RPKM) RNAP II (RPKM)
Gimap6 8,91 11,99 Hist1h3a 20,67 22,89
Gm11808 10,65 26,03 Hist1h3g 44,23 40,49
Gm15772 9,23 13,64 Hist1h3h 33,45 28,03
Gm5464 7,83 14,14 Hist1h3i 13,48 16,19
Gm5774 22,38 36,24 Hist1h4a 47,65 55,34
Gnb2l1 12,21 21,68 Hist1h4b 16,41 17,00
Gng5 7,69 6,65 Hist1h4c 19,15 28,51
Gnl3 11,48 14,05 Hist1h4d 22,67 32,09
Gps2 18,98 32,52 Hist1h4f 18,47 25,92
Gpx1 14,88 26,40 Hist1h4h 26,01 31,57
Grap 10,97 25,06 Hist1h4i 47,90 35,79
Grcc10 26,17 38,52 Hist1h4j 13,59 20,81
Gstt2 9,49 27,71 Hist1h4k 13,63 18,07
H2-Aa 21,55 32,01 Hist2h2ab 34,81 30,95
H2-Ab1 16,59 31,48 Hist2h2ac 36,42 42,24
H2-D1 7,73 18,42 Hist2h2be 22,86 23,98
H2-Eb1 14,30 27,66 Hist2h4 38,56 50,38
H2-K1 8,59 18,46 Hist3h2a 22,27 21,38
H2-Ke6 7,79 16,42 Hist4h4 43,56 48,86
H2af 12,82 16,99 Hmbs 7,25 7,70
H2afx 41,29 58,91 Hmga1 10,83 22,13
H2afz 12,33 17,55 Hmgb1 8,12 11,93
H3f3b 25,04 26,99 Hmgb2 9,87 15,66
Hexim1 9,26 17,51 Hmgn2 7,59 12,54
Higd2a 8,97 14,40 Hnrnpa0 13,49 26,48
Hirip3 8,61 15,55 Hnrnpa2b1 20,35 18,28
Hist1h1a 40,08 46,78 Hnrnpa3 8,76 9,10
Hist1h1b 51,77 68,68 Hnrnpab 13,42 22,68
Hist1h1c 69,40 84,34 Hnrnpf 12,08 13,18
Hist1h1d 35,85 38,24 Hnrnph1 7,40 10,41
Hist1h1e 45,53 56,45 Hnrnpk 8,86 13,38
Hist1h2ab 16,71 21,05 Hnrnpl 8,91 20,83
Hist1h2ac 18,15 17,27 Hnrnpu 13,15 14,59
Hist1h2ad 9,50 14,58 Hnrpdl 12,18 17,43
Hist1h2ae 43,69 30,53 Hsp90ab1 14,13 25,11
Hist1h2af 12,27 11,70 Hspa5 17,02 25,55
Hist1h2ag 37,44 32,66 Hspa8 16,08 22,58
Hist1h2ah 28,31 30,29 Hspe1 8,11 14,18
Hist1h2ai 24,98 28,07 Htra2 10,19 20,05
Hist1h2ak 52,73 41,50 Id3 7,95 22,18
Hist1h2an 16,65 19,46 Idh3b 17,01 22,55
Hist1h2bb 18,95 25,00 Ier2 13,55 31,89
Hist1h2bf 17,35 14,99 Ier5 14,92 24,93
Hist1h2bh 23,28 21,22 Igg1 15,54 67,39
Hist1h2bj 36,67 32,45 Igm 37,83 97,18
Hist1h2bk 25,56 24,99 Il4i1 7,14 54,63
Hist1h2bl 26,83 30,78 Il4ra 11,28 48,77
Hist1h2bm 10,86 17,60 Imp3 8,15 10,43
Hist1h2bn 49,05 42,73 Ing1 8,92 20,00
Hist1h2bp 18,47 11,67 Insm1 8,31 17,30
Gene SPT5 (RPKM) RNAP II (RPKM) Gene SPT5 (RPKM) RNAP II (RPKM)
Jun 13,53 26,07 Pim1 20,40 63,74
Junb 16,99 52,00 Plekhj1 15,03 27,79
Jund 16,29 39,50 Pnrc2 12,39 14,93
Lcmt2 8,72 13,44 Polr1c 7,42 12,81
Limd2 10,27 25,86 Pop7 12,72 24,12
Lipt2 7,48 11,87 Pou2af1 7,16 19,86
Lsmd1 8,33 14,73 Ppan 8,37 20,65
Ly6e 18,75 53,15 Ppia 19,89 30,52
Lyl1 11,19 30,77 Ppp1r10 11,30 16,08
Mageb3 7,14 12,74 Ppp1r14b 8,32 17,43
Manf 11,69 20,05 Ptbp1 7,65 21,51
Mat2a 15,90 15,17 Ptma 13,28 38,45
Maz 7,76 16,97 Ptprcap 12,64 30,33
Mbd3 8,77 18,59 Ptrh2 9,07 8,01
Mcl1 17,37 28,93 Purb 8,19 16,44
Mgat2 12,06 20,89 Pycard 11,13 13,89
Mocs3 8,81 17,50 Rabggtb 16,28 17,44
Mogs 7,22 14,15 Rad23a 12,75 16,66
Mrp63 9,46 16,06 Ran 8,06 15,63
Mrpl41 10,08 21,67 Rbm3 13,16 17,48
Mrpl49 8,19 21,71 Rbm39 10,90 7,08
Mrpl51 9,38 15,39 Rdm1 12,05 14,33
Mrpl53 9,23 17,92 Refbp2 42,42 38,07
Mrps18b 10,54 16,00 Rfc4 7,64 8,04
Mrps34 9,37 22,94 Rnf167 18,39 36,87
Myc 9,91 33,37 Rnu11 24,87 41,70
Myl6 7,27 14,46 Rnu12 27,88 43,91
Naca 7,18 10,90 Romo1 14,39 17,48
Nanos1 10,45 6,58 Rpl10 14,94 21,34
Ncl 23,38 20,48 Rpl10a 17,82 35,83
Ndufa2 8,22 13,58 Rpl11 9,59 20,72
Ndufa4l2 9,46 12,01 Rpl13 11,48 24,12
Ndufaf3 18,66 39,53 Rpl13a 18,13 36,79
Ndufb10 14,02 22,98 Rpl14 10,62 17,08
Nfkbia 12,84 33,71 Rpl17 10,54 19,24
Nme3 7,97 17,22 Rpl18 12,97 26,39
Nop10 8,35 11,30 Rpl19 10,76 18,43
Nop56 18,67 27,69 Rpl23 11,89 17,51
Npm1 14,79 9,92 Rpl23a 10,85 13,35
Nrp 15,67 19,13 Rpl26 9,17 13,56
Nt5c 8,14 15,29 Rpl27 8,01 15,24
Oasl1 11,58 22,55 Rpl27a 18,74 25,72
Obfc2a 10,70 17,59 Rpl28 13,88 29,86
Pa2g4 7,34 10,40 Rpl29 8,35 16,42
Pcbp1 15,33 36,40 Rpl3 27,13 39,31
Pcna 12,16 14,84 Rpl30 11,19 15,61
Pex12 10,22 14,09 Rpl34 11,80 17,79
Pfn1 20,74 45,00 Rpl35 8,37 19,44
Pgp 10,42 24,54 Rpl35a 10,80 16,48
Pigw 9,35 13,94 Rpl36 11,78 26,09
Gene SPT5 (RPKM) RNAP II (RPKM) Gene SPT5 (RPKM) RNAP II (RPKM)
Rpl36a 8,99 14,71 Sfpq 10,80 12,69
Rpl36al 14,65 29,99 Sfrs1 14,03 13,77
Rpl37 8,41 22,15 Sfrs13a 7,18 6,89
Rpl38 13,76 22,55 Sfrs2 23,29 34,35
Rpl4 12,46 15,70 Sfrs3 11,08 12,67
Rpl41 21,60 28,13 Sfrs5 9,37 15,78
Rpl5 9,41 12,68 Sfrs6 13,54 14,14
Rpl7a 11,59 27,21 Sfrs7 12,95 12,68
Rpl8 11,39 24,43 Shisa5 14,84 41,21
Rpl9 10,76 20,83 Slc25a11 7,90 15,71
Rplp0 11,26 18,41 Slc35b2 21,27 33,93
Rplp1 14,42 25,95 Slc39a7 9,10 18,52
Rplp2 11,06 17,91 Snapc5 14,05 15,56
Rps10 7,37 20,60 Snora62 13,30 22,34
Rps11 23,77 44,19 Snora64 45,15 66,25
Rps12 19,45 29,16 Snora68 8,32 25,41
Rps13 10,43 17,06 Snora70 11,09 10,54
Rps14 8,93 17,55 Snora74a 17,06 16,19
Rps15 10,78 26,18 Snord22 32,29 22,02
Rps15a 10,49 14,75 Snord32a 18,25 26,92
Rps17 8,66 21,00 Snord33 15,72 33,09
Rps18 13,53 25,95 Snord34 14,13 39,21
Rps19 9,77 21,92 Snord35a 12,79 41,41
Rps2 21,38 35,04 Snord35b 11,37 25,04
Rps20 16,70 27,60 Snord82 13,62 13,20
Rps21 19,04 28,08 Snord87 23,51 26,63
Rps24 8,04 13,73 Snx5 12,60 10,70
Rps25 9,86 17,42 Socs1 14,70 54,06
Rps27 15,76 20,64 Sra1 7,33 9,95
Rps27a 15,30 19,80 Srm 8,21 15,40
Rps28 14,13 22,82 Surf1 11,54 21,03
Rps29 7,30 16,28 Syngr2 9,11 37,94
Rps3 8,56 15,35 Syvn1 11,70 31,39
Rps3a 8,31 14,18 Taf10 8,29 15,55
Rps4x 10,97 14,80 Taf1d 13,45 13,84
Rps5 12,97 23,55 Tardbp 10,69 10,85
Rps6 11,50 20,70 Tceb2 8,30 10,34
Rps8 13,67 28,04 Tcta 8,02 16,94
Rps9 18,72 33,62 Terc 9,15 17,04
Rpsa 12,86 23,68 Tgif1 10,01 13,67
Rraga 13,17 18,87 Timm13 8,50 18,26
Rrm2 10,26 19,22 Timm8b 11,09 18,07
Sac3d1 7,60 11,42 Tk1 15,83 44,20
Scand1 13,63 25,40 Tlcd1 22,31 32,21
Sdf2l1 11,80 23,61 Tmem126a 9,64 6,41
Sdhaf1 9,05 14,55 Tmem179b 14,83 29,41
Sdr39u1 7,66 15,05 Tmem55b 7,79 16,79
Serinc3 7,81 11,91 Tmsb10 8,58 17,01
Serp1 11,33 14,82 Tmsb4x 15,15 25,42
Setd6 7,98 11,59 Tnf 9,41 26,33
Gene SPT5 (RPKM) RNAP II (RPKM)
Tnfrsf13b 10,27 27,45
Tnfrsf13c 7,11 25,23
Trex1 26,68 65,80
Trim41 9,78 16,12
Trmt112 9,23 23,70
Trmt2a 14,10 25,34
Tspan31 10,23 9,77
Tssc4 8,35 22,25
Tssk6 11,67 26,23
Ttpal 8,91 11,12
Tuba1b 13,34 20,64
Tubb2c 10,65 23,17
Tubb5 10,87 23,54
Txnip 8,37 9,94
Uba52 10,63 25,93
Ubb 11,41 19,46
Ubc 10,54 20,56
Ucp2 10,84 23,40
Ufsp1 11,38 25,81
Uqcrq 7,08 11,52
Utp3 9,02 15,73
Wdr38 11,63 21,55
Wdr5b 7,59 11,21
Xbp1 9,34 41,90
Zbtb32 12,34 18,24
Zc3h10 14,90 22,80
Zfp207 7,59 6,05
Zfp36 10,13 36,28
Zfp36l1 8,06 21,67
Zfp36l2 7,41 18,62
Zfp513 9,85 26,87
Znhit2 14,00 29,19
Annex IV. Per nucleotide mutation frequency of the 21 AID targets frequently found 
mutated in human DLBCL tumors measured in Ung-/-Msh2-/- mice. Background, 
quantified as the mutation frequency found in each nucleotide in Aicda-/- mice, was 
subtracted before plotting.
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INTRODUCTION
Activation-induced deaminase (AID) is a crucial enzyme 
for the immune response because it generates high-affinity 
and switched antibodies in germinal center (GC) B cells 
by somatic hypermutation (SHM) and class switch recom-
bination (CSR; Muramatsu et al., 2000; Revy et al., 2000). 
AID initiates SHM and CSR through the deamination of 
deoxycytidine residues into deoxyuridines on the DNA of Ig 
genes (Muramatsu et al., 2000; Petersen-Mahrt et al., 2002; 
Di Noia and Neuberger, 2007; Stavnezer et al., 2008). The 
resulting U:G mismatch can be alternatively recognized and 
processed by base excision repair (BER) or mismatch repair 
(MMR) pathways, leading either to point mutations, in the 
case of SHM, or to double-strand breaks (DSBs) followed 
by a recombination reaction, in the case of CSR (Di Noia 
and Neuberger, 2007; Stavnezer et al., 2008; Reynaud et al., 
2009; Methot and Di Noia, 2017). Although AID activity has 
a strong preference for Ig genes, it can also target other genes, 
giving rise to point mutations (Shen et al., 1998; Pasqualucci 
et al., 2001; Liu et al., 2008) or oncogenic chromosome trans-
locations (TCs; Ramiro et al., 2004, 2006; Robbiani et al., 
2008). Understanding AID specificity, or targeting, has been 
hindered by the technical challenge of detecting AID-induced 
mutations, which occur at very low frequencies. Here, we 
have used next generation sequencing to directly measure 
raw AID mutational activity on a broad representation of the 
genome and thus gather conclusions on AID specificity, DNA 
repair, and lymphomagenesis.
RESULTS AND DISCUSSION
Capture-based deep sequencing allows high-throughput 
identification of AID targets
To explore the scope of AID-induced mutations at a high- 
throughput scale, we designed a capture library against 1,588 
regions corresponding to 1,379 different genes as a representa-
tion of the B cell genome (Table S1; see Design of DNA capture 
library in the Materials and methods). Genomic DNA from GC 
B cells was isolated, captured, and deep sequenced (Fig. S1, A 
and B). We made use of a mouse model deficient for both BER 
and MMR pathways (Ung−/−Msh2−/− mice). In the absence 
of BER and MMR, AID-induced U:G mismatches remained 
unprocessed and were replicated over, thus leaving behind 
almost solely C→T and G→A transitions, the footprint of 
AID de amination events on DNA (Rada et al., 2004; Methot 
and Di Noia, 2017). This approach allowed an extremely ef-
ficient enrichment and sequencing depth (Fig. S1, A and 
B). We found a set of 291 genomic regions (corresponding 
to 275 different genes) that were reproducibly mutated in 
Ung−/−Msh2−/− GC B cells when compared with Aicda−/− 
GC B cells (q ≤ 0.05; Fig. 1 A; Fig. S1, C–E; and Table S2; 
representative targets were validated by Sanger sequencing; 
Fig. 1 B and Table S3). Importantly, the 275-gene target col-
lection included 30 of the 35 previously known AID targets, 
such as Bcl6, Pim1, RhoH, Pax5, and Cd83 (Fig.  1  C and 
Table S2; Pasqualucci et al., 2001; Liu et al., 2008; Methot and 
Di Noia, 2017). Mutations detected in the 291-target regions 
strongly accumulated in AID mutational hotspots (WRC(Y)/
(R)GYW; underlined letters specify deaminated nucleo-
tides; W = A/T; R = A/G; Y = C/T; Fig. 1 D; Rogozin and 
Kolchanov, 1992). Finally, we found that our 275-target set in-
Activation-induced deaminase (AID) initiates antibody diversification in germinal center (GC) B cells through the deamination 
of cytosines on immunoglobulin genes. AID can also target other regions in the genome, triggering mutations or chromosome 
translocations, with major implications for oncogenic transformation. However, understanding the specificity of AID has 
proved extremely challenging. We have sequenced at very high depth >1,500 genomic regions from GC B cells and identified 
275 genes targeted by AID, including 30 of the previously known 35 AID targets. We have also identified the most highly 
mutated hotspot for AID activity described to date. Furthermore, integrative analysis of the molecular features of mutated 
genes coupled to machine learning has produced a powerful predictive tool for AID targets. We also have found that base 
excision repair and mismatch repair back up each other to faithfully repair AID-induced lesions. Finally, our data establish a 
novel link between AID mutagenic activity and lymphomagenesis.
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cluded a big proportion of genes subject to DSBs or chromosome 
TCs (Fig. S1 F; Chiarle et al., 2011; Klein et al., 2011; Stasze-
wski et al., 2011; Qian et al., 2014; Dong et al., 2015). Thus, our 
deep sequencing approach has allowed the discovery of an un- 
precedented, massive collection of AID targets.
Identification of AGCTNT as a novel AID hotspot
To gain insights into the local sequence preference of AID, 
we first analyzed the mean mutation frequency at individ-
ual WRCY/RGYW hotspots across all 291 AID targets and 
found a wide range of mutability, with AACT and AGCT 
Figure 1. High-throughput analysis of AID-induced mutations. DNA from Peyer's patch GC B cells was captured with a probe library for 1,588 ge-
nomic regions (Table S1) and deep sequenced. AID targets were identified as those regions accumulating significantly more C→T transition mutations in 
Ung−/−Msh2−/− than in Aicda−/− mice (Table S2; FDR ≤0.05, one-tail Fisher test and Benjamini-Hochberg correction; two independent experiments; see 
Materials and methods). (A) Circos plot representation of the AID targets identified in this study and their associated molecular features. The outer ring 
shows chromosome location and is followed by C→T transition mutation frequency in Ung−/−Msh2−/− (red) and Aicda−/− (gray) mice. (B) Validation of 
representative AID targets by Sanger sequencing (one-tail Fisher test; Table S3). (C) Overlap between the targets discovered in this study and previously 
reported AID targets. (D) Mean transition frequency in total C/G nucleotides and in C/G within WRC(Y)/(R)GYW hotspots (W = A/T; R = G/A; Y = C/T) of 
the 291 AID targets (two-tailed Student’s t test; two independent experiments). (E) Logo representation of the sequence context of mutated cytosines 
(mutation frequency ≥4 × 10−3). Statistically significant enrichment of nucleotides surrounding the mutated C is indicated (*, FDR ≤10−3, one-tail Fisher 
test and Bonferroni correction; see Materials and methods), and numbers indicate percentages. (F) Mean mutation frequency of cytosines within the indi-
cated motifs (dark blue bar, newly identified hotspot; gray bar, control motif for newly identified hotspot; light blue bars, WRCY hotspots; red bars, random 
four-nucleotide motifs; two-tailed Mann-Whitney test). *, P ≤ 0.05; ***, P < 10−3; ****, P < 10−4. Error bars depict SEM.
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as the top mutated hotspots in both strands of DNA, which 
may reflect an intrinsic preference for AID deaminase activ-
ity. Next, we performed an unbiased analysis of the sequence 
context of mutated cytosines. We found that A, G, and T nu-
cleotides were the preferred nucleotides at −2, −1, and +1 
positions (Pérez-Durán et al., 2012; Wei et al., 2015; Yeap et 
al., 2015), respectively, but we further uncovered a significant 
preference for T at +3 (Fig. 1 E and Fig. S2). Indeed, cytosines 
lying at the AGCTNT motif were significantly more mutated 
than those in AGCTNV (where V is A, C, or G) or than other 
WRCY/RGYW hotspots (Fig. 1 F and Fig. S2, A and B). 
Thus, our study has revealed AGCTNT as a novel and the 
most highly mutated AID hotspot identified so far.
Prediction of AID targets
Using the uniquely large set of AID-mutated genes identified 
in this study, we performed a comprehensive analysis of molec-
ular features that associate with SHM, including transcription, 
epigenetic marks, and regulatory sequences (Fig. 1 A; Storb, 
2014; Methot and Di Noia, 2017). We first observed that tran-
scription levels and transcription rates are significantly higher 
in AID targets than in nontargets and that this difference is 
even higher for highly mutated targets (Fig.  2  A). We also 
found that RNAPolII and the stalling factor Spt5, previously 
described to associate with AID (Nambu et al., 2003; Pavri 
et al., 2010), show higher binding density within AID muta-
tional targets (Fig. 2 B). Likewise, AID targets were enriched 
in marks of active enhancers and transcriptional elongation, 
such as Med12, H3K36me3, and H3K79me2 (Fig. 2 C). Fi-
nally, we found that primary AID targeting, as measured by 
AID mutations in the absence of repair, also focuses prefer-
entially in the vicinity of superenhancers (Fig. 2 D) and in 
regions subject to convergent transcription (Fig. 2 E; Meng 
et al., 2014; Qian et al., 2014). Together, our mutagenesis 
study shows that several mechanisms linked to transcription 
are critical for AID activity, as suggested in previous studies 
(Nambu et al., 2003; Pavri et al., 2010; Meng et al., 2014; 
Qian et al., 2014; Wang et al., 2014). Our data also indicate 
that AID targeting cannot be defined by any of these features 
alone. To approach whether a combination of these molecular 
features could be used to predict AID targeting, we developed 
a prediction model using a machine-learning algorithm, fed 
with the collection of genes analyzed here together with the 
set of molecular features described in Fig. 2 (A–E) (Fig. S3, 
A and B; see Machine learning to predict AID targets in the 
Materials and methods for details). We found that a combi-
nation of high-density RNAPolII and Spt5 binding, found 
in 2.3% of genes in the whole genome (Fig. S3 B), predicts 
AID specificity with 77% probability (P < 0.001; Fig.  2  F 
and Fig. S3 A). Conversely, low RNAPolII binding combined 
with low gene expression predicted the absence of muta-
tions for 95% of genes (Fig. 2 F). To test the accuracy of our 
prediction model, we analyzed the mutation frequency of a 
new collection of genes (not included in our capture library) 
with high-density RNAPolII and Spt5 binding (Fig. S3 C 
and Table S4). We found that 11/12 of the analyzed genes 
were significantly mutated (Table S4 and Fig. 2 G). Indeed, 
two genes (Hist1h1c and Clec2d) were mutated at the range 
of the top 20% mutated genes at frequencies similar to those 
found in Pax5 or Rhoh (Table S2 and Table S4). Thus, we 
have built a powerful predictive tool for AID activity.
BER and MMR back up each other to faithfully 
repair AID-induced lesions
BER and MMR act downstream of AID-induced U:G 
mismatches so that UNG is critical for the generation of 
transversions at C:G pairs while MSH2 facilitates the intro-
duction of mutations at A:T pairs (Frey et al., 1998; Phung 
et al., 1998; Rada et al., 1998, 2002, 2004; Methot and Di 
Noia, 2017). UNG and MSH2 can also promote conven-
tional, faithful repair of AID-induced U:G mismatches (Liu 
et al., 2008; Pérez-Durán et al., 2012). To explore the con-
tribution of BER and MMR to AID mutagenic activity, we 
analyzed GC B cells from single-deficient Ung+/−Msh2−/− 
and Ung−/−Msh2+/− mice and from control Ung+/−Msh2+/− 
mice and compared the mutation frequency of the 291 AID 
target regions identified in this study (Table S2). We found 
similar mean mutation frequencies in B cells deficient for 
UNG alone, MSH2 alone, or proficient for both, whereas 
AID targets harbored significantly more mutations in the 
combined absence of UNG and MSH2 (Fig.  3, A and B). 
Indeed, only a small proportion (∼6%) of the genes mutated 
in Ung−/−Msh2−/− cells was also mutated in single-knockout 
and double-heterozygous cells (Fig. 3 C and Table S2). More-
over, we found that classical AID off targets, such as Bcl6 or 
Pim1, although mutated in all genotypes analyzed, harbored a 
significantly bigger load of mutations in Ung−/−Msh2−/− cells 
than in Ung+/−Msh2−/−, Ung−/−Msh2+/−, or Ung+/−Msh2+/− 
cells (Fig. 3 D). Together, these data indicate that BER and 
MMR back up each other to faithfully repair most of the 
AID-induced lesions in GC B cells.
AID targets are recurrently mutated in human lymphomas
We next assessed the contribution of AID off-target muta-
tions to B cell–derived malignancies by making use of avail-
able sequencing data on human lymphomas. We found that 
AID targets are significantly enriched in genes mutated in 
human B cell lymphomas (see Annotation of AID targets 
in the Materials and methods for details; Fig. 4 A). Indeed, 
21/275 (7.6%) of our set of AID target genes are mutated in 
diffuse large B cell lymphomas (DLB CLs; Fig. 4 B), a highly 
prevalent, aggressive form of lymphoma (Shaffer et al., 2012). 
Lymphoma genes mutated by AID included Bcl6, RhoH, 
Pim1, Ebf1, Eif4a2, and Pax5, which is in agreement with 
previous studies (Shen et al., 1998; Pasqualucci et al., 2001; 
Liu et al., 2008). In addition, we identified nine novel genes 
mutated in human DLB CLs that accumulate AID-induced 
mutations (Fig. 4 B), including Mef2b, Lyn, Tnfaip3, Gna13, 
and Irf8. Remarkably, we found many instances where the 
exact same mutations described in human lymphoma genes 
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were also found in the AID targets identified in this study 
in nontransformed mouse B cells (Fig.  4 C and Table S5). 
Together, these results suggest that off-target AID mutagenic 
activity can contribute to GC-associated lymphomagenesis.
Until now, the study of AID specificity has been hin-
dered by the technical challenge of detecting AID-induced 
mutations; indeed, only a limited number of genes has been 
directly interrogated for AID-mediated mutagenesis (Pasqua-
lucci et al., 2001; Liu et al., 2008; Methot and Di Noia, 2017). 
However, genome-wide AID specificity has been inferred 
from high-throughput analysis of AID binding, which does 
not warrant AID activity, AID-induced DSBs, or chromo-
somal TCs, which involve complex processing of the initial 
lesion induced by AID (Chiarle et al., 2011; Klein et al., 2011; 
Staszewski et al., 2011; Yamane et al., 2011; Meng et al., 2014; 
Qian et al., 2014). The strategy developed in this study has 
provided an unprecedented scope to the analysis of AID tar-
geting: we describe here the broadest collection of AID mu-
tational targets (275 genes) to date, 10-fold larger than the 
previously known targets. The strength of this analysis is well 
supported by the confirmation of the vast majority of previ-
ously identified AID targets and the validation of targets by 
conventional Sanger sequencing.
Here, we have integrated our mutation data with a collection 
of molecular features of GC B cells to feed a machine-learning 
algorithm. According to the machine-learning tree gener-
ated here, the combined binding of Spt5 and RNAPolII at 
high density is the best predictor for AID mutability, although 
Figure 2. Molecular features of AID targets predict mutability. (A) Expression level of highly mutated (top 20% mutated genes, C→T transition 
frequency >3 × 10−4), mutated (rest of mutated), and nonmutated genes in Peyer's patch GC B cells as measured by RNA-Seq and transcription rate of AID 
targets in GC B cells from lymph nodes as measured by GRO-Seq. TPM, transcripts per million. (B) Recruitment of RNAPolII and Spt5 to AID targets and 
nontargets measured in in vitro activated splenic B cells by ChIP-Seq. RPKM, reads per kilobase per million reads mapped. (C) Transcription and transcription 
elongation marks in AID targets and nontargets by ChIP-Seq analysis of in vitro activated splenic B cells (Med12, H3K4me1, H3K36me3, and H3K79me2). (D) 
Proportion of highly mutated, mutated, and nonmutated genes regulated by superenhancers (SE) in GC B cells (see Materials and methods). (E) GRO-Seq 
analysis of convergent transcription (ConvT) in AID targets and nontargets from GC splenic B cells obtained from SRBC-immunized mice. (F) Representation 
of the machine-learning approach used for AID target prediction. (G) Validation of representative genes predicted to be mutated by the model by PCR-Seq. 
Statistical tests: two-tailed Student’s t test (A, B, and G) and one-tailed Fisher test (C–E). ***, P < 10−3; ****, P < 10−4.
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additional combinations of transcriptional traits bear some 
predictive power as well. Furthermore, we have performed 
independent experimental validation showing that randomly 
picked Spt5highRNAPolIIhigh genes indeed are very frequently 
mutated by AID. This is, to our knowledge, the first instance of 
a tool that successfully predicts the potential of a gene to be tar-
geted by AID. Regarding the fate of AID-induced lesions, BER 
and MMR have long been known to broaden the diversity of 
SHM with an apparent perverted recruitment of error-prone 
polymerases and to do so in a cooperative manner (Rada et 
al., 2004; Di Noia and Neuberger, 2007; Methot and Di Noia, 
2017). The mechanisms responsible for the error-free versus 
error-prone activity of UNG and MSH2 are far from un-
derstood, and both gene-specific and local sequence contexts 
may play a role in defining the fate of the U:G resolution (Liu 
et al., 2008; Pérez-Durán et al., 2012; Wei et al., 2015). Strik-
ingly, here we show that the fate of the majority of off-target 
lesions induced by AID is to undergo faithful repair by BER 
and MMR and that, again, both pathways can back up each 
other in this task with only a minor fraction of the mutations 
escaping them. Whether this reflects gene-specific qualities or 
is the consequence of excessive mutation load will deserve fur-
ther investigation. We would speculate that a minor fraction 
of unrepaired mutations in prolymphomagenic genes could 
provide cell growth advantage and account for the predomi-
nance of AID-mediated mutations in lymphomas. Regardless 
of oncogenic relevance, it is remarkable that even though our 
mutation analysis was performed in nontransformed cells, we 
could detect individual AID-induced mutations that are recur-
rently mutated in lymphoma. Thus, our results yield a novel 
perspective on the contribution of AID activity to B cell trans-
formation through the introduction of mutations.
Figure 3. BER and MMR back up each other to error-free repair AID-induced lesions. (A and B) Total mutation frequency of AID targets in 
Ung+/−Msh2+/−, Ung−/−Msh2+/−, and Ung+/−Msh2−/− GC B cell mice compared with that of Ung−/−Msh2−/− mice (mean of two independent experiments; see 
Materials and methods; Table S2). (C) Heat map representation of AID targets in Ung+/−Msh2+/−, Ung−/−Msh2+/−, Ung+/−Msh2−/−, and Ung−/−Msh2−/− GC B 
cells. (D) Mutation frequency of representative genes in Ung+/−Msh2+/−, Ung−/−Msh2+/−, Ung+/−Msh2−/−, Ung−/−Msh2−/−, and Aicda−/− GC B cells. Red dots 
indicate statistically different mutation frequencies between the indicated genotypes. Mutation frequency found in Aicda−/− mice was substracted before 
plotting A–C. (A and D) Two-tailed Student’s t test; *, P ≤ 0.05. Error bars depict SEM. N.S., not significant.
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We expect our mutational study will be valuable for 
other research questions, including validation of novel mo-
lecular mechanisms involved in AID targeting, prediction of 
novel targets, or assessment of cancer-associated mutations. 
Furthermore, similar approaches would be of immediate in-
terest to broaden our knowledge on the role of AID or other 
mutagenic activities not only in B cell lymphomas, but also in 
malignancies from any origin.
MATERIALS AND METHODS
Mice
Ung and Msh2 mutant mice used in this study were generated 
by crossing Ung−/− mice (Nilsen et al., 2000) and Msh2−/− 
mice (Reitmair et al., 1995). Aicda−/− mice have been previ-
ously described (Muramatsu et al., 2000). Mice were housed 
in specific pathogen-free conditions. Male and female mice 
between 20 and 28 wk were used for the experiments. The 
number of animals per group to detect biologically signifi-
cant effect sizes was calculated using an appropriate statistical 
sample size formula. All experiments were done in concor-
dance with EU Directive 2010/63EU and Recommendation 
2007/526/EC regarding the protection of animals used for 
experimental and other scientific purposes, enforced in Span-
ish law under RD 53/2013.
Design of DNA capture library
A set of 1,379 mouse genes was selected as a representation 
of the genome (Table S1). 85% of all genes were randomly 
picked, ensuring even representation of chromosomal loca-
tion by bioinformatic analysis and unbiased biological func-
tion. ∼15% of the library corresponded to previously known 
AID targets (Müschen et al., 2000; Pasqualucci et al., 2001; 
Gordon et al., 2003; Liu et al., 2008; Robbiani et al., 2009; 
Pavri et al., 2010), IgH probes, and other controls. Probes 
were designed in eArray (Agilent) to capture the first 500 bp 
downstream of each transcriptional start site (TSS) of each of 
the 1,379 genes. Because various genes contained more than 
one predicted TSS, the library includes a total of 1,588 dif-
Figure 4. AID targets are recurrently mutated 
in human lymphomas. (A) AID targets are enriched 
in genes involved in lymphoma development. Per-
centage of lymphoma genes within AID target and 
nontarget genes. Annotation was done from public 
data on human lymphoma sequencing (see Materials 
and methods; two-tailed Fisher test; ****, P < 10−4). 
(B) Mutation frequency in total C/G nucleotides and 
C/G nucleotides within WRC(Y)/(R)GYW hotspots (W 
= A/T; R = G/A; Y = C/T) of the 21 AID target genes 
involved in human DLB CL development analyzed 
in Ung−/−Msh2−/− mice (mean of two independent 
experiments; see Materials and methods). (C) Muta-
tion profiles of representative DLB CL genes analyzed 
in Ung−/− Msh2−/− mice. Blue bars indicate muta-
tions identical to those found in human lymphoma 
tumor samples (Table S5); asterisks indicate muta-
tions occurring in a WRC(Y) hotspot. The diagrams 
below the graphs represent the complete gene (not 
to scale), and blue boxes indicate the region depicted 
above. Mutation frequency found in each nucleotide 
in Aicda−/− mice was subtracted before plotting.
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ferent genomic regions. Library design included 50 extra nu-
cleotides at both ends of each region to optimize the capture 
yield. A custom target enrichment capture library was then 
synthesized by the manufacturer (SureSelectXT; Agilent).
DNA capture and sequencing
GC (Cd19+Fas+GL7+) B cells were isolated from Peyer’s 
patches of Ung+/−Msh2+/− (n1 = 10; n2 = 11), Ung−/−Msh2+/− 
(n1 = 46; n2 = 8), Ung+/−Msh2−/− (n1 = 46; n2 = 2), and 
Ung−/−Msh2−/− (n1 = 37; n2 = 8) littermates and Aicda−/− (n 
= 31 mice) mice by sorting in a FAC SAria cell sorter (BD 
Biosciences) after staining with anti–mouse antibodies to 
Cd19, Fas, and GL7 (BD Biosciences). Genomic DNA was 
isolated by standard procedures and quantified in a fluorome-
ter (Qubit; Invitrogen). DNA capture, library preparation, and 
DNA sequencing were performed by the Genomics Unit at 
Centro Nacional de Investigaciones Cardiovasculares (CNIC). 
In brief, DNA was fragmented in a sonicator (Covaris) to 
∼200 nucleotide-long (mean size) fragments and purified 
using AMPure XP beads (Agencourt). Quality was assessed 
with the 2100 Bioanalyzer (Agilent). Then, fragment ends 
were repaired, adapters were ligated, and the resulting library 
was amplified and hybridized with our custom SureSelectXT 
library of RNA probes. DNA–RNA hybrids were then cap-
tured by magnetic bead selection. After indexing, libraries were 
single-end sequenced in a HiSeq 2500 platform (Illumina).
Target enrichment assessment by quantitative RT-PCR
Noxa1, Ostn, and Pcna amplifications were quantified with 
green assay (SYBR; Applied Biosystems) in a real-time PCR 
system (AB7900 Standard; AbiPrism). Gapdh amplifications 
were used as normalization controls. The following prim-
ers were used: Gapdh (forward), 5′-TGA AGC AGG CAT CTG 
AGGG-3′; Gapdh (reverse), 5′-CGA AGG TGG AAA GTG 
GGAG-3′; Ostn (forward), 5′-CAT AGT GTT GCT GTG GTT-
3′; Ostn (reverse), 5′-CAT TAT ATT GGT CTG CTG TT-3′; 
Noxa1 (forward), 5′-CGC GGG ACA GCA ATG AGA AG-3′; 
Noxa1 (reverse), 5′-CCA TCT ACT CAG TTT CAA GGA-3′; 
Pcna (forward), 5′-CTC CAG CAC CTT CTT CAG-3′; and 
Pcna (reverse), 5′-TCT CAT CTA GTC GCC ACA-3′.
SDS software (Applied Biosystems) was used 
for analysis of the data.
Sanger sequencing
Regions to be sequenced were amplified from 160–200-
ng genomic DNA in four independent reactions to mini-
mize possible PCR biases. The following primers were used: 
Hist1h1b (forward), 5′-ATG CCT TAG ACT TCA CCG CC-
3′; Hist1h1b (reverse), 5′-TTG TAA CCT TGA GTC GCC 
GC-3′; miR142 (forward), 5′-CGG TCC CTG GGA AGT 
TAC AC-3′; miR142 (reverse), 5′-AAC GAG AGG CAA ACA 
GTC TTCA-3′; Cd19 (forward), 5′-GCC CCT CTT CCC 
TCC TCA TA-3′; Cd19 (reverse), 5′-CCT GCA CCC ACT 
CAT CTG AA-3′; Cdk4 (forward), 5′-TCT GGC AGC TGG 
TCA CAT GG-3′; and Cdk4 (reverse), 5′-GAT CAC CAG 
CTA GTC GTC CC-3′. Amplification reactions were car-
ried in a final volume of 25 µl using 2.5 U Pfu Ultra HF 
DNA polymerase (Agilent) and the following PCR setup: 
95°C for 2 min, 25 (Cd19 and Cdk4) or 26 cycles (miR142 
and Hist1h1b) of denaturation at 94°C for 30 s, annealing at 
57°C (miR142 and Hist1h1b) or 58°C (Cd19 and Cdk4) 
for 30  s, extension at 72°C for 1 min, and a final stage of 
72°C for 10 min. PCR products were purified from a 1% 
agarose gel (Illustra Gel Band Purification kit; GE Health-
care) and cloned into pGEMT vector (Promega). Competent 
DH5α Escherichia coli bacteria were transformed with the 
constructs, and individual colonies (192–288 per gene) were 
grown in 96-well plates. Plasmidic DNA was then isolated 
(Plasmid MiniPrep kit; Millipore) and sequenced by Sanger 
sequencing using SP6 universal primer. Sequence analysis was 
performed using SeqMan software (Lasergene).
PCR-Seq to validate the machine-learning approach
40–50 ng of genomic DNA was amplified using the follow-
ing primers: Apobec3 (forward), 5′-GTC TTC CAT AGC CTG 
CTC ACA-3′; Apobec3 (reverse), 5′-TAG CTG ACT GGT 
GTG GTT CC-3′; Aurkaip1 (forward), 5′-ACT TGT CAC 
TTC CGC AGT CC-3′; Aurkaip1 (reverse), 5′-CCA TCC 
CCA AGT CAG GTG TG-3′; Ccdc17 (forward), 5′-TCT TTT 
CTG TCC AGT CCG CC-3′; Ccdc17 (reverse), 5′-ACA AAT 
GGG CAG AGT CAG GG-3′; Cd52 (forward), 5′-TAC TGC 
CGC ACA CAT GAC TC-3′; Cd52 (reverse), 5′-TGA GGT 
GGG AAG CCA AAC AT-3′; Cd68 (forward), 5′-AGG GGC 
TGG TAG GTT GAT TG-3′; Cd68 (reverse), 5′-GGA GTC 
AGG ACT GGA TTT GAC-3′; Cd69 (forward), 5′-TCT 
AAA GGT TTT GAG ACC CCC-3′; Cd69 (reverse), 5′-
TGA AGC CTC ATC AAC GCA CT-3′; Clec2d (forward), 
5′-GGC TCC TGA CCT TGA AAT GC-3′; Clec2d (re-
verse), 5′-AGG CAA CTT CTG CCA CTA TGC-3′; Coro1a 
(forward), 5′-AGG GCT CTG GGG TTC TAC TT-3′; Co-
ro1a (reverse), 5′-GGA AAT GAC CAC GGG GGT TT-3′; 
Hist1h1c (forward), 5′-CTC TAT CGG CGT ACT GCC AC-
3′; Hist1h1c (reverse), 5′-ATC GAG TCC CTT GCA ACC 
TT-3′; Il4i (forward), 5′-ATT CCC GAG GGA GGT GAG 
TG-3′; Il4i (reverse), 5′-GGT AGC TTC TCT CCG TCA 
CAC-3′; Maz (forward), 5′-GTC AAC AAA GAA CCC CTC 
CCT-3′; Maz (reverse), 5′-CAC CTG TCC CCT GAG TTG 
TG-3′; Trex1 (forward), 5′-GCC TAA CAG GTT TGA TTG 
TCC T-3′; and Trex1 (reverse), 5′-TAG GCT GAG CAC 
TCC CAG TC-3′. Amplification reactions were carried in a 
final volume of 25 µl using 2.5 U Pfu Ultra HF DNA poly-
merase (Agilent; 95°C for 2 min, 26 cycles of 94°C for 30 s, 
55°C for 30  s, 72°C for 1 min, and a final stage of 72°C 
for 10 min). PCR products were purified and fragmented 
using a sonicator (Covaris), and libraries were prepared by 
the CNIC Genomics Unit according to the manufacturer’s 
instructions (NEBNext Ultra DNA Library Prep; New En-
gland Biolabs). Sequencing was performed in a HiSeq 2500 
platform (Illumina). Analysis was performed as previously 
described (Pérez-Durán et al., 2012).
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Gene expression profiling by RNA-Seq
GC (CD19+Fas+GL7+) and resting (CD19+Fas−GL7−) B 
cells were sorted from Peyer’s patches of littermate 12-wk-
old WT C57BL/6 mice. Three biological replicates were 
analyzed, each composed of a pool of five female mice. 
RNA was purified from pellets of 2–2.5 × 104 cells, and 
DNaseI treatment was applied to avoid DNA contamina-
tion (RNAeasy MiniKit; Qiagen). RNA quality was assessed 
with the 2100 Bioanalyzer, showing high RNA purity and 
integrity. Sequencing libraries were prepared by the CNIC 
Genomic Unit according to the manufacturer’s protocol 
(NEB NEXT Ultra RNaseq Library Prep kit; New England 
Biolabs) from 100 ng RNA per replicate and sequenced 
in a HiSeq 2500 platform.
Computational analysis
Pipeline to identify and annotate AID-induced mutations. 
Raw reads were demultiplexed by Casava v1.8 to generate a 
fastq file that was aligned to the mouse genome (NCBIm37 
v61 Feb 2011) with Novoalign 2.08.01 (command line op-
tions: -o SAM -F ILM1.8 -H -r None -q 2). Sam files were 
processed with Samtools 0.1.19 to generate a sorted bam file 
that was piped to a custom Perl script for the analysis of AID 
mutations. In brief, the software analyzes the regions of inter-
est in the bam file, annotates hotspots, localizes and suppresses 
annotated single nucleotide polymorphism positions (Sanger 
Mouse Genomes Project SNP and Indel Release v2), and 
reports relevant information about AID activity. AID targets 
were identified as those genes accumulating significantly 
more C→T transition mutations in Ung−/−Msh2−/− than in 
Aicda−/− mice (false discovery rate [FDR] ≤0.05, one-tail 
Fisher test and Benjamini-Hochberg correction).
Mutation frequencies were calculated as follows:
  Total mutation freq =  Total number of mutations  ___________________Total sequenced length , 
  Mutation freq  C/G =  
 ( Mutated cytosines + Mutated guanines ) 
   _______________________________ 
 ( Seq length cytosines + Seq length guanines ) , 
and
  
 Mutation freq  WRC ( Y ) / ( R ) GYW   =
   
 
 ( Mutated cytosines WRC ( Y )  +  Mutated guanines  ( R ) GYW )     _______________________________________  
 ( Seq length cytosines WRC ( Y )  +  Seq length guanines  ( R ) GYW ) 
.
 
(Only cytosines in WRC(Y) and guanines in 
(R)GYW were considered to calculate mutation 
frequency at hotspots.)
Integration of AID targets with public data on TC and DSB 
occurrence. The bar graph included in Fig. S1 F represents 
overlaps in the 1,375 genes analyzed in this study (divided 
into mutated and nonmutated genes) and genes where TCs or 
DSBs occur in B cells: Meng et al. (2014) refer to TC sites 
identified by HTG TS in αCD40+IL4-activated B cells as 
published in Table S2 from their study; Klein et al. (2011) refer 
to TC sites identified by TC-Seq in IgHI-Sce LPS+IL4-activated 
B cells as published in Table S4 from their study; Chiarle et al. 
(2011) refer to TC sites identified by HTG TS in c-myc25xI-SceI 
αCD40+IL4-activated B cells as published in Table S3 (signif-
icant hits at P ≤ 0.05) from their study; Qian et al. (2014) refer 
to DSBs identified by replication protein A (RPA) differential 
recruitment (RPA–chromatin immunoprecipitation [ChIP]) 
in IgkAID 53BP1−/− in vitro activated B cells as published in 
Table S1 A from their study; and Staszewski et al. (2011) refer 
to DSBs identified by Nbs1 binding (ChIP-on-ChIP) in 
LPS+αIgD-dextran+BLySS-activated B cells as published in 
Table S1 (P ≤ 0.05) from their study.
Sequence context of mutated cytosines. The sequence con-
text of mutated cytosines (C→T transition frequency ≥4 × 
10−3) was analyzed in a window of 10 nucleotides. Logo rep-
resentation was done using WebLogo3, and the percentage of 
each nucleotide in each position surrounding the mutated 
cytosine was calculated by a custom Perl script. Enrichment 
for adenosine, guanine, cytosine, or thymine was tested against 
the sequence context of all cytosines present in the 1,588 re-
gions analyzed in this study (one-tailed Student’s t test + 
Bonferroni correction).
Gene expression profiling by RNA-Seq. After demultiplexing 
by Casava v1.8, read quality was assessed by FAS TQC, and 
sequencing adapters were removed from sequence reads by 
cutadapt v1.9. The resulting reads were aligned to and quan-
tified on the mouse transcriptome (NCBIm38 v75, Feb 
2014) using RSEM v1.2.25 with the following parameters: -p 
3–time–output-genome-bam–sampling-for-bam–bowtie-e 
60–bowtie-m 30–bowtie-chunkmbs 512–fragment-length- 
mean 180–fragment-length-sd 50.
Transcription rate analysis (GRO-Seq). Reads were mapped 
to the mouse genome (mm9/NCBI37) using bowtie2, and 
uniquely mapped, nonredundant reads were kept. Reads 
mapping in ±1 kb from TSSs were quantified and summa-
rized at the gene level using HTSeq.
PolII and Spt5 recruitment. Quantification of PolII and Spt5 
recruitment was extracted from Table S3 A in Pavri et al. (2010).
Superenhancer analysis. Data were extracted from the catalog 
of superenhancers that overlap with gene bodies identified in 
GC B cells as published in Table S3 in Meng et al. (2014) 
(GEO accession no. GSE62296).
Epigenetic mark analysis. Sequencing data (fastq files) for 
each epigenetic mark were aligned to the mouse genome 
(NCBIm37 v61, Feb 2011) using bowtie 1.1.1 (command 
line options:–best -m1 -n2 -p2). Alignment files were pro-
cessed by Samtools 0.1.19 to generate a sorted bam file. Peak 
calling was done using MACS2 (v2.1.0.20140616) according 
to the optimal parameters for a histone modification status 
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profiling as reported by the creators of the tool (Feng et al., 
2011). Mapping of annotated peaks to genes was done 
using GRE AT (version 3.0.0).
Convergent transcription analysis (GRO-Seq). Convergent 
transcription data analysis was performed as described in 
Meng et al. (2014). In brief, reads were mapped to the mouse 
genome (mm9/NCBI37) using bowtie2, and uniquely 
mapped, nonredundant reads were kept. HOM ER (v4.6) was 
used with default parameters to identify transcribed regions 
from both strands and bedtools (v2.24) to find and annotate 
ConvT regions (regions where >100 bp of sense and anti-
sense transcription overlap occurs).
Machine learning to predict AID targets. The conditional in-
ference tree for classification was built using the ctree func-
tion from the party R package with default parameters. Genes 
with a background mutation frequency >5 × 10−4 were ex-
cluded to avoid artifacts. The following variables were fed into 
the model for each of the 1,339 genes analyzed: expression, 
transcription rate, PolII recruitment, and Spt5 recruitment 
(quantitative, continuous); Med12 recruitment, H3K4me1 re-
cruitment, H3K36me3 recruitment, H3K79me2 recruitment, 
regulation by superenhancers, and occurrence of convergent 
transcription (qualitative, discrete). All variables were assigned 
equal weights to fit the model.
Annotation of AID targets. Annotation of AID targets was 
performed based on public data on sequencing of human 
DLB CLs, Burkitt lymphomas, and follicular lymphoma tu-
mors (Lohr et al., 2012; Love et al., 2012; Morin et al., 2013; 
Zhang et al., 2013; de Miranda et al., 2014; Okosun et al., 2014).
Data availability
Sequencing data generated for this study are avail-
able through the GEO database: targeted DNA deep se-
quencing (accession no. GSE102944) and RNA-Seq 
(accession no. GSE98086).
The rest of the datasets analyzed in the current study are 
publicly available through the GEO and/or Sequence Read 
Archive: GRO-Seq (accession no. GSE62296), GC B cells (ac-
cession nos. SRR1611832, SRR1611833, and SRR1611834), 
naive B cells (accession nos. SRR1611829, SRR1611830, 
and SRR1611831), ChIP-Seq of PolII and Spt5 (accession 
no. GSE24178), and ChIP-Seq data of epigenetic marks 
Med12 (accession no. SRX347810), H3K4me1 (accession no. 
SRX347815), H3K36me3 (accession no. SRX185869), and 
H3K79me2 (accession no. SRX185843).
Statistical analysis
Statistical analyses were performed with stats R package 
v3.1.1. Error bars in figures represent SEM. Student’s t test was 
applied to continuous data, and a Fisher test was used to assess 
differences between categorical variables. P-values were cor-
rected for multiple hypothesis testing by Benjamini-Hochberg 
or Bonferroni method where appropriate. Differences were 
considered statistically significant at P ≤ 0.05 or q ≤ 0.05.
Online supplemental material
Fig. S1 shows the experimental workflow used to identify 
AID targets and technical controls. Fig. S2 shows mutation 
analysis of WRCY/RGYW hotspots. Fig. S3 shows details 
on the machine-learning classification tree used for the pre-
diction of AID targets. Table S1 contains a list of the genes 
included in the capture library. Table S2 A contains a de-
tailed mutation analysis of AID targets in Ung+/−Msh2+/−, 
Ung−/−Msh2+/−, Ung+/−Msh2−/−, and Ung−/−Msh2−/−. Table 
S2 B contains a list of the 18 AID targets mutated in re-
pair-proficient GC B cells. Table S3 shows mutation analy-
sis of genes validated by Sanger sequencing. Table S4 shows 
mutation analysis of the genes selected for machine-learning 
validation. Table S5 contains a list of the mutations found 
in Ung−/−Msh2−/− GC B cells that have been identified in 
cohorts of human lymphoma patients.
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Figure S1. Identification of AID targets by target enrichment coupled to next generation sequencing. (A) Target enrichment protocol allows a 
2,000-fold enrichment of selected genes. Genomic DNA corresponding to genes included (Noxa1 and PCNA) and not included (Ostn) in the SureSelect 
capture library was quantified by quantitative RT-PCR before and after DNA capture enrichment. Graph represents fold depletion or fold enrichment calcu-
lated as 2(CTInput-CTEnriched fraction). Mean of two independent experiments is represented. (B) Schematic representation of the experimental approach used. GC 
(CD19+Fas+GL7+) B cells from Peyer’s patches were isolated by cell sorting, and genomic DNA was extracted, sheared, and captured with a custom library 
of RNA probes. Enriched DNA was subjected to next generation sequencing to achieve a mean depth of 2,300 reads per nucleotide. (C) Two independent 
experiments were performed (Table S2) with 457 mutated targets found in Exp1 and 399 in Exp2. An overlap of 291 AID targets was found between Exp1 
and Exp2. (D) Experimental distribution of random overlaps simulated for 1,000 iterations. For each iteration, random groups of 457 and 399 genes were 
selected from the genes included in the SureSelect capture library, overlapped, and the number of coincident genes reported. The probability to find an 
overlap of 291 genes by chance is <1 out of each 1016 times tested. Two-tailed Fisher test; P = ∼10−16. (E) Mutation frequencies of the 1,588 TSS proximal 
regions analyzed and the 291 targets found in two independent experiments. (F) Percentage of genes undergoing DSB/TC+ according to the indicated 
studies within AID mutational targets described in this study (SHM+; 275 genes obtained in two independent experiments) and percentage of SHM+ genes 
within DSB/TC+ genes (see Materials and methods).
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Figure S2. Mutation analysis at WRCY/RGYW hotspots in Ung−/−Msh2−/− GC B cells. (A) Percentage of mutated cytosines within AGCTNT and 
AGCTNV hotspots and CTCA and GGCA non–hotspot motifs (Fisher test; ****, P < 10−13). (B) Plots show mutated individual hotspots (WRCY, left; RGYW, 
right). Newly identified AGC TNT/ANA GCT hotspots are shown in the top row. Within each plot, each dot represents an individual WRCY/RGYW motif found 
mutated at least once. Each position in the x axis corresponds to a different gene, and the y axis shows mutation frequency of each individual hotspot within 
a gene. Mean mutation frequency is indicated and depicted with a red line. Number of mutated hotspots is indicated.
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Figure S3. Machine learning to predict AID targets genome wide. (A) Recursive partitioning tree model classifies AID targets based on different 
molecular features: mRNA expression, PolII and Spt5 recruitment, and presence of H3K79me2 epigenetic mark (see Materials and methods). Each node 
splits the genes into two significantly different groups based on a particular feature. Numbers within the branches indicate the thresholds used to make 
the groups; p-values of each decision are included below the parameter measured in each node. (B) Bar graph depicting the proportion of SureSelect genes 
(1,339 genes; closed bars) or of total genes in the mouse genome (17,858 genes; open bars) that meet the thresholds established in each node. (C) Box plot 
depicting genome-wide data of PolII and Spt5 recruitment in in vitro activated B cells. Black dots and squares mark the 12 genes selected for the validation 
of the model prediction. RPKM, reads per kilobase per million reads mapped.
Tables S1–S5 are provided in separate Excel files. 
Table S1 contains a list of the genes included in the capture library. 
Table S2 A contains a detailed mutation analysis of AID targets in Ung+/−Msh2+/−, Ung−/−Msh2+/−, Ung+/−Msh2−/−, and 
Ung−/−Msh2−/−. Table S2 B contains a list of the 18 AID targets mutated in repair-proficient GC B cells. 
Table S3 shows mutation analysis of genes validated by Sanger sequencing. 
Table S4 shows mutation analysis of the genes selected for machine-learning validation. 
Table S5 contains a list of the mutations found in Ung−/−Msh2−/− GC B cells that have been identified in cohorts of 
human lymphoma patients.
